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Alzheimer’s disease is fast becoming the greatest healthcare challenge of our time, with no 
known cure to-date. Brought about by the toxic formation of plaques of amyloid-β and 
tangles of tau in the brain, much is still unknown about the precise mechanisms that initiate 
these protein accumulations, thought to occur decades before clinical manifestation of 
symptoms. One theory is that an imbalance between the production of these proteins and 
their removal from the brain promotes retention that eventually aggregates into entities that 
devastate molecular and cellular machinery. Thus, targeting waste clearance mechanisms 
responsible for removing cerebral metabolites, including amyloid-β and tau, present novel, 
enthralling research targets. The glymphatic system is one such pathway that has been 
recently characterised. Considered a surrogate for lymphatics which are largely lacking in 
the brain, this fluid network relies on the water channel aquaporin-4, expressed highly on 
glia, thus being named “glymphatics”. In this work, first, a surgical protocol was established 
in the mouse brain to facilitate the delivery of tracer molecules into the cerebrospinal fluid. 
Direct, single time-point, histological assessment of fluorescent tracer distribution was 
performed to check consistency with previous characterisation of glymphatics in the mouse 
brain.   Glymphatics were then visualised dynamically across the whole brain using magnetic 
resonance imaging. Glymphatic patterns were investigated in real-time by imaging fluid 
dynamics in the brain alongside a potent blocker of aquaporin-4. Next, imaging was used to 
characterise glymphatic changes and aquaporin-4 profiles in mouse models of Alzheimer’s 
pathology. This revealed a time-dependant relationship between glymphatics and tau 
accumulation. Finally, the findings were extrapolated onto humans by studying aquaporin-
4 modifications in subjects with and without cognitive deficits. Here, the crucial relationship 
between aquaporin-4 and pathological aggregates of tau and amyloid-β was determined. 
Furthermore, dystrobrevin, a membrane protein linked to aquaporin-4, was also profiled in 
the setting of aging and amyloid-β pathology. The work presented herein elucidates the role 
of glymphatic perturbances in the context of Alzheimer’s disease and clarifies the 






The work presented in this thesis focuses on a novel research arm in Alzheimer’s disease 
biology. Research in glymphatics is a recent but rapidly developing topic in the neuroscience 
research domain. The novel knowledge and discoveries presented in this body of work adds 
significant volume to the current understanding of waste clearance from the brain and its 
implications in neurodegenerative disease. Hence, it accelerates the understanding of a 
devastating human disease that is widespread. A clearer understanding of the disease onset 
is still lacking and thus, these novel data are beneficial in supporting the progress of  both 
clinical and basic science research. Elucidating these new disease mechanisms may also 
speed up the discovery of disease modifying therapies, which are desperately needed. 
Alzheimer’s disease is the 5th biggest killer globally and is still without a cure. This is largely 
due to the lack of a full picture of the mechanistic causes underlying disease onset. As such, 
the innovative research angles and novel data presented here in the context of a still poorly 
understood malady provides new scientific insights, which are necessary for the development 
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1. Alzheimer’s Disease 
This chapter aims to provide an introductory snapshot of the Alzheimer’s disease landscape, 
starting from its early beginnings, to the current state of understanding and progress made 
within its research avenues. 
 
1.1  A brief history of Alzheimer’s disease 
The first published case of Alzheimer’s disease in 1907 remains a seminal piece of work in a 
disease which, over a century later, still remains to be cured. In the original publication by 
German psychiatrist and neuropathologist Alois Alzheimer, entitled “Über eine eigenartige 
Erkrankung der Hirnrinde (About a Peculiar Disease of the Cerebral Cortex)”, he described 
behavioural changes in patient Auguste Deter, who at age 51 had begun to experience such 
severe cognitive and behavioural decline, that it was deemed rare, curious and clinically 
unusual. Upon her death four and a half years later, neuropathological assessment would 
reveal that the changes to her central nervous system were clinically distinct from any other 
previously reported disease. Using the then state-of-the-art silver protocol of Bielschofsky 
staining, Alzheimer defined the presence of tangled bundles of neurofibrils, the deposition of 
“peculiar matter” (Figure 1) and the disappearance of numerous ganglion cells in the upper 
layers of the cortex [1,2].  
 
 
Figure 1. Drawings by Alzheimer of Auguste Deter’s brain preparations, showing different tangle 




Given the young age of this patient, the case was subsequently designated as presenile 
dementia. With reports of 4 additional cases presenting similar clinical and 
neuropathological features, Alzheimer’s colleague Emil Kraepelin, a prominent psychiatrist, 
named the disease after Alzheimer, citing the young age, distinct behavioural anomalies and 
severe dementia presented in these cases as the reason to distinguish this condition from 
senile dementia [4].  
 
 
Figure 2. Drawings by Fischer showing detailed staging of plaque pathology as well as tangle pathology. 
Reproduced from Goedert, 2009 [4].  
 
Interestingly, in the same year, a Czech psychiatrist and neuropathologist Oskar Fischer also 
described the presence of neuritic plaques in 12 of 16 cases of presenile dementia. He 
subsequently published a larger study of 56 cases, describing the presence of neurofibrillary 
tangles alongside plaques, in a selection of cases that showed a clinical presentation of what 
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he described as presbyophrenic dementia. Whilst the drawings of the pathologies both 
scientists describe appear remarkably similar, Fischer went on to describe these plaques in 
much greater detail (Figure 2). Some early texts, including one written by Alzheimer, would 
even refer to plaques as “Fischer's plaques”, with presbyophrenic dementia and Alzheimer’s 
disease being used interchangeably [4].  
However, the two scientists did not believe they were describing the same condition, with 
there being much academic debate between the rivals. Alzheimer’s career thrived, until ill 
health brought about his untimely death in 1915, but his legacy carried on [4,5]. With the 
rise of the National Socialist regime, in the late 1930s Fischer’s career declined, ending 
tragically with his arrest in 1941 and death a year later whilst in captivity. Despite his 
significant research contributions, by 1955 much of Fischer’s work on presbyophrenic 
dementia was considered obsolete (until the rediscovery of his work in the 2000s) and 
presenile dementia with plaques and tangles became widely known as Alzheimer’s disease 
(AD) [4,6].  
Primarily only covering the presenile form of dementia when observed under the age of 65, 
the definition of AD was widely discussed and argued by academic scholars throughout the 
20th century. In the 50s, presenile and senile dementias were classified under the umbrella 
term “chronic organic brain disease”, which covered all neurodegenerative conditions 
leading to a diagnosis, owing to the lack of understanding of the diseases underlying 
dementia [5].  Increasing evidence of the presence of plaque and tangle pathology in what 
was then separately known as “senile dementia of the Alzheimer’s type” (when observed 
over the age of 65) emerged from the 60s through to the 70s. By the late 70s, substantial 
evidence of both conditions pointing to a single disease had gathered [7], and given that the 
two conditions were neuropathologically indistinguishable, both presenile and senile forms 
were categorised singly into what is now known as AD [8]. 
This categorisation marked a turning point for AD research. Senile dementia was no longer 
considered a normal by-product of aging. The need for improved understanding and research 
into AD began to grow urgent, particularly after World War II. As life expectancy increased 
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through the 20th century, the incidence of AD also began to rise, bringing with it an ever 
increasing socioeconomic burden. Understanding the aetiology of AD quickly became a 
research priority. By the 80s, discernible scientific and public interest in AD encouraged 
increased funding to be pushed towards this cause [5].    
Today, dementia is a global epidemic. Although it has come a long way since 1907, the field 
of dementia noticeably took time to gain momentum. We now know the pathological 
characteristics as originally described in the case of Auguste Deter, as the hallmark triad of 
AD neuropathology – neurofibrillary tangles, amyloid plaques and neuronal loss. Recent 
rediscovery and reanalysis of material from this historic patient case has confirmed that the 
nature and severity of pathology observed still stands as a typical diagnosis of AD by current 
standards [9]. Whilst the revisiting of this original work may serve as a symbolic 
demonstration of the scientific progress made within the field, the need for this re-
examination of the first known case also highlights the lack of understanding of a complex 
disease, which began as a rare curiosity but became a global crisis.  
 
1.2  Present day prevalence of dementia  
Dementia is a syndrome brought about by one or more diseases, characterised by a range of 
symptoms including memory loss, language problems, psychological difficulties and 
psychiatric disturbances, all of which severely affect day to day living and quality of life for 
sufferers and their caregivers. AD is the most common cause, accounting for approximately 
75% of dementia cases. Several other forms of dementia causing diseases are now known, 
including vascular dementia, dementia with Lewy bodies, frontotemporal dementia, as well 
as mixed dementia where one or more forms exist together. Huntington’s disease, 
corticobasal degeneration, Creutzfeldt-Jakob disease and normal pressure hydrocephalus are 
also known causes but are less common by comparison [10]. 
The World Health Organisation lists AD and other dementias as the 5th biggest cause of 
death [11]. Globally, the incidence of dementia continues to climb. Dropping global fertility 
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rates combined with increased life expectancy is contributing rapidly to overall population 
ageing, resulting in a surge in age-related chronic conditions such as dementia. In 2015, there 
were an estimated 900 million people living over the age of 60, with 46.8 million people 
living with dementia [12]. 58% of these cases come from low and middle income countries. 
It is forecast that the total number of global cases will double every 20 years, reaching a 
staggering 131.5 million by 2050. The World Alzheimer Report estimates that this translates 
to one new case of dementia every 3.2 seconds worldwide [12].  
This predicts an overwhelming global socioeconomic burden. The estimated global cost of 
dementia in 2015 was 818 billion US dollars, accounting for medical expenses, social care, 
residential, nursing and unpaid care costs [12]. Given the rate at which new diagnoses are 
predicted and the cost this will amount to, dementia is fast becoming one of the greatest 
social and healthcare challenges of our time.  
 
1.3  Pathogenesis of AD 
Despite decades of investigation, the root cause of the physiological events leading up to AD 
are still not clear. Research advances over the many decades have given rise to several key 
hypotheses which now provide the framework for AD research today. This section will 
explore these hypotheses, beginning with the macroscopic clinical picture of AD, and then 
briefly delve into the biology underpinning the current understanding of its pathogenesis.  
1.3.1 The spread of pathology in the AD brain 
AD is characterised by the build-up of extracellular amyloid plaques and intracellular tangles 
of tau, subsequently leading to neurodegeneration. During the later and most severe stages 
of the disease, shrinkage of the brain (Figure 3) results in the devastating symptoms observed 
in those suffering from the disease. Whilst these behavioural changes usually manifest much 
later in life, it is now widely believed that the formation of the hallmark lesions of AD occur 





Figure 3. Cartoon of a coronal human brain section illustrating the macroscopic changes that are visible 
in the most severe forms of AD. Image reproduced from the Wikimedia Commons free media repository. 
 
Plaques and tangles have a characteristic pattern of spread through the brain during AD 
pathogenesis. Plaque burden can be highly variable between individuals, but is broadly 
categorised into three neuropathological stages, clinically designated A, B and C (Figure 4). 
In the first stage, the earliest amyloid deposits are seen in the isocortex, mostly limited to the 
frontal, temporal and occipital lobes, with no deposits observed in the hippocampal 
formation. By the second stage, a higher density of amyloid deposits are observed in all 
isocortical regions, with some hippocampal involvement. In the third and most severe stage, 
a very high density is observed throughout the isocortex, with some also present in the 
striatal, thalamic and hypothalamic regions [14]. This neuropathological staging has been 
adapted into a standardised practical clinicopathological scoring system, based on analysis 
of post-mortem brain samples, instigated by the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD). CERAD assessment utilises selected anatomical brain 
regions in its scoring protocol – middle frontal, superior and middle temporal gyri, inferior 
parietal lobule, hippocampus, entorhinal cortex and substantia niagra. A minimum of five 
requisite sections are stained and neuropathalogically scored for plaque density based on 
standardised representative diagrams. The scores are then cross-correlated against age and 




Figure 4. Diagrammatic depiction of the spread of plaques and tangles during AD. Darker shading 
represents density of spread. Modified from Braak and Braak, 1991 [14]. 
 
Tangles have a more distinct pattern of spread, and can be visualised in six stages. Stages I – 
II represent the prodromal phase, where tangles appear in a single layer of the transentorhinal 
cortex with mild hippocampal involvement in the CA1 region. During stages III – IV, the 
severity of the transentorhinal and entorhinal regions increases, with the appearance of ghost 
tangles – the remnants of a neuron containing NFTs. Increased tangle populations in the 
CA1 hippocampal subfield is observed, with an equivalence to the clinically diagnosed stage 
of AD. Stages V – VI sees the infestation of the isocortex and all hippocampal regions to a 
devastating degree, corresponding to fully developed AD [14]. This staging has gained 
prominence in neurology since it was first defined by Braak and Braak, and is now canon in 
AD neuropathological assessment. Braak staging uses three standardised anatomical blocks, 
which capture the anteromedial portion of the temporal lobe, parahippocampal and occipito-
temporal gyri, medial and superior temporal gyri, and the base of the occipital lobe. The 
selected sections are histologically stained, and a score of I – VI is allocated based on the 
topographical spread of tangle pathology. Scoring requires expert knowledge of 
neuroanatomy and familiarity of tangle progression [16], and post-mortem Braak staging is 
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now a routine clinicopathological praxis alongside CERAD scoring, to reach a conclusive 
AD diagnosis. 
Whilst these semi-quantitative scores form the crux of AD diagnosis, it still leaves a 
confirmed verdict only possible post-mortem. Clinical diagnosis relies on an array of 
neuropsychological evaluations to measure cognitive changes, alongside neuroimaging tests 
which currently only reliably detect brain changes that occur in the mid to late stages of the 
disease [17] (discussed in more detail in section 1.7), and the majority of these evaluations 
are triggered only when a patient enters a clinic experiencing cognitive disturbances. AD 
urgently requires robust biomarkers sensitive to the diverse array of lesions and biological 
changes that arise decades before the onset of cognitive decline. To that end, understanding 
the biology underlying the earliest in-life changes in the AD brain is paramount. 
1.3.2 Amyloid 
Since the isolation of amyloid as the main constituent of brain plaques [18], and through 
much of the early years of AD research, amyloid protein biology has taken centre stage in 
understanding AD aetiology. This was strengthened by the proposal of the amyloid 
hypothesis, put forward by Hardy and Allsop in 1991, which described a cascade of events 
leading from the accumulation of plaques to neuronal death (Figure 5) [19].  
The hypothesis postulates that amyloid is the key component of AD pathogenesis. Within 
the scope of this hypothesis, genetic mutations or other environmental factors may give rise 
to altered amyloid processing. This is then thought to result in the accumulation of amyloid 
into plaques - the presumed initiator of AD pathogenesis, followed by the downstream 
phosphorylation of tau and the formation of tangles, consequently causing neuronal damage 
and ultimately manifesting as dementia [19]. A closer look at the biochemical, structural and 





Figure 5. The hypothesised cascade of events leading from Aβ production to dementia. Reproduced from 
Hardy and Selkoe, 2002 [20]. 
 
The classic plaque is formed of a dense aggregate of extracellular of amyloid beta (Aβ) 
peptide, with closely packed abnormal axons and dendrites, or neurites. This deposit is 
usually surrounded by a halo of reactive astrocytes and activated microglia, thus forming a 
complex lesion of multiple cell types, with Aβ at its core [21]. Whilst this paints a classic 
picture of the well-known amyloid plaque, plaques are structurally diverse, and a more 
abundant variant of these deposits are diffuse plaques. These granular Aβ lesions are less 
distinct in structure, lack reactive glia and have far fewer abnormal neurites. Thought to be 
an early form of the plaque, these deposits represent a complex continuum of Aβ aggregation 
during AD pathogenesis [21]. An additional variant of plaque pathology is amyloid 
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angiopathy, where deposition of Aβ occurs in the walls of meningeal and parenchymal 
arterioles, venules and capillaries [22]. 
The Aβ peptide, found consistently in all these plaque variants, arises from the proteolytic 
cleavage of amyloid precursor protein (APP), a membrane glycoprotein associated with a 
range of biological functions including the regulation and maintenance of synapses [23] and 
axonal transport [24]. Proteolytic cleavage of this protein can occur via the non-
amyloidogenic or amyloidogenic pathways. In the non-amyloidogenic pathway, APP is 
cleaved via the enzyme α-secretase, giving rise to a membrane tethered α-C-terminal 
fragment (CTF), and releasing soluble APPα. In the amyloidogenic pathway, APP is first 
cleaved at the N-terminus via  the enzyme β-secretase, also known as beta-site APP cleaving 
enzyme (BACE), found abundantly in neurons, resulting in a β-CTF, which is then 
sequentially cleaved by ɣ-secretase [25]. ɣ-secretase is a complex membrane protein formed 
of four other protein subunits – presenilin (PS), nicastrin, presenilin enhancer 2, and anterior 
pharynx-defective 1, with PS forming the catalytic subunit of this composite enzyme [26].  
The final cleavage step by ɣ-secretase causes extracellular release of Aβ. 
This monomeric Aβ can assemble into a myriad of oligomeric forms as well as fibrils. Fibrils, 
which form the main makeup of Aβ plaques, are large in molecular weight and insoluble. 
Oligomers are heterogenous, assuming medium to low molecular weight forms, and are 
soluble [25]. Whilst the plaque-associated fibrillar form was always thought to be linked with 
neurotoxicity in AD, the oligomeric soluble form is emerging as a close contender, given its 
ability to readily spread throughout the brain and bind to extracellular receptors [27]. The 
formation of these different conformations is facilitated by the very nature of amyloidogenic 
processing by ɣ-secretase. Cleavage can occur at several sites, giving rise to multiple amino 
acid lengths ranging from 37 – 46 residues [25], including the 40 and 42 length isoforms Aβ40 
and Aβ42, which are abundantly found during AD pathogenesis. Aβ42 more readily 
aggregates into fibrils whilst Aβ40 forms a more soluble variant [28]. 
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Whilst the biochemistry of Aβ paints a complex picture of its dynamics, it is key to 
understanding the basis of the amyloid hypothesis, as modifications to amyloid metabolism 
via changes to the APP gene reliably establishes AD pathology. The earliest evidence to 
support this theory came from studying patients with Down syndrome, a condition which 
triplicates chromosome 21, where the APP gene is also located in humans. Virtually all 
patients with Down syndrome go on to develop AD pathology, with the deposition of 
amyloid plaques preceding neurofibrillary tangle formation [29]. A notable phenotype in 
these cases is that the predominant species of Aβ found in dense and diffuse plaques is the 
Aβ42 isoform, whilst the Aβ40 species is more readily detectable in angiopathy, when 
observed in these patient groups [30]. The next evidence backing the amyloid hypothesis 
came from discovery of familial mutations in the APP gene that gave rise to cerebral amyloid 
angiopathy (CAA) [31] and AD [32,33] in Dutch and Swedish populations. Subsequent 
study of mutations in the PS genes revealed that mutations in presenilin 1 (PS1 / PSEN1) 
and presenilin 2 (PS2 / PSEN2) result in an increase in the Aβ42 to Aβ40 ratio [34,35]. 
Moreover, when Aβ species from familial AD cases were assayed, the Aβ42 isoform, known 
for its fibrillar properties and susceptibility to aggregate, was consistently found to be elevated 
[36,37]. This cemented the notion that amyloid biology is fundamental to disentangling the 
complex neuropathology of AD. 
Nevertheless, not everyone with an AD diagnosis carries mutations in these genes, with these 
cohorts only accounting for a small subset of all cases. In addition, amyloid load does not 
correlate well with cognitive impairment in human patients [38]. Furthermore, it is also now 
known that some individuals can maintain a high cognitive reserve during neuropathology. 
This is the brain’s ability to cope when it undergoes damaging changes and compensate 
efficiently to preserve cognitive abilities during pathology [39]. These individuals can live a 
lifetime without an AD diagnosis, despite developing considerable plaque pathology. As 
such, the amyloid hypothesis has come under scrutiny, with research focus being directed 




Though debate over the validity of the amyloid hypothesis prevails, it still forms a central 
dogma of AD aetiology. Within the amyloid cascade, the formation of neurofibrillary tangles 
(NFT) of phosphorylated tau is said to form an intermediary link between plaque formation 
and dementia onset (Figure 5) [20]. Notably, NFT spread reliably precedes the pattern of 
neurodegeneration in AD, and this regional pattern of atrophy is closely correlated to the 
impairment of brain function [14]. Thus, tau is perhaps the molecular candidate closest to 
revealing the precise mechanisms driving neurodegeneration. As such, in recent years, tau 
has emerged as a strong candidate towards illuminating the precise pathophysiological 
cascade of AD.  
Prior to the isolation of tau, NFTs were known as intracellular filamentous aggregates 
composed of a little known polypeptide, structurally termed paired helical filaments (PHF). 
Isolation of PHF from AD brains enabled the biochemical identification of the polypeptide 
within PHF to be microtubule-associated [40], and subsequently, it was identified to be 
abnormally phosphorylated tau protein [41]. In the AD brain, deposition of tau can occur as 
a spectrum, ranging from small PHF and straight filaments in neuronal processes or neurites, 
known as neuropil threads (NT), to larger NFT deposits within the cell body of a neuron, 
which go on to become “ghost tangles” upon death of the neuron. Tau in dystrophic neurites 
can also be associated with amyloid plaques, morphologically recognised as neuritic plaques 
(NP) [42].    
The discovery of mutations in the tau gene leading to frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17) hinted strongly at tau’s causative role in 
the development of neurodegenerative disease. Individuals with FTDP-17, brought about by 
tau mutations, show frontotemporal atrophy, neuronal loss and tau deposits in neuronal and 
glial cells.  In some cases, these tau deposits are identical to the PHF and filamentous forms 
of tau seen in AD [43].  This put tau in the spotlight as the molecule that may hold the key 
to uncovering mechanisms behind neuronal death in AD.  
41 
 
Tau is now fairly well characterised as an intracellular microtubule-associated protein 
(MAP), expressed highly in the axons of central nervous system (CNS), and to a lesser 
degree, in the peripheral nervous system [44]. Microtubules are polymeric proteins that form 
the cellular cytoskeleton. Tau is required for microtubule assembly and stabilisation [45], 
cellular polarity and transport [46]. The microtubule-associated protein tau (MAPT) gene, 
located on chromosome 17, expresses six isoforms of tau in the CNS. These isoforms are 
broadly recognised based on the number of microtubule binding repeat domains they possess 
on the carboxy-terminal – 3R tau, containing 3 repeats and 4R tau, containing 4. The ratio 
of these two tau isoforms is in the brain is roughly one to one, but alterations in this ratio are 
recurrently observed in tau-driven pathologies [47].  
Hyperphosphorylation of tau is another significant feature that is consistently observed in 
tau aggregates in the AD brain. Phosphorylation is a requisite regulatory mechanism in 
protein function and in its regular form, tau is a highly soluble protein, containing up to 85 
phosphorylation sites [47]. Tau phosphorylation is regulated by a variety of kinase and 
phosphatase activity, and it is thought that imbalances in activity between these enzymes can 
result in hyperphosphorylation. In turn, proteolytic cleavage of tau and its misfolding into 
abnormal conformations are also influenced by phosphorylation status. Species of tau that 
are hyperphosphorylated, have undergone cleavage or have altered conformations are all 
found in the brains of several tauopathies  [47]. Thus, the regulation of tau going awry is a 
pivotal component in the neurodegenerative process.   
The isoform and phosphorylation status of tau is crucial to its various biological roles, 
including the regulation of its microtubule binding affinity [48]. It is widely theorised that 
hyperphosphorylation of tau causes it to dissociate from microtubules, and that this unbound 
tau is prone to aggregate [44]. Once dissociated, monomeric hyperphosphorylated tau 
structures gain affinity for each other and begins to oligomerise. Oligomers can assume two 
intermediate forms – a soluble oligomer, and a granular insoluble form [49]. The granular 
oligomer can polymerise even further to form the characteristic fibrils that then aggregates 




Figure 6. Schematic representation of tau oligomerisation and the role of each form in the different stages 
of tau pathology. Reproduced from Takashima, 2013 [49]. 
 
However, it is not NFTs themselves that are considered cytotoxic. The generation and 
characterisation of transgenic mouse models of tauopathy have fostered the understanding 
of tau pathogenesis and driven the tau hypothesis forward by leaps and bounds. One such 
mouse model, known as Wtau-Tg which expresses wildtype human tau, revealed that 
hyperphosphorylated tau alone can cause synaptic loss, resulting in learning and memory 
defects, without the aggregation into insoluble species or neuronal loss [51]. Furthermore, 
mouse models of FTDP-17 that do show neuronal loss reveal the presence of oligomeric 
insoluble tau aggregates. Taken together, these serve as testimony that the intermediate 
oligomeric forms are responsible for neurotoxicity, with tangles being the final tell-tale 
residual marker of neuronal death [49].  
Whilst several mutations are now known to be associated with FTDP-17, a missense 
mutation known as P301L is the most common. This mutation has been studied in depth by 
integration into a transgenic mouse line, known as JNPL3. This mouse line exhibits 
progressive motor and behavioural dysfunction, with a gene-dose dependence on NFT 
accumulation. Additionally, the insolubility of tau species and hyperphosphorylation status 
matches the degree of NFT formation in these mice [52]. Thus, this tau mutation produces 
a phenotype that is strikingly similar to that observed in AD, strengthening the speculative 
role tau may have in its pathogenesis over Aβ.  
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Interestingly, when Aβ42 was injected into the brains of P301L transgenic mice, it 
exacerbated the NFT pathology, normally observed with just the transgene alone [53]. This 
therefore suggests that Aβ still has a steadfast role in accelerating AD pathogenesis via tau-
driven neurodegeneration. Furthermore, much like in the case of the familial mutations 
linked to Aβ pathology, mutations in tau are not requisite for the development of all 
tauopathies. So, whilst tau holds an undeniable role in the neurodegenerative and dementing 
process, it cannot be interrogated in isolation to disentangle AD pathogenesis.  
1.3.4 Neuroinflammation 
Neuroinflammatory changes are a significant observation in AD and the activation of glial 
cells are a known occurrence in its pathogenesis. Microglia, the primary immune cells of the 
CNS, police the brain by scanning for pathogens, cellular debris or insults. They play a key 
role in regulating synaptic remodelling and maintaining neuronal plasticity. Pathological 
insults such as protein aggregation or neuronal death in AD can cause microglia to become 
reactive [54]. Studies of post-mortem plaque pathology and in vitro experimental evidence 
shows that pathogenic Aβ can be engulfed by microglia to facilitate clearance. The binding 
of Aβ to scavenger receptors activates microglia, initiating phagocytosis but also causes the 
release of proinflammatory cytokines [55]. However, the signalling feedback mechanisms 
triggered as a consequence of cytokine release can be damaging to neuronal cells. In addition, 
these neuroinflammatory processes can also contribute to tau phosphorylation [56], further 
contributing to pathology.  
Astrocytes, the cell type most abundant in the CNS, are also known to respond during AD 
pathogenesis. Reactive astrogliosis, that is an increase in the number of astrocytes at the area 
of pathology, is a feature of AD reported in both humans and mouse models [57]. Both in 
vivo and in vitro evidence suggests that astrocytes are recruited in AD for the clearance of Aβ 
– in mouse models of amyloid pathology, astrocytes closest to plaques express neprilysin, an 
enzyme that degrades amyloid [58]. In culture, astrocytes  demonstrate the ability to mobilise 
towards Aβ and degrade it, with this observation also replicated on brain sections in situ [59]. 
This suggests a protective role for astrocytes during pathology. However, astrocyte 
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activation, much like microglial activation, can also trigger cytokine expression, which can 
trigger oxidative stress and cascade into neuronal damage, thereby contributing to 
neurodegeneration [60].  
Thus, the neuroprotective and neurotoxic mechanisms of neuroinflammation are blurred. 
Nonetheless, activated microglia, astroglia and elevated cytokines are a consistent feature of 
AD pathology (Figure 7), and thus form another branch in studying the neurodegenerative 
process in AD and present additional targets in the search for therapeutics. 
 
 
Figure 7. Hypothesised schema depicting the cascade of neuroinflammatory events leading to AD onset. 
Reproduced from Ahmed et al., 2019 [60]. 
 
1.3.5 Cholinergic hypothesis 
The loss of cholinergic neurons of the basal forebrain is another feature of AD. This 
observation lead to the proposal of the cholinergic hypothesis of AD, which postulated that 
the loss of cholinergic neurotransmission held responsibility for cognitive decline observed 
in AD [61]. The cholinergic system is implicated in learning and memory, sleep and 
wakefulness, stress responses and attention – functions in the brain that are all affected during 
AD. Cholinergic neurons are widespread in the brain, and utilises acetylcholine (ACh), a 
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major neurotransmitter in the CNS. ACh is synthesised by choline acetyltransferase (ChAT), 
and when released into the synapse can activates muscarinic receptors or nicotinic receptors, 
triggering the action of the enzyme acetylcholinesterase (AChE) to hydrolyse it and remove 
it from the synapse [62].   
In post-mortem brains of individuals with AD and cognitive impairment, ChAT activity 
declines with increasing NP density. Cholinergic loss also correlates with NFT burden in the 
AD cortex [63]. Rodent studies have recapitulated similar findings, demonstrating that 
lesions in cholinergic neurons increased Aβ deposition and tau hyperphosphorylation [64]. 
Further experimental studies have shown that Aβ accumulation can deplete cholinergic 
synapses [65]. Thus there is ample evidence for cholinergic involvement during AD 
pathogenesis. Whilst the precise mechanisms behind this hypothesis continues to be a topic 
of research interest, the robust loss of cholinergic neurons are a sufficient feature to warrant 
its perusal in comprehending AD aetiology. Furthermore, drugs to target the cholinergic 
system are currently the most prevalent strategy used clinically to improve the cognitive 
symptoms of AD.           
 
1.4  Risk factors for AD 
Advancing age is the biggest known risk factor for AD onset. From the age of 65, the risk 
increases markedly – currently 3% of individuals between the age of 65 and 74 suffer from 
the disease. This jumps to 17% in individuals aged 75 – 84, and even further to 32% in those 
aged 85 and up [66].  
Alongside age, a family history of AD can also be useful to clinicians when trying to identify 
dementia risk. This however is not purely based on a shared genetic makeup predisposing 
individuals to the disease. Common environmental influences and lifestyle factors play into 
inherited disease risk, and thus, studying ancestral history is beneficial in understanding 
familial risk [67]. AD is a chronic disease, and decades of study have teased out a range of 
46 
 
modifiable risk factors, in addition to genetic predispositions, that contribute to disease onset. 
These risk factors are discussed in brief in this section.  
1.4.1 Genetics 
Whilst genetics play an indisputable role in familial AD cases, it is useful to parse if genetic 
risk patterns are polygenic – where generationally shared environmental factors act together 
with genetic variations to increase sporadic disease risk, or if they follow Mendelian genetics 
– where a mutation in a single gene that is passed on, causes the familial form of the disease. 
Notably, it is only a small number of familial cases that account for AD, with just over 500 
families in the global population of AD sufferers reported to have known disease-causing 
mutations [67]. 
The most extensively studied mutations for familial AD are those in genes that influence Aβ 
metabolism – APP, PSEN1 and PSEN2. Mutations in any of these three genes, or duplication 
of APP, results in autosomal dominant AD in 50% of affected cohorts, usually manifesting 
as an early-onset form of the disease. Symptoms become apparent as early as 30 – 50 years 
of age in carriers of PSEN1 mutations. APP mutation carriers typically have an age of onset 
between 45 and 60, and PSEN2 mutation carriers display a wider range of onset age. Whist 
mutations in these three genes can have varied mechanisms of abhorrent Aβ processing, a 
commonality observed in these cases is that they increase Aβ42 production, thereby altering 
the Aβ42: Aβ40 ratio [68]. 
A significant genetic risk factor for sporadic AD is the apolipoprotein E (APOE) gene. APOE 
is a glycoprotein which facilitates lipid metabolism by receptor-mediated endocytosis of 
lipoproteins, and in the brain, it is mostly expressed in astrocytes and some microglia  [69]. 
Single nucleotide polymorphisms (SNPs)  – a single-base mutation that naturally gives rise 
to variants of genes in the human genome – can influence the level of risk a gene can impose. 
The APOE gene has three common SNPs that give rise to variants of the gene, or alleles – 
designated ε2, ε3 and ε4, which encode the isoforms APOE2, APOE3 and APOE4. 
Possession of one ε4 allele increases the risk of AD up to 3 fold, whereas possession of two 
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can increase the risk up to 12 fold. Conversely, the ε2 allele is known to be associated with 
reduced AD risk  [69]. The precise pathogenic mechanisms underlying APOE in AD are not 
fully understood, but clinical and experimental evidence would suggest that the ε4 allele 
increases the propensity of Aβ to accumulate by running interference with APP trafficking, 
encouraging Aβ oligomerisation or impairing Aβ clearance [70]. Some research also 
indicates that APOE4 is neurotoxic and may encourage NFT formation by influencing levels 
of tau phosphorylation. Genetically, APOE ε4 poses the strongest susceptibility to late-onset 
AD, with over 50% of sporadic late-onset cases being influenced by APOE allele status [70]. 
This suggests that other genetic components and environmental influences still account for a 
large proportion of sporadic AD cases. However, given the strong predisposition to disease 
onset, APOE and its mode of action in AD pathogenesis is of significant interest in disease 
understanding and drug discovery.  
Interestingly, APOE is also a substrate for a receptor called “triggering receptor expressed on 
myeloid cells 2” (TREM2), expressed on microglia [71]. TREM2 has more recently been 
identified via genome-wide association studies (GWAS), as a candidate gene whose variants 
have a strong association with increased risk for late-onset AD [72]. Heterozygous possession 
of TREM2 variants can confer risk to AD to a similar degree to those carrying one copy of 
APOE ε4 [73]. Whilst the biology underlying these variants and their contribution to AD 
pathology is still under rife investigation, it is now well established that TREM2 variants can 
contribute to a 2 – 4 times increase in AD predisposition [74].  
Mutations for tau have not been implicated in AD risk per se, but MAPT mutations have 
been widely studied in related dementias such as frontotemporal dementia, particularly 
FTDP-17. Variants in MAPT have also been identified in families who clinically present with 
an AD phenotype, mixed dementia or have other known AD risk alleles, but there is 
insufficient data from population studies to conclusively identify genetic tau variants as a risk 
for pure AD [75,76]. Nonetheless, extensive investigation of these mutations has bolstered 
the field of tau biology, and in doing so, continues to provide crucial clues towards advancing 
the understanding of AD pathogenesis.  
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With the advent of GWAS and whole-exome sequencing technology, the potential to 
uncover more gene variants contributing to AD risk has been enabled. These new advances 
could help further our understanding of both polygenic and Mendelian genetic risk patterns 
for AD, and the identification of new gene variants could also divulge novel mechanistic 
links to the pathogenic pathways of AD. 
1.4.2 Modifiable risk factors 
Sporadic AD cannot be fully explained by genetic factors, and as such, a range of other 
modifiable risk factors have been identified through population studies. As yet, no single 
factor has been identified as one that could reverse or halt AD. But recognising these 
contributors to disease risk is helping the AD research community make evidence based 
recommendations to lifestyle changes in an effort to reduce AD risk in populations. Meta-
analyses across populations have enabled the identification of a range of modifiable risk 
factors. 
The strongest modifiable risk factor for AD and other dementias is cardiovascular health. 
Circumstances that are detrimental to cardiovascular health all contribute to increased 
dementia risk, which include smoking, diabetes, hypertension and obesity [66]. This risk can 
be modulated by lifestyle changes that are protective to heart health, which consequently also 
protect brain health. Physical activity is one such factor that is now known to be modestly 
protective against AD and cognitive decline. The exact nature, duration and regimen of 
activity that is most effective in reducing AD risk remains to be clarified, but it is thought 
that the mechanistic link between increased physical activity and reduced AD risk lies 
contemporaneously with reducing the risk of metabolic conditions such as cardiovascular 
disease and diabetes [77]. In a comparable manner, nutrition too has been reasonably 
recognised as a protective factor in AD prevention. The mechanisms of protection are 
predominantly attributed to improved heart health and reduced risk of diabetes arising from 
diets rich in fruit, vegetables, whole grains, fish, chicken and nuts, and low in saturated fats 
and sugar [66,78]. Moderate alcohol intake has also shown some protective effect against 
AD. The direct role this plays in reducing risk is unclear, but it must be noted that this is 
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outweighed by the damaging health effects that are brought about by excessive alcohol 
intake, which include neurotoxicity and a higher predisposition to dementias [79]. 
A strong association between the level of education and dementia risk has also been 
established. Individuals with fewer years of formal education are at higher AD risk than those 
with more years of education [80]. A further association between education level and 
socioeconomic status is also linked to AD risk. People from lower socioeconomic 
backgrounds are less likely to have good access to healthcare, tend to suffer poorer diets and 
are less likely to take up physical activity, factors which then predispose them to 
cardiovascular disease and diabetes risk, which therefore increases their AD risk. Level of 
education being protective is also believed to be in part due to a higher level of cognitive 
reserve in those who remain in education for longer, as well as in those who take up 
professions that are mentally engaging [66]. Thus, this presents an ostensive protective factor. 
But it must also be noted that though AD sufferers with higher cognitive reserve and more 
education have a delayed clinical age of onset, they can experience faster decline in cognitive 
ability post diagnosis [39].  
On a related theme, cognitive training activity has similarly been explored for protective 
effect against AD. Whilst evidence from observational studies would suggest that engaging 
in cognitive activity lowers AD risk, the results are not clear cut. Whether interventional 
cognitive training is an effective strategy for AD remains inconclusive. Nonetheless, it is 
recognised that engaging in physical and social activities that are mentally stimulating can 
be beneficial in maintaining a better quality of life for older adults [81].  
As we are a social species, it is perhaps unsurprising that remaining socially engaged 
throughout life is vital for maintaining brain health. Social engagement is linked to a reduced 
risk of AD later in life, possibly by building and maintaining cognitive reserve [66].  The 
purported mechanisms through which this is protective is unknown, however, there is 
evidence demonstrating that social isolation and loneliness is associated with poorer 
cognition [82] and increased AD risk later in life [83], and that amyloid burden increases in 
cognitively normal older adults experiencing loneliness [84]. Hearing loss in older adults is 
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also known to accelerate cognitive decline, in part by increasing vulnerability to social 
isolation and exhausting cognitive reserve [85]. This thus highlights social isolation as a 
multifaceted risk factor for AD.  
Head injury is another factor that can increase the risk of dementia. Clinically known as 
traumatic brain injury (TBI), it was first identified as a risk in the early 90s after studying 
boxers who began to show neurodegenerative symptoms [86]. More recent evidence shows 
that mild TBI and repetitive concussions sustained from contact sports or warfare can 
precipitate a neurodegenerative condition known as chronic traumatic encephalopathy 
(CTE), which is clinically indistinguishable from AD. CTE is classified as a tauopathy, 
featuring NFTs and NPs, but can only be diagnosed neuropathologically on post-mortem 
examination [87]. 
Sleep disturbances are common in patients with mild to moderate AD, with around 25 – 40% 
experiencing this symptom. Experimental evidence alludes to Aβ imbalances brought about  
by disrupted sleep physiology as the mechanistic link here. [88]. Furthermore, sleep 
fragmentation has been implicated in faster cognitive decline and increased risk for AD. This 
implicates sleep disorder as a feature underlying the degenerative process, presenting it as a 
risk factor for AD [89]. Thus, sleep research offers an additional interventional avenue for 
AD research.  
The factors presented above are not an exhaustive list of risk factors for AD onset. Additional 
factors including depression, statin use, nutritional supplements and several others [90] have 
been investigated within this context, but aren’t discussed here. Nonetheless, with increasing 
population studies across international cohorts, the list continues to grow. Overall, the 
overarching evidence would suggest that a healthy approach to aging is the key to reducing 




1.5  Mouse models 
AD research has taken giant strides with the advent of transgenic mouse models of the 
disease, which have enabled researchers to dissect out the various pathophysiological 
pathways and study them in isolation as well as in tandem. Transgenic technology has been 
developed and honed over decades and generating transgenic models of disease in mice offers 
several advantages over other model organisms. Mice share almost 99% of the genome with 
humans, and have comparable anatomy, physiology and development [91]. The mouse 
genome has also been well characterised by international large-scale sequencing efforts, and 
this, combined with the power of transgenic manipulation of the genome, makes the 
laboratory mouse a powerful research tool [91]. Furthermore, mice are relatively inexpensive 
to maintain and have quick lifespans enabling cost-effective acceleration of research output. 
Over a hundred different lines of mouse models are currently in use amongst the AD research 
community [92]. This not only represents the complexities of  studying human disease in a 
separate host species, but also demonstrates the value of this approach in understanding 
disease aetiology and drug discovery. An ideal transgenic model organism requires the 
disease to have a genetic origin, as well as have fairly well characterised pathology, 
physiology and behaviour in humans that can be recapitulated for in depth experimental 
exploration [93]. As such, AD mouse models largely rely on the known mutations in AD-
causing genes as well as the known features of plaque and tangle pathology to recapitulate 
clinical AD-like phenotypes in mice.  
The APP, PSEN1 and MAPT gene mutations identified in human AD cohorts feature heavily 
in AD transgenic models, with PSEN2, APOE and TREM2 mutants also providing valuable 
alternative models for the mechanistic exploration of the AD pathophysiological cascade. 
Mutant forms of these genes have been used in isolation to generate single gene transgenic 
models, as well as in combination for multi-transgene models based on the research question 
the model aims to address [92]. In the work presented in this thesis, a selection of these 
models have been utilised. These are described in brief below and discussed further in the 




Figure 8. Cartoon depicting an example of a transgenic mouse model. Here, the transgenic constructs 
that generate and modulate tau pathology in the rTg4510 mouse model are shown. This model is 
generated by crossing a transgenic mouse containing the P301L human tau mutation, with a second 
transgenic containing a transactivator under the CaMKIIa promoter which drives forebrain expression 
of mutant tau in the bigenic progeny. Expression of this construct can be halted by tetracycline analogue, 
Docycycline.  
 
The rTg(tauP301L)4510 (rTg4510) mouse model is a model of tauopathy that has 
prominently been used in the laboratory study of tau physiology. The model is generated out 
of a transgenic line which carries the human MAPT gene harbouring the P301L mutation, 
crossed with a second transgenic line that carries a forebrain specific expression promoter, 
calcium/calmodulin-dependent protein kinase type II alpha (CAMKIIα). The bigenic 
progeny of these two mouse lines therefore results in robust overexpression of human mutant 
tau throughout the forebrain. The genetic design of this line also enables the systemic 
modulation of transgene expression by manipulating the tetracycline-controlled 
transactivator built into the transgenic construct; forebrain expression of mutant tau can be 
halted using the tetracycline analogue doxycycline [94] (Figure 8). The model rapidly 
develops insoluble hyperphosphorylated tau species, accumulates NFTs, and exhibits 
neuronal loss, gliosis and atrophy in an age-dependant pattern, with impairments in 
cognition and behaviour which are phenotypically relatable to AD [95]. 
Incorporating the earliest familial APP mutations into transgenic lines has advanced the 
study of Aβ  pathology, and one such line is the J20(PDGF-APPSw,Ind) (J20) [96]. This 
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transgenic line incorporates the Swedish APP mutation as well as an additional APP mutation 
identified in Romanian kindreds, first isolated by a research group in Indiana. The transgene 
is driven by a neuron-specific promoter called platelet derived growth factor (PDGF), and 
the model expresses elevated levels of Aβ and robust plaque pathology, with gliosis, some 
neuronal loss in the hippocampus but no gross atrophy. Learning and memory deficits are 
also observed in J20 mice [97], thus enabling the study of the cognitive and pathological 
changes of AD solely driven by plaques, without being confounded by aggressive tangle-
driven neurodegeneration.  
Whilst these and other murine models continue to propel the understanding of AD aetiology, 
overexpression models have faced criticism due to their propensity to drive phenotypes in an 
artificial way, thus making data interpretation challenging.  These criticisms are fuelling the 
evolution of new models to address these challenges. One such line is the APP NL-F Knock-
in (NL-F). This mutant line combines the Swedish mutation along with an APP mutation 
from a patient of Iberian ancestry, but is only expressed at endogenous levels [98]. The 
phenotypes seen in this model are only driven by the combined effects of the two mutations 
and avoid being confounded by overexpression. The resulting mouse model develops cortical 
plaque pathology at an early age, but does not show cognitive deficits till later in its lifespan, 
thus recapitulating a more realistic disease progression. Generation of such innovative lines 
is unlocking new potential in the use of transgenic technology to uncover the complex nature 
of AD pathogenesis.  
But newer mouse lines have not devalued the use of long-existing transgenics, which still 
prove useful today. One of the earliest overexpression models, known as Tg2576, which 
incorporates only the Swedish mutation [99], is still widely in use in AD basic science 
research today. This line displays a similar phenotype to the J20, but progresses plaque 
pathology at a slower rate. Such utilisation of various transgenic lines targeting different 
aspects of pathology with differential progression, highlights the pressing need to target the 
cascade of AD pathophysiology with fine detail in order to fully comprehend a disease which 
is still not fully understood.  
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Scores of other mouse models that replicate tauopathy, amyloidopathy and the other 
molecular and cellular characteristics of AD pathology continue to be the subjects of 
extensive research investigation [100]. It must be noted however, that no mouse model exists 
that fully recapitulates all neuropathological features, behavioural changes and progression 
of AD in one, and has thus proven to be an added challenge in the search for candidate 
therapies that can interfere with the pathophysiological cascade.  
  
1.6  Current approaches to therapeutics  
The pursuit of a disease modifying therapy for AD has been vigorous and met with many 
challenges and failures. This is owing to the fact that we still do not fully understand the 
complete picture of AD pathogenesis, nor have we conclusively identified the root cause of 
the disease. Drugs that are currently in use in the clinic only help alleviate the symptoms of 
mild to moderate AD, but none exist that fully cease the neurodegenerative process.  
204 candidate therapeutics for AD have entered investigative trials to date, of which 78 are 
already discontinued. Five of these are currently approved for use by the Federal Drug 
Administration (FDA), all of which target neurotransmission – Donepezil, Galantamine, 
Rivastigmine and Tacrine which target the cholinergic system by inhibiting AChE, and 
Memantine an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors [101]. 
During AD development, AChE activity increases, thereby hydrolysing an excess of ACh, 
causing a decrease in the availability of this neurotransmitter at the synapse, and this 
impairment at synapses manifests as cognitive deficits observed in patients [102]. AChE 
inhibitors act by targeting this process, thus facilitating symptomatic relief by increasing ACh 
availability.  
NMDA receptors on the other hand work by reducing neurotransmitter activity. Whilst this 
may seem counter intuitive, NMDA receptor overactivity is thought to contribute to the 
neurodegenerative process by becoming neurotoxic – a phenomenon known as excitotoxicity 
[103]. Normally, NMDA receptors are implicated in synaptic plasticity. They act by binding 
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glutamate, a potent neurotransmitter, which then results in postsynaptic depolarisation via 
ionic sodium (Na+) and calcium (Ca2+) influx [104]. During AD, it is thought that 
overactivity of NMDA glutamate receptors causes an excess of Ca2+ influx, to a level which 
triggers cellular injury or death [103]. Thus, NMDA glutamate receptor antagonists mode of 
action is to reduce excitotoxic neurodegeneration. This is a challenging strategy, as 
therapeutics that block synaptic neurotransmission have to act such that they do not then 
cause further neurological adverse effects in trying to prevent excitotoxicity. Memantine is 
the only clinically used drug that uses this strategy, and it is designed such that it only blocks 
the NMDA receptor once the receptor has been activated for a long time by an excess of 
glutamate [103]. 
Whist these strategies are a step in the right direction, the holy grail of AD drug discovery 
would be one that ameliorates Aβ and tau accumulation. Numerous disease modifying 
therapies targeting these hallmark proteins have entered drug discovery pipelines but to little 
or no avail.  In 2018, 26 candidates reached Phase III trials, of which 14 aimed to target 
amyloid and one was aimed at tau [105]. This not only provides a snapshot of the challenging 
landscape of AD drug discovery, but also alludes to the ebb and flow of therapeutic 
approaches to AD.  
 
Figure 9. Summary of drugs in Phase III trials targeting mechanistic pathways of AD. Reproduced 
from Cummings et al., 2018 [105]. 
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In the search for a disease modifying therapy, amyloid research still dominates the AD drug 
discovery arena (Figure 9) [105]. Aβ targeted therapies aim to intervene at the early stages of 
the amyloid cascade by interfering with production, preventing aggregation or reducing 
deposition [106]. As such, targeting APP cleavage has been of significant focus, either by 
inhibiting β- or ɣ-secretase activity or upregulating the non-amyloidogenic pathway via α-
secretase activity. Targeting α-secretase may seem a viable strategy, however, more APP is 
processed via this non-amyloidogenic pathway, and several other substrates for this enzyme 
exist. Thus this pathway would need to be upregulated significantly to elicit a therapeutic 
effect, and the consequence to its other substrates are unknown. Whilst inhibiting ɣ-secretase 
activity seems more feasible, and has been approached, it is now known that several other 
substrates for ɣ-secretase are vital components for development, thus posing toxicity issues 
and preventing its therapeutic use [107]. This leaves β-secretase as the front runner in this 
strategy, and several BACE inhibitors have entered therapeutic trials. However, this is not 
without its challenges – numerous previous BACE trials were halted from not passing safety 
standards, or due to lack of therapeutic effect in mild to moderate AD.  The focus of using 
BACE inhibitors is thus now shifting towards its use in asymptomatic individuals at risk of 
developing AD [108]. 
Immunotherapy approaches have also shown promise in targeting Aβ, with much of the 
early evidence coming from active immunotherapy approaches in mouse models, where a 
synthetic version of the peptide is used to induce an immune response against endogenous 
Aβ. Immunotherapy against Aβ by anti-amyloid antibodies is thought to work via three 
different approaches – by microglial activation and phagocytosis, by preventing aggregation 
or by sequestering Aβ and draining it into circulation [107]. Initial trials in humans were 
halted due to adverse effects brought about by active immunisation in 6% of subjects, with 
autopsy of two of these cases revealing an autoimmune T-cell response, thought to arise from 
the C-terminus region of the peptide. However, a further three autopsies from these trials 
also showed no cortical plaques thus providing some confidence in this therapeutic approach 
[106]. The next generation of immunotherapy candidates are being designed to take a passive 
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immunisation approach using monoclonal antibodies against Aβ, or by modifying the 
peptide conformation to overcome autoimmune responses associated with the active 
approach [109]. Whether these approaches will be fruitful are yet to be revealed, with several 
vaccines still in trials. 
Tau is emerging as a more lucrative target for AD drug development in recent years, 
particularly with the failure of large numbers of amyloid-focussed therapies. This is perhaps 
unsurprising given the indisputable role it plays in the neurodegenerative process, as tau 
burden in AD and other dementias correlates well with clinical measures [38]. Early 
approaches to tau targeted therapy focused on manipulating kinase and phosphatase activity 
to circumvent hyperphosphorylation, preventing aggregation of tau [106] or restabilising 
microtubules. Success with these strategies waxed and waned, and eventually proved 
unfruitful, so more recently, immunotherapy against tau has gained popularity. Tau 
antibodies may act extracellularly by sequestering aggregates and activating microglial 
phagocytosis, thus preventing further spread, or may also bind intracellularly and promote 
removal via lysosomal degradation. Animal studies have shown promising results with both 
active and passive immunisation strategies, and several tau vaccines are entering trials on 
this basis [110]. However, it is too early to tell if these approaches will yield the desired 
outcome, particularly as translating therapeutic improvements from animals to humans is 
challenging.      
Developing a drug to halt AD is an arduous task. The ideal candidate needs to be a small 
molecule capable of crossing the blood-brain barrier, not produce deleterious effects, be able 
to reverse or halt the neurodegenerative process and alleviate cognitive and neuropsychiatric 
symptoms. It is likely that a combination approach tackling multiple aspects of the disease 
may be efficacious and this can only be elucidated once ongoing trials are complete. There 
is also a shift in focus towards targeting the prodromal phase of AD, which may be a more 
prudent strategy. But this requires reliable markers for screening and thus highlights the 
urgent need for robust biomarkers that are sensitive to the earliest cellular and molecular 
changes in the AD brain. 
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1.7  Biomarkers for diagnosis 
In the original clinical criteria, biomarkers did not play a part in AD diagnosis. Without the 
use of biomarkers, diagnosis was tiered – the highest tier, “definite AD”, was only designated 
upon post-mortem neuropathological confirmation. During life, the diagnoses allocated were 
“probable AD”, described by amnestic disorders with gradual functional and cognitive 
impairment, or “possible AD”, the lowest of the three tiers, identified as an atypical amnestic 
patterns with mixed aetiology. These clinical diagnoses took into account the patient’s 
medical history, along with measures of cognition, social function, depression and anxiety, 
assessed using the Mini Mental State Examination (MMSE), the Blessed Dementia Scale, 
the Hamilton Depression Scale and the Present State Examination. In addition, further 
sensory and motor tests, as well as psychiatric evaluations were performed to eliminate all 
other causes, thus reaching a diagnosis of AD by process of elimination [111].  
With the identification of AD as a continuum of disorders, the term “mild cognitive 
impairment” (MCI) was later introduced. This categorisation identified those individuals 
who fell in the symptomatic spectrum between normal aging and probable AD, thus 
signifying AD at its prodromal phases. Individuals with MCI show some neuropathological 
features of dementia diseases, such as NFTs and atrophy, and is thus thought to be predictive 
of AD onset [112]. Updates to the diagnostic criteria aimed to improve the accuracy of AD 
and MCI diagnoses, and thus introduced the use of biomarkers alongside the battery of 
neuropsychological measures. Its use is now recommended in those who approach the 
criteria for probable AD [17].  
An ideal biomarker is defined as a reproducible measure that can accurately quantify 
physiological changes brought about by disease. Ideally, the perfect AD biomarker would 
enable the detection of the disease prior to the significant loss of neurons, thus enabling 
beneficial interventions to halt the disease. Biomarker use in AD diagnosis currently takes a 
two-pronged approach – one looks at the markers of amyloid, measuring levels of Aβ42 in 
cerebrospinal fluid (CSF) and amyloid positron emission tomography (PET) imaging. The 
second looks more broadly at markers of neurodegeneration, by measuring CSF tau, 
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including levels of total tau (T-tau) and phosphorylated tau (P-tau), 18fluorodeoxyglucose 
(18F-FDG) PET and structural magnetic resonance imaging (MRI) [17]. Patient data from 
those recruited into large scale longitudinal human cohort studies, such as the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network 
(DIAN), have enabled researchers to track and detect the patterns of these biomarkers in 
sufferers and those predisposed to AD [113,114]. Such studies have revealed that biomarker 
changes accelerate during the initial stages of  the pathology and decelerate in the later stages 
of the disease, thus assuming a sigmoidal trajectory [114]. The use of multi-factorial analyses 
of data from these cohorts have continually facilitated the understanding of the temporal 
specificity of discrete biomarkers with disease progression [115]. As such, a  model of the 
pathological cascade against biomarker detectability has been proposed, demonstrating the 
order of sensitivity against disease progression (Figure 10).  
 
Figure 10. An updated model of AD biomarker detection. Using data from ADNI, each biomarker is 
modelled to a sigmoidal trajectory as it changes from the  healthy state to AD. This model reveals that 
vascular dysfunction is the earliest change, followed by Aβ deposition and metabolic dysfunction. CSF 
biomarkers come later in the temporal cascade of pathophysiological events and increase in sensitivity 
with disease progression (HC = healthy controls; EMCI = early MCI; LMCI = late MCI; LOAD = 




1.7.1 CSF biomarkers 
CSF for diagnosis is extracted via lumbar puncture, using a needle placed into the 
subarachnoid space between the 3rd and 4th lumbar vertebrae. The technique is safe and 
relatively quick, but can induce a mild post-lumbar puncture headache in some cases [116].  
Meta-analyses of vast datasets from human cohort studies have provided validation for 
numerous fluid biomarkers, including the core CSF measures, Aβ42, T-tau and P-tau, which 
have up to 90% accuracy for detecting AD and MCI [117]. 
CSF Aβ42 decreases with AD progression. As this decrease correlates well with increased 
parenchymal amyloid counts, it is discernibly hypothesised that Aβ42 accumulation into 
plaque pathology is responsible for the decline of this species in CSF. Low CSF Aβ42 is also 
concordant with amyloid PET positivity in AD patients. Although Aβ40 is relatively 
unaffected, the ratio of Aβ42:Aβ40 has particularly proven itself a strong biomarker for AD 
and is usually used in conjunction with Aβ42 [118]. CSF T-tau and P-tau on the other hand, 
increases with AD. CSF T-tau is taken as a measure of neuronal damage, as this metric is 
also elevated in other conditions such as stroke and TBI, where it also correlates to the degree 
of tissue damage. P-tau, a measure of phosphorylation status, correlates reliably with NFT 
pathology and hippocampal atrophy [116]. 
More recently, a class of phosphorylated neuronal proteins known as neurofilaments are 
emerging as promising markers for axonal damage . Neurofilaments are cytoskeletal proteins 
made of  three subunits. Elevated levels of the neurofilament light chain (NfL) subunit are 
reliably detectable in AD compared to controls. This may provide a new and robust CSF 
biomarker for AD [117], but at present is only used as a research tool.  
1.7.2 PET  
The development of in vivo imaging technologies sensitive to the pathological features of AD 
provide a rare yet crucial opportunity to visualise the pathogenic features of AD during the 
lifetime of a patient, which previously was only possible at autopsy. Nuclear imaging 
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techniques such as PET do so by highlighting regions of pathology by means of systemically 
administered radioactively labelled compounds, sensitive to the target features of pathology.  
Pittsburgh Compound B ([11C]PiB) is one of the earliest PET ligands developed for Aβ 
visualisation, and is still in use today [119]. [11C]PiB  has high affinity to fibrillar forms of 
amyloid and thus recognises vascular and parenchymal plaque pathology. Increased uptake 
of [11C]PiB is seen in the in cortical regions as well as the cingulate gyrus, precuneus and 
striatum, thus following a characteristic pattern of disease spread which also corelates well 
with plaque distribution at autopsy. [11C]PiB can also predict the conversion of MCI to AD 
with high specificity, thus providing an early indicator of disease onset [120].  
But the carbon-11 radionucleotide gives [11C]PiB a relatively short half-life (20 minutes) 
[121], and so it is impractical for routine use, as it requires cyclotron technology to be in close 
proximity to scanning sites. This has paved the way for the development of durable ligands 
with longer half-lives. [18F]Florbetapir is one such ligand which is conjugated to fluorine-18. 
With a longer activity (100 minute half-life) [121], it enables sufficient time for transport and 
handling, thus facilitating widespread use [122]. [18F]Florbetapir has slightly less sensitivity 
compared to [11C]PiB, but reliably replicates the detection specificity observed with [11C]PiB, 
and its binding to fibrillar Aβ has been confirmed by autopsy [123]. Development of 
fluorinated compounds are gaining popularity in neuroimaging, and an array of other 
compounds continue to enter this research domain, namely, [18F]florbetaben, 
[18F]flutemetamol, [18F]AZD4694 and [18F]FIBT all of which show promise as agents with 
high specificity to AD [120]. 
18F-FDG PET has also long been used in AD research and quantifies glucose metabolism in 
the brain, which is reduced during AD due to synaptic decline. Thus it provides an indirect 
measure of  synaptic activity. Hypometabolism measures using 18F-FDG have up to 70% 
specificity in detecting AD from healthy controls, and through the differential stages of the 
disease. During the early stages, it is observed in the posterior cingulate cortex and 
precuneus, later in the posterior temoro-parietal cortex and finally in the frontal cortex during 
the most advanced stage. 18F-FDG can also reliably predict the progression of MCI 
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individuals to AD, as those subjects that progress to AD show lower uptake in the temporal 
and parietal cortices [120].  
The development of tau PET ligands however, has been faced with a plethora of challenges. 
Primarily, the predominant intracellular location of tau requires a ligand to be able to 
overcome the blood brain barrier (BBB) and then also cross the cell membrane. Tau also 
assumes multiple isoforms, which undergo various post translational modifications and these 
pose challenges to the structural design of a viable molecule. Furthermore, tau is lower in 
concentration compared to Aβ, can assume similar structural conformations to Aβ sheets  
and is also found in white matter regions, thus posing multiple complications with binding 
specificity [124].  
The first generation of tau PET tracers that overcame these hurdles were fluorinated 
quinoline derivatives, collectively known as THKs, and although they showed good affinity 
to tau, the use of these agents were continually hampered by white matter binding and off 
target binding [125]. Subsequent development of carbon-11 conjugated phenyl/pyridinyl-
butadienyl-benzothiazoles/benzothiazolium (PBB) tracers have achieved greater success. 
[11C]PBB3 has high affinity for dystrophic neurites and NFTs, is retained in the medial 
temporal region, precuneus and frontal cortex and correlates well with cognitive decline 
[126]. Fluorinated versions of this compound are currently in development. Another 
fluorinated tracer that has made strides in tau neuroimaging is a molecule called AV-1451. 
The spatial distribution of [18F]AV-1451 localises well to tau deposition in a way that can be 
linked to Braak staging, thus enabling the progressive tracking of disease severity [125].   
However, development of these novel ligands is not without its challenges. It is recognised 
that each of these ligands have differential affinity to the various sub species of tau associated 
with different proeteinopathies – for instance, THKs recognise NFTs which contain both 3R 
and 4R tau, but are less competent at recognising tauopathies which only have one of these 
species, unlike PPBs which detect all tau compositions [127]. Furthermore, off target binding 
is not fully resolved even in these ligands. These issues call into question the veracity of tau 
PET as a biomarker, and validation of tau PET ligands in further longitudinal studies is 
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crucial for its advancement into the clinic [128]. Thus, the utility of tau PET remains as  a 
developmental research tool for now.  
1.7.3 MRI 
MRI has long served as a reliable and useful diagnostic tool to assess macroscopic brain 
changes that occur during mid and severe stages of AD. The regional and progressive pattern 
of atrophy measurable by MRI reliably mirrors the cognitive and behavioural changes 
reported in clinic [129]. The earliest changes are seen in the entorhinal cortex, hippocampus 
and posterior cingulate cortex, correlating to memory impairments, whereas the later stages 
see atrophy take hold of the temporal, parietal and frontal cortices, reflecting the observed 
deficits in language, and behaviour [130].  
Hippocampal and medial temporal lobe atrophy measures taken using structural MRI are 
consistently calculable with roughly 80% specificity for both AD and MCI, with 
hippocampal volume also correlating well with NFT Braak staging. Additionally, rates of 
change of cortical regions as well as ventricular enlargement, measurable by MRI, correlate 
well with the cognitive changes clinically observed. It is important to note that the various 
structural markers obtainable by MRI are differentially useful for the various stages of disease 
progression. Although measures have sensitivity to the prodromal stages of the AD 
continuum, markers of  Aβ pathology still provide greater sensitivity to the early stages. 
These markers plateau later during the diseased state, and regional differences in atrophy 
then provide better information on disease progression (Figure 11) [131]. Although these 
macroscopic changes observed by MRI  provide a valuable clinical biomarker, the use of this 
modality to probe the microstructural and functional changes that precede the macroscopic 
changes can profoundly increase its potential to provide a more sensitive biomarker for early 
detection. To this end, MRI is profusely pursued in AD biomarker research. 
Hippocampal volume reductions have been a predominantly useful measure in assessing 
those with MCI and genetic predispositions to AD. But the predictive power of hippocampal 
volume changes can be markedly strengthened by using hippocampal subfield 
measurements. In particular, the CA1 region of the hippocampus has consistently been found 
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to be reduced in volume in MCI subjects compared to healthy controls, and is able to predict 
the conversion from MCI to AD.  Probing subregions of the brain most vulnerable to AD 
therefore increases the effectiveness of MRI as an early biomarker, as this could detect subtle 
brain changes up to a decade before clinical onset [132].  
 
 
Figure 11. Representation of disease progression against diagnosis by MRI. The preclinical stages are 
better diagnosed with non-MRI markers, whilst the clinical stages have sensitivity to disease stage. 
Reproduced from Frisoni et al., 2010 [131]. 
 
MRI has also gained repute in detecting microstructural changes that occur in the brain 
during neurodegenerative disease. White matter lesions are a commonly observed feature of 
AD, believed to be brought about by axonal loss and demyelination [133]. Diffusion tensor 
imaging (DTI), which measures the Brownian motion of water, is particularly useful in 
following these white matter changes brought about by pathology. In myelin fibres, this 
pattern of movement is restricted to the structural tracts of the  tissue. The consequential 
change and directionality of diffusion can be quantified using DTI [134]. Disarray of white 
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matter tracts driven by AD pathology can therefore be assessed. At present, MCI can be 
differentiated from AD using DTI, but the sensitivity does not exceed that attained from 
volumetric measures [135], and so while it can add profound diagnostic value to other 
biomarkers, it may not be a steadfast marker specific to AD in isolation.  
Being the most energy intensive organ in the body, the brain requires good blood flow to 
maintain brain health. Significant evidence implicates vascular pathology and cerebral 
hypoperfusion as a causative element in the pathogenies of AD [136]. Thus, it is pertinent to 
explore cerebral perfusion as a marker. MRI measures of cerebral blood flow (CBF) have 
been widely explored in AD patients and they consistently show a reduction in CBF by 
approximately 40%, with regional correlations to NFT pathology. The outlook of this marker 
in MCI present a mixed picture. Both hyperperfusion and hypoperfusion are reported in MCI 
subjects. It is hypothesised that hyperperfusion alludes to a compensatory mechanism that 
precedes the hypoperfusion that indicates the disease onset [137]. Until there is resolute 
understanding  of these observations, it is difficult to perceive CBF as a clinically translatable 
biomarker for early onset. However, it’s use in AD research is prolific in exploring the 
pathogenic changes via non-invasive imaging.  
Brain connectivity is another aspect that is gaining research interest in AD, given the 
implication of synaptic dysfunction in the disease, and this can be measured using functional 
MRI (fMRI). fMRI enables the quantification of blood oxygenation as a measure of brain 
activity, and  this measure can be used as a surrogate for functional connectivity of neural 
networks. In particular, the default mode network (DMN) has been extensively studied 
within this context [132]. The DMN describes a functionally connected network of brain 
regions which include the medial prefrontal cortex, posterior cingulate cortex, inferior 
parietal lobule, lateral temporal cortex and hippocampus [138]. The DMN is understood to 
be  highly metabolically active at rest and is downregulated during task-based activities that 
require attention, a feature measurable using fMRI. This downregulation is impaired in 
individuals with MCI, and impaired even further during AD. Furthermore, depletion of 
DMN activity is distinguishable in mild AD compared to healthily aging individuals [139]. 
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Functional measures using MRI show promise in biomarker utility and may be particularly 
apt for early detection, as functional changes precede the detrimental morphological changes 
of the AD brain. 
Several laboratories, including ours, continue to develop and refine quantitative MRI 
techniques sensitive to the early changes of AD, including methodologies sensitive to the 
pathogenic accumulation of proteins. It is also advantageous over PET measures of brain 
function, as it overcomes the requirement for radioactive tracers, and MRI is a modality that 
is more widely accessible, thus lends itself readily for clinical translation. Nonetheless, much 
like the case of novel PET ligands, any given quantitative MRI biomarker remains a research 
tool until it is sufficiently validated via human cohort studies. 
 
1.7.4 The next generation of biomarkers 
Although neuroimaging is undeniably valuable in assessing the various stages of AD, a 
significant challenge with its utility as a routine biomarker remains to be its cost, accessibility 
and throughput.  This has spurred efforts to rapidly identify fluid biomarkers, which are more 
readily accessible. As such, blood based biomarkers are rapidly developing [140]. Blood 
presents a tangible source of markers, as blood withdrawal is quick, inexpensive, and inflicts 
minimal discomfort to patients over CSF extraction.  
Plasma markers of Aβ and tau have gained notable research interest, but thus far only plasma 
T-tau has reached the strengths of sensitivity their CSF counterparts can achieve. Other 
indirect markers of neuronal markers such as NfL, as well as as visinin-like protein 1 (VLP-
1), a neuronal cytoplasmic protein, and neuron specific enolase (NSE), a neuronal enzyme, 
are gaining attention due to their significant CSF presence in AD [117]. Plasma NfL as a 
marker of axonal damage in particular has come through as a strong biomarker, correlating 
well with CSF levels [118]. These new candidates provide promising new accessible markers 
for early detection. 
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AD is also widely understood to be caused by an imbalance between production and 
clearance of pathogenic proteins [141]. If imaging accumulation indicates a point in the AD 
continuum that is too little too late, then useful biomarkers sensitive to the physiological 
processes that precede accumulation or impede clearance need to be developed. Tests 
sensitive to the pathways implicated in clearance may therefore provide fruitful avenues for 
novel biomarker development and viable therapeutic intervention, and also advance our 






2. The Glymphatic System 
This chapter will introduce and define the glymphatic system, a focal theme of the work 
presented in this thesis, and explore its implication in Alzheimer’s disease pathology.   
 
The glymphatic system describes a fluid network of exchange between cerebrospinal fluid 
(CSF) which surrounds the brain, and interstitial fluid (ISF) found in the extracellular space. 
It is considered a surrogate for conventional brain lymphatics, which are largely lacking in 
the brain. It gets its name from its close association with glia, as it is highly reliant on 
astrocytes for its function. This system facilitates the flushing of solutes and metabolic waste 
from the extracellular space by influx of CSF into the brain parenchyma, and thus CSF 
dynamics form an important facet of its function. 
 
2.1 Cerebrospinal fluid 
The brain, being such a vital organ, is protected by several physiological layers, the meninges. 
Beneath the skull, the dura mater forms the first tough meningeal membrane, followed 
closely by leptomeninges – the arachnoid mater and pia mater. The space between the 
leptomeninges forms the subarachnoid space (SAS), which holds a layer of CSF surrounding 
the entire brain. CSF is dynamic – it pulsates and flows around the brain and spinal cord, 
and  through the ventricular network (Figure 12). Multiple forces contribute to these 
dynamics –  CSF appears to follow a pulsatile pattern mirroring the cardiac cycle [142], as 
well as respiratory stimuli [143]. In addition, rapid bulk flow occurs through the ventricular 
system [144]. CSF production at the choroid plexus drives it through the lateral ventricles 
and into the third ventricle, down the aqueduct and into the fourth ventricle, which exits into 
the SAS via the cisterna magna. Reabsorption of CSF occurs at the arachnoid villi which 
protrude through the arachnoid membrane into the superior sagittal sinus at the top of the 
skull, where it drains into venous blood. Additionally, CSF can also drain along cranial 
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nerves to reach the extracranial lymphatics  [145]. Careful physiological equalisation of 
production and reabsorption maintains intracranial pressure, which is vital for brain health. 
 
 
Figure 12. Diagram depicting CSF flow within the cranium. CSF is produced at the choroid plexus 
within the lateral ventricles, flows through the third ventricle, into the aqueduct down to the fourth 
ventricle. From here, it flows into the cisterna magna via the median aperture and spreads into the spinal 
chord and recirculates around the skull, draining into the superior sagittal sinus via the arachnoid 
granulations. Image reproduced from the Wikimedia Commons free media repository. 
 
The extension of the CSF space into the parenchyma occurs along the main penetrating 
vessels. The main vessels feeding the brain originate at the circle of Willis at the base of the 
brain, which separate into three pairs of major arteries – the anterior, the middle and the 
posterior cerebral arteries. These pial vessels which sit within the SAS, between the 
leptomeninges, are surrounded by CSF and branch further into arteries and arterioles. The 
arterioles that begin to dive into the brain parenchyma create a continuation of the SAS 
between the pial and parenchymal vessels, called the Virchow-Robin space, taking with it a 
continuation of the pia and the glia limitans – a layer formed of astrocytic end feet that sit 
directly underneath the pia (Figure 13). As these arterioles branch deeper into the brain, they 
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change structurally. The layers of the pia and glia limitans discontinue and eventually, the 
vessels form the capillary bed.  This then feeds into the venous drainage system, but an 
important feature of the capillary microcirculation network is that it forms the neurovascular 
unit and blood brain barrier (BBB) [146].  
 
 
Figure 13.  Cross sectional schematic showing a diving feeding pial or leptomeningeal artery and its 
cellular associations as it variegates into the capillary bed. Pial artieries dive into the brain along with 
the pia and glia limitans forming the Virchow-Robin space. As vasculature branches and penetrates 
deeper into the brain, it changes structurally. Arteries are distinguishable from their multiple layers of 
vascular smooth muscle cells (VSMC). Capillaries are formed of a single layer of endothelium and 
associated with pericytes. Astrocytic processes surround the entire network of brain vasculature. 
Reproduced from Zlokovic, 2011 [147]. 
 
2.2 The blood brain barrier 
The BBB is formed of the endothelial lining of microvasculature throughout the brain. 
Specialised contractile cells called pericytes sit on endothelial cells of the microvasculature, 
and together are encased in the basal lamina, formed of a variety of extracellular matrix 
proteins [146]. The endothelial layer is largely impermeable to macromolecules, with tight 
junctions between cells acting as a seal preventing plasma proteins from leeching from the 
blood into the brain, which can otherwise have damaging consequences. In order to transport 
nutritional molecules from circulation to parenchyma, this seal is specifically equipped with 
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a variety of  transport systems. [148]. The barrier is permeable to other small lipophilic 
molecules, oxygen and carbon dioxide [147]. 
A uniquely important feature of the entire vascular network of the brain is that it is closely 
associated with astrocytes via astrocytic end foot processes that almost wholly ensheathe the 
entirety of brain vasculature. The overlap between these end feet form clefts of roughly 
20nms, and these inter-end feet gaps allow microglial processes to interact with the basal 
lamina [149]. Gap junctions present between individual astrocytic processes also facilitate 
intercellular exchange between astrocytes, and this unique feature enables a network of 
communication via the formation of a non-overlapping syncytium [150]. The inter-end feet 
gaps may provide an entry route for proteins and other macromolecules within this size range 
to move between the parenchyma and the CSF, but restricts entry into circulation. Thus the 
BBB serves a crucial protective function in maintaining brain health.  
 
 
Figure 14. Structural elements of the BBB and the neurovascular unit. At the capillary bed, astrocytic 
end feet processes surround the pericyte and capillary endothelial cell. Tight junctions between 
endothelial cells prevent passive entry and exit of molecules between blood and brain tissue. Microglia 
can interact with the endothelium via gaps between end feet. Reproduced from Abbott et al., 2010  [148]. 
 
The close association of the microcirculation with neurons as well as astrocytes, microglia 
and pericytes also forms an important physiological entity known as the neurovascular unit 
(Figure 14). The neurovascular unit works carefully to control the chemical makeup of the 
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interstitium around it, to ensure healthy physiological function. The interplay and cross 
communication between this myriad of neuronal and non-neuronal cell populations in the 
brain serves to regulate BBB permeability and cerebral blood flow, thus monitoring critical 
aspects of normal brain function [147].  
 
2.3 Glymphatic exchange 
The continuous fluid network formed from CSF penetrating the brain, first along the 
Virchow-Robin spaces, and then following the perivascular spaces along the basal lamina to 
reach the interstitum bathing the cells of the brain, gives way for fluid exchange. The forces 
of CSF movement, which include cardiac pulsation, respiration and CSF production provide 
driving forces for CSF to move along this low-resistance pathway to reach the brain 
parenchyma. Here, CSF moves into the brain parenchyma and exchanges with ISF by 
convective bulk flow [151]. This enables rapid exchange of CSF with ISF, which then, driven 
by vectoral convective flux, is drained along the perivascular spaces around draining veins 
(Figure 15), then getting flushed into the recently discovered meningeal lymphatic vessels 
[152] and ultimately into the cervical lymph nodes [153].  
The mechanisms by which this process occurs have long been debated and probed. Early 
work by Cserr et al. measured the exit rates of radioactive tracers of varying sizes injected 
into the rat brain, expecting smaller molecules to clear faster if diffusion was the only fluid 
driving force in the interstitium. They found that tracers cleared at similar rates, thus pointing 
to bulk flow [154]. Shortly afterwards, work by Rennels et al. in cats and dogs showed that 
infusing tracers into the SAS caused them to travel along perivascular routes and enter the 
parenchyma, with this effect being diminished by partially ligating the brachiocephalic 
artery. They deduced that cerebral arterial pulsations were requisite to the entry of solutes 
into the brain along this pathway [155].  
More recently, the workings of this system have reproducibly and comprehensively been 
demonstrated in the mouse brain. Using fluorescent dyes infused into the SAS and confocal 
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microscopy, Iliff et al. showed that the entry of fluorescently tagged CSF occurs along the 
penetrating arteries, and also attributed this to the pulsatility of the smooth muscle in the 
arterial walls [151]. In a subsequent experiment, they verified the crucial role of arterial 
pulsation, by showing that glymphatic flux was impaired when the carotid artery was ligated 
to reduce arterial pulsatility in the brain by 50%, and conversely, increasing pulsatility by 
60% using an adrenergic agonist sped up this mechanism [156]. The initial experiments also 
elegantly demonstrated the unique reliance of periarterial and perivenous routes for entry 
and exit respectively. Using a combination of genetic reporter mice that fluorescently 
distinguish arteries from veins, and fluorescent tracers injected into the SAS and the 
parenchyma, they showed that while CSF entry occurred along periarterial routes, exit routes 
for all these fluid solutes were along the margins of central draining veins. In this work, they 




Figure 15. Diagrammatic depiction of CSF-ISF exchange via glymphatic flow. Arterial pulsations drive 
CSF along periarterial spaces, where AQP4 can facilitate exchange with ISF. Bulk flow drives waste 
metabolites along with CSF towards perivenous drains [157]. 
 
Using AQP4 deficient mice, they found that bulk CSF flow into the Virchow-Robin spaces 
was unaffected, but CSF tracer exchange into the parenchyma was impaired in the absence 
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of AQP4. Additionally, they found that tracers injected into the AQP4 null brain interstitium 
were not efficiently removed, reporting up to a 70% impairment. This crucially demonstrated 
that the glial water channel AQP4, which is densely expressed at the abluminal surface of 
the astrocytic end feet which wall the perivascular space, had a significant responsibility in 
facilitating this fluid exchange network. Because this system behaves as a substitute for brain 
lymphatics, and relies on glia, the term “glymphatics” was coined [151].   
Although evidence demonstrating the workings of this pathway continues to build [158], the 
precise origin of the driving forces of convective exchange remain dubious. Global CSF flow, 
diffusion and arterial pulsation have all been put forward, but not fully proven as drivers. 
The aforementioned early work by Cserr et al.,  demonstrated that diffusion alone would be 
insufficient to facilitate the exit rates of tracers [154]. Further studies combining 
mathematical modelling to infusion studies continued to support the notion that  diffusion 
alone was insufficient to drive influx, and additional forces driving bulk flow within the ISF 
were at play [159]. Iliff et al. put forward the concept of a hydrostatic arteriovenous gradient, 
created by the combination of arterial pulsation, rapid fluid exchange into tissue via AQP4 
and low pressure sinks in perivenous routes [151]. Recent mathematical experiments 
modelling perivascular CSF inflow and exchange with ISF have suggested that arterial 
pulsation may not be the sole driving force of inflow. Asgari et al. propose the concept of 
rapid dispersion, described as a combined effect of diffusion in the brain and macroscopic 
ventricular CSF motion arising from cardiac and respiratory brain deformation. Based on 
their model, they suggest that rapid dispersion of solutes as a consequence of arterial 
pulsation facilitates fast transport along perivascular routes, and net bulk flow would require 
additional driving forces [160]. Physiological evidence for this hypothesis as well as the 
driving forces for bulk flow is yet to be pinpointed. It is fathomable that the multitude of flow 
vectors at play within the cranium and the various fluid compartments contribute variably to 
net flow. A recent study by Ray et al. simulated both interstitial bulk and diffusive flow and 
compared it to  a wealth of experimental data that supported both these mechanisms. This 
study concluded that both these mechanisms are relevant to fluid transport in the 
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interstitium, with their findings pointing to bulk flow is an important facilitator in moving 
larger molecules, which diffuse less readily and slowly in the tortuous extracellular space 
than smaller molecules [161].  
The crucial contribution of AQP4 in this system has also been modelled to test the movement 
of fluid from the periarterial to perivenous side. Asgari et al. modelled the astrocytic 
syncytium between these two locations, by including AQP4 on the plasma membranes, an 
abundance of AQP4 on the perivascular surfaces, 20nm inter-end feet gaps and gap junctions 
within their model (Figure 15). They demonstrated the movement of fluid through both a 
tortuous extracellular route (around astrocytes and cells of the brain neuropil) as well as a 
simpler intracellular route (through astrocytes, via AQP4 and gap junctions), occurring in 
parallel. They note that these parallel routes work in harmony, as depleting AQP4 at the end 
foot domain hinders the net flow, including reduction of movement through gap junctions  
and the inter-end feet gaps, where metabolites would be expected to move through, possibly 
driven by a pressure gradient, although the presence of such a gradient has not been 
physiologically proven [162]. These observations however mirror in vivo data and reinforce 
the idea that effective CSF-ISF exchange relies on a high density of AQP4  on the 
perivascular domains.  
 
Figure 15. Schema of the mathematical model to simulate periarterial inflow, AQP4 mediated fluid 
flow and perivenous drainage. A continuous non-overlapping network of astrocytes with AQP4 is 
modelled here to test the movement of fluid from periarterial to perivinous compartments. Reproduced 
from Asgari et al., 2015 [162]. 
77 
 
2.4 Aquaporin 4 
AQP4 is one of several aquaporins which form a family of cellular water channels. Earliest 
investigations of aquaporins were focused on organs such as the kidneys where a high level 
of water exchange is crucial in function [163], and subsequently also studied in the eye, lungs 
and brain of rodents [164]. Aquaporins are crucial in the brain, where careful control of water 
homeostasis is critical in regulating normal function. AQP1 is found on the epithelial cells of 
the choroid plexus, whereas AQP4, 5 and 9 are present on the ependymal cells that line 
ventricles, and on astrocytes [165]. AQP4 is the most abundant form in the brain, highly 
expressed on astrocytes, and expressed in two isoforms – M1 and M23. The M23 isoform 
assembles in highly complex structured orthogonal arrays, with a preference towards the end 
foot process, whereas the M1 isoform individually spreads and moves through the plasma 
membrane, with a regional preference towards extending membranes [166]. High densities 
of AQP4 are found at the end feet processes of astrocytes that surround the vasculature 
network, and also form the glia limitans [164]. This astrocytic feature gives AQP4 a key role 
in water homeostasis in the brain.   
AQP4 has been implicated in a range of brain conditions including neuroinflammation, 
stroke, oedema and traumatic brain injury (TBI) and experimental evidence in mice have 
provided a wealth of evidence towards this. For example, in experimental models of water 
intoxication and stroke, AQP4 null mice show lowered susceptibility to brain oedema and 
neurological impairment than their wildtype counterparts, providing evidence for its role in 
water homeostasis during disease [167]. In studying post TBI seizures, AQP4 null mice 
experienced more severe seizures, increased microgliosis and decreased astrogliosis 
compared to wildtypes, which contributed to weaker scar formation, thus giving AQP4 a 
protective role [168]. In a model of TBI, AQP4 has been found to undergo an overall increase 
in expression along with astrogliosis, but a reduction in polarisation [169].  
If AQP4 changes occur in the brain in response to an insult, and polarisation is an important 
feature in the fluid-mediated transit of brain metabolites, then probing pathologies of the 
brain within the context of  the glymphatic system is of interest. In AD, this system provides 
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a viable route for tau and Aβ spread through and clearance from the brain. In order for this 
to be feasible, these proteins need to reach the interstitial fluid in the extracellular space.  
 
2.5 Aβ and tau in the extracellular space 
The imbalance between protein production and clearance has implicated impaired clearance 
as a potential mechanism contributing to aggregation during proteinopathies [170]. The 
initiators of Aβ and tau pathology remain elusive, but investigation into the spread of these 
pathogenic proteins provide insights into the possible mechanisms underlying AD onset. Aβ 
is an extracellular lesion which appears early during the disease, whereas tau pathogenesis 
begins intracellularly and later in the AD cascade, and they both have distinct patterns of 
spread. Thus, the mechanisms by which this occurs can be regarded individualistically and 
mouse models have been valuable assets in exploring these mechanisms. 
APP processing at the plasma membrane releases Aβ into the extracellular space which 
oligomerises and accumulates into plaques [25]. It is however increasingly evident that 
intracellular Aβ oligomers are neurotoxic over the fibrillar extracellular plaque forms [27]. In 
vitro, Aβ can be internalised at distal axons and travel to cell bodies in a retrograde manner, 
and then transneuronally spread to neighbouring neurons. In vivo, Aβ is seen to spread via 
neuroanatomically connected regions in the mouse brain [171]. It is hypothesised that 
oligomeric Aβ is secreted extracellularly via exosomes, and then internalised endosomally, 
where it then collects in lysosomal vesicles. Support for this theory is evident in cell culture, 
where endosomal-lysosomal trafficking of oligomeric intracellular Aβ42 has been 
demonstrated [172]. When internalised, Aβ is devastating to cellular machinery, as it can 
interfere with synaptic function, disrupt enzymatic activity and disturb calcium homeostasis 
[173]. In mice, oligomeric extracellular Aβ can also act as seeds around existing plaques, 
thereby promoting  formation of new plaques [174].  
Hyperphosphorylation of tau inside the neuron causes it to dissociate from microtubules and 
aggregate in an incremental manner until it forms an NFT. Although tau is an intracellularly 
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aggregating protein, the appearance of P-tau in CSF during AD indicates that the release of 
pathogenic tau species into the extracellular space is a key event in initiating its spread. It is 
hypothesised that pathogenic conformations of tau in the extracellular space can act as a seed 
and propagate misfolding and spread through synaptically connected neurons in a prion-like 
manner [175]. This has been demonstrated in mice [176]. When insoluble tau species 
extracted from mutant tau mice are injected into the brains of transgenic mice expressing 
wildtype human tau, it induces the formation of pathogenic tau fibrils, which spreads through 
anatomically connected regions and progresses with age [177].  The transmission of tau from 
cell to cell has been probed in vitro, and when cells with fluorescently tagged tau is cocultured 
with naive cells, it is seen to leave one cell and enter neighbouring cells when cocultured.  
Unlike Aβ, it is the filamentous form of tau that exacerbates propagation, whereas the 
oligomeric forms do not succeed in propagating pathology [178].  
It is clear that spread of the pathogenic forms of Aβ and tau require its presence in the 
extracellular space. It is also apparent that transmission of these abhorrent proteins is 
encouraged, pointing to an inefficiency in clearance mechanisms at play within the brain 
during pathogenesis. Thus, probing dysregulation of clearance may offer vital clues towards 
the onset of AD. In addition, understanding the failure of clearance may offer new targets 
for therapeutic intervention.  
Protein waste can be degraded via a myriad of mechanisms, including and not limited to 
enzymatic degradation (both intracellular and extracellular), bulk ISF flow and BBB 
transport, and whilst several clearance systems have been widely studied, the relative 
contributions of each system remain unknown. It has long been understood that BBB was 
the prime site of clearance of metabolites, including Aβ clearance [179]. However, research 
in glymphatics has demonstrated that it has the potential to clear Aβ with up to 65% 
efficiency [151]. It is important to note that whilst glymphatic system has been proposed as 
a surrogate solution for the lack of brain lymphatics, meningeal lymphatic vessels have also 
recently been identified in the dural sinuses of the mouse brain, bringing important new 
insights into waste removal routes in the brain [152]. Evidence for a further perivascular 
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clearance pathway along basement membranes of capillaries and arterial walls  in the reverse 
direction to glymphatic flow also exists, with important implications in the development of 
to cerebral amyloid angiopathy CAA [180]. The glymphatic system offers a new mechanistic 
window into the efficient removal of pathogenic substances from the extracellular space and 
therefore warrants investigation in the AD setting, given that much is still undiscovered in 
its pathogenesis. 
 
2.6 Aβ and tau as glymphatic substrates 
The entry and exit of parenchymal metabolites via the glymphatic system has been 
demonstrated using a variety of techniques In the preliminary experiments by Iliff et al., in 
addition to characterising the pattern of periarterial to perivenous transit, they also showed 
that Aβ is a substrate for removal via this mechanism. Using fluorescently labelled Aβ, they 
showed its presence along capillaries and draining veins, and when radioactively labelled 
Aβ40 was injected into the parenchyma, they showed gradual removal of this substrate over 
time. When injected into the SAS, an increase in tagged Aβ was detected in the brain over 
time. Importantly, both these observations were significantly marred when repeated in AQP4 
null mice [151]. Glymphatic Aβ clearance has also been investigated with sleep cycles, as 
both APP mice, as well as human subjects show increases in ISF Aβ levels that correlate 
with wakefulness. In addition, APP mice that are sleep deprived show increased cortical 
plaque burden [181].  Based on this finding, and the observation that sleep disturbances are 
prevalent in AD subjects, Xie et al. measured glymphatics in awake and sleeping mice by 
infusing fluorescent traces onto the SAS. They found that wakefulness impaired the amount 
of tracer influx, and attributed this to extracellular space  changes, as they found that the 
interstitial volume increased by up to 60% during anaesthesia-induced sleep. They then tested 
the clearance of radioactively labelled Aβ and found a twofold increase in clearance in 
sleeping mice [182]. In another study which looked at the relationship between aging and Aβ 
removal, clearance of radiolabelled Aβ was seen to be impaired with advancing age of the 
mouse, at a rate comparable to co-infused tracers which would exclusively be cleared via 
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bulk flow. These observations were attributed to reductions in arterial pulsatility also 
observed within these aging mice  [183]. Taken together, these studies collectively pose Aβ 
as a substrate for glymphatic clearance.  
The evidence for tau as a glymphatic substrate comes from studies investigating TBI. When 
mice that underwent TBI were assessed for changes in their glymphatic components, several 
observations were made. First, the inflow of fluorescent tracers and clearance of radiotracers 
were reduced in the post-TBI brain. In addition, AQP4 polarisation was reduced following 
TBI.  P-tau levels were elevated following TBI, but importantly, when this experiment was 
repeated in AQP4 null mice, a significant elevation in P-tau and neurodegeneration was 
observed [184]. These findings imply that perturbances of AQP4 can contribute to elevated 
tau pathology via glymphatic impairment. 
These experimental findings lay important groundwork for investigating novel clearance 
mechanisms of Aβ and tau to further our understanding of AD progression. The work 
presented in the context of aging is of particular relevance, given that age is the biggest risk 
factor for AD [66]. In addition to the experimental observations cited here in models of AD 
and TBI, glymphatic fluctuations are also observed in mouse studies investigating stroke 
[185], alcohol use [186], exercise [187].  This is fascinating, given that these are all known 
factors that pose risk for or modulate AD. This growing body of work in this emerging field 
is paving the way for new avenues in neurodegenerative research.  Thus, it is prudent that 




2.7 Aims of this project  
The glymphatic system is a newly discovered clearance pathway which has been implicated 
in clearing waste from the brain, and the workings of this system during AD pathology, 
which are not fully explored, have been interrogated in the work in this thesis. Within this 
research programme, I set out to quantify glymphatic inflow in mouse models of AD, taking 
a whole-brain 3-dimentional imaging approach. My thesis aimed to:  
1. Set up a robust surgical methodology which would provide a suitable experimental 
system to image glymphatics in mouse models.   
2. Build on the understanding of the role of AQP4, by modulating it pharmacologically 
to determine if artificial impairment of glymphatics are reliably measurable in vivo 
using MRI.  
3. Identify if glymphatic changes precede pathology, by carrying out whole brain MRI 
at select time points on mouse models of tau and Aβ, to better understand if 
fundamental variations in clearance bring about AD-related molecular changes.  
4. Extend my findings to human AD, to bridge the gap between basic science and 
clinical data, by studying AQP4 profiles in post mortem brains and their relationship 
to pathological burden.  
Quantifying glymphatic function during pathology and modulating AQP4 as a therapeutic 
intervention are emerging concepts in AD research and the novel data presented in this thesis 
contributes to that growing body of work. 
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3. A Surgical Mouse Model to Assess Glymphatic Inflow 
In this chapter, a surgical method to measure glymphatic inflow in the mouse brain is 
established as a proof of concept. This in vivo setup serves as the basis for experiments in wildtype 
and transgenic mice in subsequent chapters. 
 
3.1 Summary 
The recently described glymphatic system may provide a novel route for the effective 
clearance of proteins such as amyloid-β and tau from the brain, and it’s role in Alzheimer’s 
disease pathology is intriguing. To study glymphatics in vivo by probing the dynamics of the 
physiologically sensitive fluid spaces in the brain, a model system needs to be robust and 
reproducible. Here, a surgical methodology that would enable dynamic imaging of the 
mouse brain with continuous infusion of contrast is established based on previous study of 
glymphatic function in rodent models. The technique is assessed using a series of dyes of 
varying sizes and infusion rates to confirm concordance with previous experimental 
evidence. This work provides confidence in the subsequent imaging studies, in the use of this 





In the brain, an imbalance between production and clearance of the pathogenic proteins of 
Alzheimer’s Disease (AD), amyloid-β (Aβ) and tau, is hypothesised to be a contributing 
factor to disease onset. The lack of robust treatment for AD has fuelled renewed interest in 
exploring novel ways in how the brain clears itself of pathogenic proteins, and has paved way 
for new research advances in the neurodegenerative disease. The glymphatic system has only 
been recently characterised as a clearance mechanism for Aβ, and is still in fairly early stages 
in research exploration, but is gaining momentum and recognition as an important removal 
route for brain metabolites [188–191]. As described in the previous chapter, using 
experimental mouse models, Iliff et al. elegantly demonstrated a periarterial influx route of 
cerebrospinal fluid (CSF) from the subarachnoid space (SAS) into the brain. They also 
showed the need for the water channel aquaporin-4 (AQP4), found highly abundant at the 
astrocytic end feet that ensheathe brain vasculature, for exchange of CSF solutes with 
parenchymal interstitial fluid (ISF). In addition, they provided evidence for the exit of 
parenchymal solutes along perivenous routes [151]. They used an intracisternal tracer 
infusion approach and showed that tracers from the SAS entered the brain along cortical 
arteries. In this work, they also demonstrated a size-based selectivity in the penetration depth 
of solutes into the brain, using both radioactive and fluorescent solutes infused into the SAS. 
The smallest molecules penetrated the deepest regions of the brain, whereas larger tracer 
molecules were restricted to the more superficial perivascular regions, an observation which 
was attributed to the 20nm gaps between the astrocytic end feet [149], sieving out molecules 
larger than this size and preventing their movement from the perivascular space into the brain 
tissue. Crucially, it was also noted that maintaining the hydraulic integrity of the intracranial 
space was requisite for the maintenance of glymphatic flow – that is, the introduction of a 
small unsealed hole into the dura was found to markedly reduce measured rates of 
perivascular contrast movement from the SAS to the brain tissue [151,192]. This 
demonstrates that careful experimental control is required when manipulating and testing 
parameters within this finely balanced system.  
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In this work the methodology employed in the previous work is reproduced, to demonstrate 
that the surgical methodological protocol is reproducible and yields results concordant with 
previous studies. First, measures of glymphatic inflow were macroscopically assessed by 
using dyes that could be visualised by the naked eye, to confirm movement of solutes along 
penetrating vessels on the surface of the mouse brain. Next, this was advanced to microscopic 
visualisation using fluorescent tracers in order to detect parenchymal penetration, and to test 
the size based patterns of glymphatic inflow previous described in Iliff et al. This provided 
reassurance that the surgical methodological protocol yielded measures that were robust and 
concordant with previous work, prior to extrapolating this work onto magnetic resonance 
imaging (MRI) experiments, which comes with its own distinct set of technical and practical 
challenges. 
 
3.3 Methods  
3.3.1 Intracisternal infusion of tracers into the mouse subarachnoid space 
8.5 month old wildtype female C57BL/6 mice were used, imported from Charles River 
(Wilmington, Massachusetts, USA). N numbers  used for each experimental set are provided 
in the subsections below. All animal work was performed in accordance with the United 
Kingdom’s Animals (Scientific Procedures) Act of 1986 and was previously approved by 
University College London’s (UCL) internal Animal Welfare and Ethical Review Body. 
Mice had unrestricted access to food and water, and were housed under automatically 
controlled temperature, humidity, ventilation and 12h light/dark cycle settings.  
Mice were anaesthetised with 2% isoflurane delivered in O2 at a delivery rate of 1l/min, and 
positioned in a stereotaxic frame (Kopf) with the head flexed to 50°. Mice were maintained 
at 37°C (±2°C) using a feedback controlled heated mat connected to a rectal core temperature 
monitor  (Harvard Apparatus). A midline incision was made at a midpoint between the skull 
base and the occipital margin to the first cervical vertebra (Figure 16). The underlying 
muscles were parted to expose the atlanto-occipital membrane and dura mater overlaying 
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the cisterna magna, and a durotomy was performed using a 23-gauge needle. An intrathecal 
catheter (35-40 mm port length, 80-90 mm intravascular tippet length, Sandown Scientific, 
Middlesex, UK) extended with polyethylene tubing (0.4 mm x 0.8 mm, Portex) and attached 
to a 100µL glass Hamilton syringe driven by a microinfusion pump (sp210iw syringe pump, 
World Precision Instruments, Sarasota, Florida, USA) was filled with the desired contrast 
agent. The catheter was advanced <1mm into the cisternal space, sealed and anchored in 
place using superglue. This setup is shown below in Figure 16. 
 
 
Figure 16. Surgical method to introduce tracers into the SAS. 1. The anaesthetised mouse is secured on 
a stereotaxic frame. An incision of the skin is made to expose muscle from occipital bone to atlas. 2. The 
of splenius capitis, semispinalis muscles and atlanto-occipital membrane are removed, revealing the 
cisterna magna. 3. The dura mater is punctured with a needle (diameter ~0.25mm). The needle tip is 
stained with ink to visualise the puncture, seen here as a blue reside around the puncture. 4. The 
intrathecal catheter advanced <1mm into cisterna magna and secured with superglue. In this image, 
the catheter contains Alexa Fluor 594 hydrazide dye. 
 
3.3.2 Evans blue dye to assess superficial tracer distribution 
A flowrate of 2μl/min (n = 4) as used in the original work by Iliff et al. [130] was tested, as 
well as a slower, more physiologically compatible flow rate [193] of and 0.6μl/ min (n = 5), 
with the intention of using this in subsequent MRI experiments. 4% Evans blue dye (EBD) 
(molecular weight 961 Da) (Sigma catalogue# E2129) prepared in filtered 0.9% NaCl was 
infused into the cisterna magna for a total of 10μl delivered volume for each flow rate. 30 
minutes after the start of the infusion, mice were euthanized by overdose with sodium 
pentobarbital (10ml/kg, i.p.). Brains were removed and photographed dorsally, ventrally and 
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laterally to capture dye distribution around the outer brain surface (my hypothesis being that 
dyes would be preferentially distributed along the para-arterial space of surface vessels). 
3.3.3 Fluorescent dyes to assess parenchymal tracer distribution 
In the fluorescent tracer experiments, only the 0.6μl/ min infusion rate (n =  4 per dye) was 
used. 0.5% solutions of Alexa Fluor 594 hydrazide (AF594-H) (molecular weight 759 Da; 
emission/excitation wavelengths: 588/613 nm) (ThermoFisher catalogue# A10438), Texas 
Red–dextran-3 (TR-d3) (molecular weight 3 kDa; emission/excitation wavelengths: 
595/615 nm) (ThermoFisher catalogue# D3329) and fluorescein isothiocyanate–dextran-
2000 (FITC-d2000) (molecular weight 2000 kDa; emission/excitation wavelengths: 490/520 
nm) (Sigma, catalogue# 52471) in filtered cortex buffer (pH 7.4) were infused into the 
cisterna magna for a total of 10μl for each flow rate. Cortex buffer was chosen as the vehicle 
for delivery here to maintain a salt solution that was more physiologically compatible with 
the brain. To collect sections without fluorescence as a reference control, one mouse was 
infused with cortex buffer without fluorescent tracers. Recipe for cortex buffer used is as 
follows: 
Reagent     Amount to add Final concentration 
NaCl     7.31 g 125 mM 
KCl     0.373 g 5 mM 
Glucose     1.802 g 10 mM 
HEPES     2.38 g 10 mM 
1 M CaCl2     2 mL 2 mM 
MgSO47H2O     0.493g 2 mM 
H2O     to 1 L -- 
 
Tracers were infused for a total of 10μl. 55 minutes after the start of the infusion, mice were 
euthanized by overdose with sodium pentobarbital (10ml/kg, i.p.). Mice were perfused with 
15 ml 0.9% saline followed by 50ml 10% buffered formalin (VWR catalogue# 9713.1000). 
Brains were rapidly removed and snap frozen in isopentane pre-chilled on dry ice to prevent 
further diffusive movement of tracers. 50μm coronal sections of the brain were collected onto 
RNase-free SuperFrost® Plus slides, using a cryostat. Slides were imaged on an Invitrogen 
EVOS FL Auto fluorescence microscope and images were analysed on ImageJ. Each slide 
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with fluorescent sections was scanned alongside a slide with sections from the control mouse 
infused with cortex buffer only.  
3.3.4 Analysis of fluorescent dye penetration 
The most medial section from each brain with minimal slicing artefacts was selected. The 
image was binarized on ImageJ and the mean intensity of the image obtained. An ROI was 
drawn around the selected slice and a threshold of 3 standard deviations from the mean signal 
of each brain was then applied to the image. The % area coverage of this threshold was taken 
as a measure of penetration into the tissue for each section. This image analysis pipeline is 
shown in Figure 17. Statistical comparisons between groups were performed via one-way 
analysis of variance (ANOVA) followed by Tukey’s multiple comparisons tests. Data is 
represented as mean ± SEM for the n number of animals in each group. Statistical testing 
was performed using GraphPad Prism (v7 for Windows, San Diego, CA, USA). 
 
Figure 17. Flow diagram showing an example of the analysis approach taken to calculate percentage 




3.4 Results  
Prior to the data reported here, I performed this surgical procedure in a total of 32 mice, 
which collectively enabled me to better control for important sources of experimental 
variation such as anaesthetic delivery, sterotaxic positioning and contrast agent buffering 
(data not shown). Once my surgical skill was honed, I commenced data collection on the 
experiments described in sections 3.3.2 and 3.3.4.  
3.4.1 Macroscopic assessment with Evans blue dye 
 
Figure 18. Photographs of brains collected following intracisternal  infusion of EBD at 2μl/min.  Each 
row represent a single mouse brain, photographed ventrally, laterally and dorsally. EBD distribution is 




Figure 19. Photographs of brains collected following intracisternal  infusion of EBD at 0.6 μl/min. 
Each row represent a single mouse brain, photographed ventrally, laterally and dorsally. EBD 
distribution is visible in blue. 
 
In the 2µl/min group (Figure 18), a high amount of tracer retention was observed around the 
brain stem close to the cisterna magna infusion site. EBD infused into the cisterna magna 
was visible at the base of the brain around the circle of Willis. Tracer was also visible along 
the middle cerebral arteries (MCA) and along the branches of the leptomeningeal arteries, 
towards the surface of the cortex. One mouse in the 2μl/min group died shortly after the 
infusion commenced. Upon necropsy, EBD was not visible on the surfaces of the brain in 
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this mouse (Figure 18, M2_2) and further dissection revealed that EBD had filled all the 
ventricles. 
In the 0.6μl/min group (Figure 19), tracer distribution was highly similar to the observations 
in the 2 μl/min group. Tracer retention along the branches of the MCA were noticeably more 
prominent. In one mouse from this group, tracer appeared to pool in the cisterna magna and 
drained out upon necropsy. No dye was observed on the brain surface (Figure 19, M0.6_4) 
or within the ventricles. EBD was not observed in the ventricles of any other mice. 
3.4.2 Microscopic assessment with fluorescent tracers 
 
Figure 20. Coronal brain sections from mice infused with small molecular weight Alexa Fluor 594 
Hydrazide  (0.76 kDa), sliced from rostral (top) to caudal (bottom) regions. Each column contains 
images from an individual mouse. Control sections were obtained from one mouse infused with cortex 




Figure 21. Coronal brain sections from mice infused with medium molecular weight Texas Red (3 kDa) 
sliced from caudal (top) to rostral (bottom) regions.. Each column contains images from an individual 
mouse. Control sections were obtained from one mouse infused with cortex buffer only (TR Emission 
/Excitation wavelengths: 595/615 nm).       
 
 
Figure 22. Coronal brain sections from mice infused with large molecular weight fluorescein 
isothiocyanate (2000kDa), sliced from rostral (top) to caudal (bottom) regions. Each column contains 
images from an individual mouse. Control sections were obtained from one mouse infused with cortex 
buffer only (FITC Emission /Excitation wavelengths: 490/520 nm).        
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The large molecular weight FITC-d2000 penetrated the brain the least (1.7% ± 1.4 SEM). 
On the micrographs (Figure 22), tracer was mostly visible on the peripheries of the brain 
tissue. This was followed by medium molecular weight TR-d3 (Figure 21) which penetrated 
up to 16% (± 5.8 SEM), travelling deeper than FITC-d2000. AF594-H, the smallest dye, 
travelled the deepest (Figure 20), achieving up to 60% (± 2.6 SEM) penetration. This tracer 
penetrated significantly deeper than TR-d3 (p= 0.0005) and FITC-d2000 (p = 0.0001, Figure 
23 A) and visibly illuminated the brain sections on the micrographs (Figure 20). This data 
was also plotted against tracer size, producing a single phase decay, as modelled in Figure 
23 B. This enabled the rough estimation of penetration that could be expected with other 
potential tracers. The experiments started with 4 mice in each tracer cohort. However, one 
mouse from the FITC-d2000 group was removed from analysis as the infusion line was 
visibly blocked and prevented tracer from entering the cisterna magna. A mouse from the 
AF594-H group was also removed from analysis due to a leak at the infusion site during the 
experiment and thus had to be terminated. In the TR-d3 group, one mouse (TR_M3; Figure 
21) appeared to have reduced penetration compared to the others in this cohort. However, 
no visible experimental observations or errors warranted its removal and thus was included 
in the analysis. 
 
Figure 23. (A) Percentage penetration of large (FITC-d2000; n=3), medium (TR-d3; n=4) and small 
(AF594-H; n=3) molecular weight dyes infused into the cisterna magna at 0.6ul/min. (B) The data 
from A, modelled against one phase decay curve. Vertical dotted line denotes the size of a proposed MRI 
contrast agent, Gd-DTPA. Error bars represent standard error of the mean (SEM). Statistical 
significance denoted by asterisks: ***=p<0.001. 
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3.5 Discussion  
This work aimed to develop a methodological protocol for reproducible assessment of 
glymphatic inflow in the mouse brain and to use this protocol to replicate previous 
experimental observations: namely the characteristic spatial distribution of tracers and the 
tracer-size dependence of these distributions [151]. Using EBD, the characteristic movement 
of tracers in the SAS along the main feeding leptomeningeal vessels was macroscopically 
observed. When fluorescent tracers were used, they were visible in the brain parenchyma, 
and followed a size-based pattern, with the smallest tracers achieving the deepest penetration 
depths. 
A key aim of these experiments was to establish a method that would enable the extension 
of these studies into MRI, to enable dynamic assessment of whole brain glymphatic function 
in AD. Anticipating that capturing dynamic real-time MRI scans would require a protocol 
with a larger volume infused over a longer period based on similar imaging experiments 
carried out in rat brains [194], the need to calibrate the infusion rate was recognised. Given 
that intracranial hydraulic integrity is a key component of maintaining CSF flow patterns, 
an infusion rate of 0.6µl/min was implemented, theorising this to be physiologically 
compatible whilst still enabling detectable contrast, and the rationale is explained henceforth. 
First, tracer movement was macroscopically tested using the infusion rate from the original 
work by Iliff et al. of 2µl/min as well as the proposed rate of 0.6µl/min. Both experimental 
cohorts showed tracers moving along the leptomeningeal vessels and branches moving 
towards the cortical surface, however, this was more prominent in the 0.6µl/min group. The 
0.6 µl/min flow rate is likely to disrupt endogenous brain fluid movement to a lesser extent 
than the 2 µl/min flow rate and interestingly, it was observed that this resulted in more 
prominent perivascular distribution of tracers, seen by qualitative, visual assessment of EBD 
distribution (Figure 19). This observation indicates that high infusion rates may 
underestimate rates of glymphatic inflow relative to lower infusion rates.  
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One explanation for this may be that faster rates could disrupt fluid dynamics in the SAS, 
possibly by interfering with intracranial pressure (ICP) and thus diminishing the pattern of 
pulsatile flow along feeding vessels. In the original work using an infusion rate of 2µl/min, 
the senior authors only noted a transient disturbance in ICP, and in a protocol subsequently 
published, they recommended a rate of 1µl/min for cisterna magna infusions [195]. Prior 
work from a different group, using a cisterna magna bolus of tracer infused at 3μl/min, had 
shown no detectable changes in ICP 10 minutes following the infusion [196]. More recently, 
a study using cisterna magna tracer infusions continuously tested ICP whilst gradually 
increasing the infusion rate. They found that a rate of 0.34 µl/min increased ICP from a 
baseline reading of 4.1 ± 0.4 mmHg to 4.2 mmHg, and at 1µl/min ICP reached 5.3 mmHg, 
but gradually decreased after the end of the infusion [197]. Thus it would seem that a variety 
of flow rates and infusion volumes do not produce marked increases in ICP using the 
experimental design implemented here. In this study, one mouse that died from the 2µl/min 
group showed tracer filled ventricles, but none along the vessels. It may have succumbed to 
adverse effects from this infusion, possibly due to a combination of the faster rate as well as  
erroneous placement of the catheter, forcing the tracer in the wrong direction, which may 
have then detrimentally disrupted cerebral physiology.  
Glymphatic inflow has previously been visualised in the rat brain by contrast-enhanced MRI 
and that study used an infusion rate of 1.6µl/min [194]. In a separate study, this group also 
used this same infusion rate in fluorescence experiments in mice alongside rats, where a 
comparable pattern of tracer distribution was observed in both species. ICP recordings taken 
in these rat brains showed no perturbances [198]. Another study in the rat brain has shown 
that intracisternal infusion only increases ICP at ≥3µl/min [199]. But, the adult mouse brain 
is approximately 4 - 5 times smaller than the adult rat brain [200] and has 4 times less total 
CSF volume [201]. Based on these metrics, an infusion rate of 0.4 µl/min would seem 
pragmatic. This rate would also be similar to the rate of CSF production in the mouse brain 
which is estimated at 0.37 ± 0.04 µl/min [193], and thus be physiologically compatible. 
However, a challenge posed by the MRI experiments was that an infusion rate too slow, or 
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a total volume of tracer delivered too small could impede meaningful signal detection. I 
therefore concluded that a compromised rate needed to be reached – whilst the ideal infusion 
rate for the mouse brain would be 0.4µl/min, the aforementioned studies provided the 
understanding that this could be pushed beyond 1µl/min without changing ICP, and thus 
conceded here at 0.6µl/min moving forward. I reasoned this rate would not markedly change 
ICP but allow reasonable infusion of contrast agent volume and detection of signal in MRI. 
It must be noted that one mouse from the 0.6µl/min cohort in the EBD experiments also did 
not show tracer along the vessels, however, it did not suffer any adverse effects and the mouse 
survived the end of the experiment. As the tracer appeared to pool around the infusion site, 
with some draining out during necropsy, it is unlikely that a block in the SAS was responsible 
for this, as such a physiological change would be devastating to its physiology. Dissection of 
this brain confirmed a complete lack of tracer in any brain region. Thus, it is likely that a 
technical error caused a blockade in the infusion line of this mouse. The remaining 4 mice in 
that group prominently displayed the characteristic distribution of tracer along the cortical 
vessels. Overall, an affirming observation in these experiments was how the macroscopic 
spatial tracer distribution on the ventral aspect of the brain and along cortical vessels were 
on par with the observations reported in the previous rat brain MRI experiments [194] and 
mouse brain fluorescence studies [151]. 
The next set of experiments used fluorescent tracers infused at 0.6µl/min and demonstrated 
that CSF tracers can enter the parenchyma. In the TR-d3 infused brains, some sections 
revealed tracer entry along penetrating cortical vessels. This is as expected, as the pulsatile 
pattern of fluid movement is thought to move solutes towards the Virchow-Robin spaces to 
facilitate parenchymal ingress [160].  A size based preference in solute size  is apparent as 
previously described – smaller molecules penetrate deeper in the brain and large molecules 
are more restricted in movement [151]. Glymphatic inflow partially relies on this pulsatile 
movement for CSF to enter the brain along penetrating arteries [156], and fluid exchange 
into the parenchyma is facilitated by aquaporin-4 (AQP4) channels, found highly polarised 
at the end feet of astrocytes that surround vessels [149]. Water enters the brain through AQP4 
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and can move through both extracellular and intracellular routes, whereas other solutes are 
restricted by cellular boundaries and may enter the brain only through the gaps between end 
feet, thought to be driven be a pressure gradient, and flow through the extracellular space 
(ECS) [162]. The restriction of larger molecules is attributed the size of these gaps, which are 
roughly 20 nm wide [149]. Additionally, the width of the ECS in the brain is estimated to be 
around 38 – 64 nm [202]. FITC-d2000 has an estimated diameter >32nm, TR-d3 is estimated 
to be between 2.7 – 3.2nm and AF594-H is around 1.1nm [203]. The large size of FITC-
d2000 would thus prevent it from moving further than the Virchow-Robin spaces, as 
observed in these and previous data. Smaller molecules such as TR-d3 and AF594-H may 
reach the parenchyma via the end foot clefts. But in the tortuous parenchymal ECS, the 
smallest molecules diffuse more freely, whereas larger molecules rely more heavily on bulk 
flow, as demonstrated by a combination of modelling and experimental data [161]. Thus the 
smallest of molecules such as AF594-H would be expected to reach the parenchyma fastest 
and move through the ECS more rapidly, thus achieving greater penetration depths than TR-
d3 and FITC-d2000. Based on these observations, one can expect a small contrast agent such 
as Gd-DTPA penetrate the brain parenchyma with up to 55% efficiency (Figure 23 B). 
These preliminary experiments emphasised the fine technicalities of working within a small 
physiological space, and thus highlighted the need for careful technical and physiological 
control for reliable utility of this methodological protocol. These data provide evidence as to 
the reproducibly of the measurement of glymphatic inflow in wildtype mice, and that 
contrast agents infused using this method follow the characteristic size-dependant pattern of 
glymphatic flow previously characterised. The data also yielded confidence that with use of 
a small MRI contrast agent,  good penetration efficiency may be attained in the mouse brain. 
In order to move into MRI experiments, a suitable infusion rate that would provide 
efficacious image contrast was also established. Using these parameters, the next study aimed 
to image glymphatic flow in the mouse brain, by combining the surgical procedures 





4. Magnetic Resonance Imaging and Pharmacological Inhibition 
of Glymphatic Function in the Mouse Brain 
The work characterising glymphatic inflow in the previous chapter is advanced to in vivo whole 
brain imaging. The work presented herein also demonstrates that the influence of 
pharmacological modulation of aquaporin-4 function on glymphatic inflow can be imaged in 
vivo using  magnetic resonance imaging. 
 
4.1 Summary 
Aquaporin-4 facilitated exchange of cerebrospinal with interstitial fluid via the glymphatic 
system, may provide a pathway by which amyloid-β and tau are cleared from the brain, and 
as such, represents an exciting new target for Alzheimer’s disease. Here, glymphatic inflow 
is dynamically imaged in real time using whole brain contrast enhanced magnetic resonance 
imaging, to investigate the spatial-temporal dynamics of contrast agent egress into the mouse 
brain. Measurements of glymphatic outflow are also performed by intracerebrally injecting 
tau and measuring clearance. The influence of aquaporin-4 on these measures of CSF-ISF 
exchange was then investigated by using a potent aquaporin-4 inhibitor. These findings 
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Exchange of cerebrospinal fluid (CSF) with interstitial fluid (ISF) via glymphatic flow is 
thought to be facilitated by the expression of aquaporin-4 (AQP4) channels on astrocytic end 
feet; animals lacking AQP4 exhibit a ~70% reduction in CSF influx and a ~55% reduction 
in parenchymal solute clearance [151,158]. Evidence demonstrating the role of AQP4 in 
exchange of fluid and solutes through the brain has spurred investigations into its implication 
in neurodegenerative conditions such as Alzheimer’s disease (AD).  
Deletion of AQP4 in APP/PS1 amyloid mice has been shown to potentiate the development 
of amyloid-β (Aβ) pathology and memory deficits in this disease model [204]. It has also 
been shown that the appropriate spatial expression pattern of AQP4 polarisation to astrocytic 
end feet is required for efficient glymphatic function [183,184], and that this polarisation in 
the brain declines with age [183,205]. Moreover, in mouse models of traumatic brain injury 
(TBI), AQP4 polarisation is demonstrably reduced, glymphatic function is impaired and 
AQP4 null mice that experience TBI are shown to experience an elevation in CSF 
phosphorylated tau (P-tau) levels [184]. These studies suggest that supressed glymphatic 
function is capable of inducing or advancing AD pathology. Furthermore, it was shown 
recently that AQP4 polarisation itself is associated with AD status [205], suggesting that 
impaired glymphatic function may play a role in rendering the aging brain vulnerable to 
aberrant protein deposition. Therefore, the ability to visualise glymphatic changes and AQP4 
driven perturbances to fluid movement can provide important insights into the changes 
preceding protein accumulation in the AD brain. 
In this study, the glymphatic system is characterised across the mouse brain in real-time using 
dynamic contrast enhanced MRI (DCE-MRI). Having previously established a surgical 
protocol for reproducible assessment of glymphatic inflow in the brain using fluorescent dyes 
and histological assessment, in this chapter I attempted to translate this technique from the 
bench to high field MRI measurement. This aimed to enable dynamic whole brain mapping 
of glymphatic function but came with considerable methodological challenges due to strong 
magnetic fields and confined space inside the bore of the magnet. Furthermore, I aimed to 
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test the sensitivity of the technique to detect a relatively marked change in glymphatic 
function prior to application to mouse models of AD. Thus, I chose to pharmacologically 
target the function of AQP4, a critical component of the glymphatic pathway, using the novel 
inhibitor TGN-020. 
By using DCE-MRI, a spatial and temporal description of the glymphatic system in the 
mouse brain is provided, and the spatially heterogeneous nature of glymphatic inflow is 
highlighted. The critical role of AQP4 to facilitate glymphatic inflow is assessed by 
pharmacologically inhibiting its function and visualising dynamic changes on MRI. The 
impact of AQP4 inhibition on outflow is also queried by testing the clearance of parenchymal 
tau using intracerebral injections and CSF sampling. 
 
4.3 Methods 
4.3.1 Mice and aquaporin-4 blocking agent 
Wildtype female C57BL/6 mice at 8.5 months of age were used for MRI, imported from 
Charles River (Wilmington, Massachusetts, USA) into the United Kingdom for study at 
University College London’s (UCL) Centre for Advanced Biomedical Imaging. N numbers  
used for each experimental set are provided in each results subsection. rTg4510 transgenic 
mice were used to extract tau for intracerebral injections. Generation of homozygous 
rTg4510 transgenic mice has been described previously [95]. The rTg4510 mice were licensed 
from the Mayo Clinic (Jacksonville, Florida, USA) and bred for Eli Lilly by Taconic 
(Germantown, Maryland, USA). For accompanying TGN-020 experiments, where stated, 
AQP4 knockout mice, generation of which has been described previously (59), (henceforth 
referred to as Aqp4-/- mice) were used, imported directly from University of Oslo, Norway. 
All animal work was performed in accordance with the United Kingdom’s Animals 
(Scientific Procedures) Act of 1986 and was previously approved by UCL’s internal Animal 
Welfare and Ethical Review Body. Mice had unrestricted access to food and water, and were 
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housed under automatically controlled temperature, humidity, ventilation and 12h 
light/dark cycle settings.  
For pharmacological inhibition of AQP4, TGN-020 (N-1,3,4-Thiadiazol-2-yl-3-
pyridinecarboxamide, Tocris Bioscience, Bristol, UK) was used [206]. In order to increase 
solubility, TGN-020 was dissolved in a cyclodextrin derivative, 20% w/v Captisol (CyDex 
Pharmaceuticals) in water for injection. For TGN-020 experiments, mice were treated 
intraperitoneally with either TGN-020 (250mg/kg in 20ml/kg body weight) or vehicle 
(empty 20% Captisol, 20ml/kg) 15 minutes prior to commencing imaging or injecting tau. 
4.3.2 Surgical preparation for contrast enhanced MRI 
 
 
Figure 24. Surgical setup and MRI bed preparation for intracisternal contrast infusion and DCE-MRI 
acquisition. Following surgical preparation to place the intrathecal catheter for contrast administration 
on a stereotaxic setup, the mouse is transferred to the MRI bed equipped with continuous physiological 
monitoring and maintenance on a feedback system. 
 
Mice were anaesthetised with 2% isoflurane delivered in O2 at a delivery rate of 1l/min, and 
positioned in a stereotaxic frame with the head flexed to 50°. A midline incision was made 
at a midpoint between the skull base and the occipital margin to the first cervical vertebra. 
The underlying muscles were parted to expose the atlanto-occipital membrane and dura 
mater overlaying the cisterna magna, and a durotomy was performed using a 23-gauge 
needle. An intrathecal catheter (35-40 mm port length, 80-90 mm intravascular tippet length, 
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Sandown Scientific, Middlesex, UK) extended with polyethylene tubing (0.4 mm x 0.8 mm, 
Portex) and attached to a 100µL glass Hamilton syringe driven by a microinfusion pump 
(sp210iw syringe pump, World Precision Instruments, Sarasota, Florida, USA) was filled 
with low molecular weight paramagnetic contrast agent Magnevist® (21mM Gd-DTPA, 
MW 938 Da; Schering Health Care Ltd., in filtered 0.9% NaCl). The catheter was advanced 
1mm into the cisternal space, sealed and anchored in place using superglue and fast setting 
resin (Araldite). This setup is shown in Figure 24. 
4.3.3 Magnetic resonance image acquisition 
 
 
Figure 25. (A) Schematic with brain regions visualised and (B) timeline illustrating experiments used 
to determine the pattern of glymphatic inflow in the mouse brain. Gd-DTPA was infused into the 
cisterna magna followed by serial acquisition of T1 weighted MR images.  
 
Following surgery, animals were transferred to an MRI compatible cradle with head held 
prone and a snout mask positioned to deliver 1.5% isoflurane in O2 at a delivery rate of 
1l/min. Core temperature and respiratory rate were monitored using a rectal probe and 
pressure pad respectively (SA Instruments). Mice were maintained at 37°C (±2°C) using 
heated water tubing and a feedback loop controlled warm air blower (SA Instruments). 
Respiration rate was maintained between 80 and 120 breaths per minute by incrementally 
adjusting isoflurane dose. All imaging was performed with a 9.4T VNMRS horizontal bore 
scanner (Agilent Inc., Santa Clara, California, USA).  A 72mm inner diameter volume coil 
(Rapid Biomedical, Rimpar, Germany) was used for RF transmission and signal was 
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received using a 2 channel array head coil (Rapid Biomedical).  A 3D T1-weighted gradient 
echo sequence was employed to detect the motion of the Gd-DTPA with parameters: TR = 
15ms, TE = 3.4ms, flip angle = 15°, NA = 3, FOV = 1.28 × 1.28 × 1.92cm, scanning time = 
12 min, acquisition matrix size of 128 × 128 × 128, yielding an image resolution of 0.1 × 0.1 
× 0.15mm. Three baseline scans were acquired prior to intracisternal infusion of Gd-DTPA 
via the indwelling catheter (30μl at 0.6μl/min, total time 50min). Acquisition of each 
timepoint took 12 minutes per scan. MR images were continually acquired throughout and 
after intracisternal infusion for a total time of 180min (Figure 25). At the end of the 
experiment the animal was euthanized by overdose with sodium pentobarbital (10ml/kg, 
i.p.). 
4.3.4 Image processing and analysis 
First, the acquired T1-weighted MRI images were converted to the 3D NIfti image format. 
Second, scan-to-scan misregistration caused by head movement was corrected by rigid-body 
alignment to the baseline volume. Next, affine registration was performed to correct 
variability between each mouse brain. Transformed T1-weighted MR images, including the 
baseline and contrast-enhanced scans, were averaged to create a template image with high-
contrast, and this image used to anatomically guide placement of 3D regions-of-interests 
(ROIs) which encapsulated most of the mouse brain (Figure 26). As the mouse models of 
AD included in this programme of work were known to present with pathology in the cortical 
and hippocampal areas, these regions were focussed on in the subsequent studies 
investigating the effects of pathology. A previous observation made by the histologists 
processing the rTg4510 brains at Eli Lilly were that the rostral and caudal cortices presented 
with differential early pathology. Based on this, the cortex was further segmented  into these 
subregions. 
A difference image was calculated for each timepoint. Signal intensity measured on the T1 
weighted MR images over time in preselected anatomical areas were used to obtain intensity 
measurements. The intensity signal for each ROI on each timepoint image was extracted and 
expressed as a % change from the average baseline image. For calculation of kinetic 
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parameters such as the maximal intensity and the time at which half maximal intensity was 










Where IntensityMax is the maximal intensity achieved in the brain region, Time50 is the time 
at which half maximal intensity is achieved, and Slope is the gradient of the linear portion of 
the fitted sigmoidal curve. Additionally, each ROI’s IntensityMax value was divided by its 
corresponding Time50 value to give a measure of ‘Penetration Efficiency’ for each region. 
 
  
Figure 26. Schematic describing the processing steps following acquisition of T1 weighted MR images. 
All images are registered to the same space, and then segmented to extract regional intensity 
measurements as shown here and described above. 
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4.3.5 Intracerebral infusion of tau homogenate and CSF collection 
Tau for intracortical injection was prepared by euthanizing an aged rTg4510 mouse (12 
months of age) by overdose with sodium pentobarbital (10ml/kg, i.p.) and dissecting out the 
cortex and hippocampus. Tissue was quickly frozen in isopentane on dry ice for storage at -
80°C. Frozen tissue was weighed, thawed, and gently mixed in a mortar with a few strokes 
of a pestle in 10% w/v volumes of cold Tris-buffered saline (TBS) containing protease 
inhibitor cocktail, phosphatase inhibitor cocktails I and II (all Sigma, UK), at a final dilution 
of 1:100, and 1mM phenylmethylsulfonyl fluoride. To estimate total human tau content, an 
Enzyme Linked Immunosorbant Assay (ELISA) of brain homogenate was performed 
(Human Tau (total) ELISA Kit (Invitrogen, UK) as per the manufacturer’s instructions, see 
below) and stock solution tau concentration adjusted to 20μg/ml with homogenisation 
buffer, and stored at -80°C until intracerebral infusion. 
 
Figure 27. (A) Schematic and (B) timeline illustrating experiments used to determine the effects of 
pharmacological inhibition of AQP4 on clearance of tau from the mouse brain. TGN-020 or vehicle was 
administered 15mins prior to injection of tau containing brain homogenate into the striatum, and CSF 




Mice were anaesthetised with 2% isoflurane delivered in O2 at a delivery rate of 1l/min, and 
positioned in a stereotaxic frame in the horizontal skull position. A midline incision was 
made on the top of the head to expose the underlying skull. A small burr hole was made, 
using a microdrill, above the location of the intracerebral injection. 50ng tau containing brain 
homogenate was infused into the striatum (anteroposterior, -0.2mm, mediolateral, +2mm 
and  ventral to dura, -1.75mm, relative to bregma) [207] using a 10μl glass Hamilton syringe 
(2.5μl at 0.25μl/min, total time 10min). Either 15, 30, or 60 minutes after the start of the 
intracerebral infusion, with the needle left in situ, a midline incision was made at a midpoint 
between the skull base and the occipital margin to the first vertebrae. The underlying muscles 
were parted to expose the atlanto-occipital membrane and dura mater overlaying the cisterna 
magna, which was thoroughly cleaned with saline. A durotomy was performed using a 23-
gauge needle, allowing CSF to be collected using a narrow bore pipette tip. CSF volume 
varied between mice: 5-8µl was routinely collected (Figure 27). At the end of the experiment 
the animal was euthanized by overdose with sodium pentobarbital (10ml/kg, i.p.). 
4.3.6 Tau enzyme linked immunosorbant assays 
The collected CSF was centrifuged and supernatant was removed and frozen at -20°C until 
further analysis by ELISA. The remaining pellet was used to assess blood contamination 
using a a NanoDrop ND-1000 spectrophotometer (Thermo Fischer Scientific, Waltham 
MA). Concentration of human tau in CSF samples was then quantified using ELISAs. CSF 
total tau was quantified using Human Tau (total) ELISA Kit (#KHB0041, Invitrogen, UK), 
and CSF phosphorylated tau was quantified using Human Tau (Phospho) [pS199] ELISA 
Kit (#KHB7041, Invitrogen, UK), as per the manufacturer’s instructions. Briefly, CSF 
samples were diluted in diluent buffer prior to being incubated in capture antibody coated 
wells for 2hrs at room temperature. Wells were washed several times before being incubated 
in detection antibody for 1hr at room temperature. Wells were washed again before being 
incubated with horseradish peroxidase conjugated secondary antibody for 30 minutes at 
room temperature. Wells were then washed again before being incubated with stabilized 
chromogen for 30 minutes at room temperature. After this incubation, stop solution was 
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added to each well and the plate was read at 450nm. A set of standards of known (p)Tau 
concentration (0, 31.25, 62.5, 125, 250, 500, 1000, 2000pg/ml for total tau, and 0, 15.625, 
31.25, 62.5, 125, 250, 500, 1000pg/ml for phospho [pS199] tau), were run in parallel for each 
experiment for quantification of CSF sample tau content from the standard curve. 
4.3.7 Statistical analysis 
Statistical comparisons between groups were performed via either a repeated measures two-
way analysis of variance (ANOVA) followed by post-hoc Bonferoni post-tests for multiple 
comparisons (for MRI data), or a regular two-way ANOVA followed by post-hoc Bonferoni 
post-tests for multiple comparisons (for all other grouped comparisons not containing 
repeated measures). Unpaired t-tests were used for single comparisons.  All statistical testing 
was performed using GraphPad Prism (v7 for Windows, San Diego, CA, USA). All data is 
represented as mean ± SEM for the n number of animals in each group, which are detailed 





4.4.1 Spatial and temporal profile of glymphatic inflow in the mouse brain 
This part of the project aimed to carry out an exploratory study to investigate the spatial and 
temporal patterns of glymphatic inflow in the mouse brain. Glymphatic inflow in healthy 
wildtype mice was characterised using contrast-enhanced MRI by quantifying the regional 
pattern of delivery of MR contrast agent Gd-DTPA from the SAS into the brain.  Gd-DTPA 
infused intracisternally with serial T1-weighted images acquired over 3 hours showed a 
distinct pattern of CSF flow into the mouse brain (Figure 28 A), and mirrored the distribution 
pattern previously reported in the rat brain [173]. 90 minutes after initiation of the infusion, 
the MRI signal plateaued in all brain regions (Figure 28 B). T1 contrast was initially observed 
in the CSF filled aqueduct, progressing to ventral nuclei (the pontine nucleus and pituitary 
recess) and the caudal cortex. Later timepoints showed advancement of the signal 
throughout the brain, in the pineal recess and cerebellum, and more rostral regions, such as 
the rostral cortex and the olfactory bulbs. This distribution pattern is schematised in Figure 
29. 
Quantification of MR signal in grey matter revealed heterogeneity of glymphatic inflow in 
the mouse brain. The rostral cortex of wildtype animals exhibited a relatively low level of 
Gd-DTPA infiltration (IntensityMax (% change from baseline), 7.44%), yet the caudal cortex 
exhibited a high level of contrast agent infiltration (IntensityMax (% change from baseline), 
60.23%, p<0.001 compared to rostral cortex) (Figure 28 C). When ‘penetration efficiency’ 
(the metric described in section 4.3.4) of these two regions were calculated, and compared 
against each other, the caudal cortex was significantly higher than the rostral cortex (Figure 




Figure 28. Glymphatic inflow in the mouse brain cortex. (A) Representative T1-weighted structural 
images of % change from baseline over time showing psuedocoloured entry of Gd-DTPA. (B) MRI T1 
signal intensity vs. time data acquired from grey matter regions of the mouse brain showing differences 
in rates and intensities of glymphatic inflow of Gd-DTPA in anatomically discreet regions over time. 
(C) IntensityMax values (maximal intensity achieved in region from sigmoidal fitting of data) in each of 
the brain regions in which raw data and sigmoidal curves are displayed in (A). (D) MRI contrast 
‘penetration efficiency’ for the rostral and caudal cortex, in which raw data and sigmoidal curves are 




Figure 29. Schematic illustrating direction of contrast agent flow into the brain following cisterna 
magna infusion, with inclusion of Time50 values (the time at which half the maximal intensity is 
reached), derived from modelling of MRI T1 signal intensity vs. time data (shown in Figure 28 B). Aqd 
= aqueduct; Cblm = cerebellum; Pon = pontine nucleus; Pit = pituitary recess; Pin = pineal recess; 
CCtx = caudal cortex; RCtx = rostral cortex; Olf = olfactory bulb. Light blue shaded region denotes the 




4.4.2 Effect of pharmacological inhibition of aquaporin-4 on glymphatic function 
The role of AQP4 in glymphatic inflow and clearance was tested by pharmacological 
blockade, with a specific inhibitor, TGN-020 [185]. To test glymphatic inflow, TGN-020 or 
vehicle were administered 15 minutes prior to cisternal infusion of Gd-DTPA, followed by 
serial acquisition of T1-weighted MR images in wildtype mice. Mice treated with TGN-020 
exhibited significant reductions in MR signal enhancement in the brain (Figure 30). A 
hotspot of contrast was visible in the aqueduct, and close to the region near the middle 
cerebral artery, where the agent appeared to pool in TGN-020 treated animals. This is evident 
in the cortex, striatum and hippocampus, with significantly reduced MR signal being 




Figure 30. Representative pseudocolored DCE-MRI scans of vehicle (20% Captisol) and TGN-020 
treated animals with Gd-DTPA infusion. Image taken at the 60 minute time point, Inflow of contrast 
into the brain of the TGN-020 treated animal is visibly marred. Contrast agent appears to pool in the 
















































































































































































































































































































































































































The maximum intensity achieved in the TGN-020 treated cortex and striatum was 
significantly reduced compared to vehicle treated animals (Figure 31 D; 62.7% less in TGN-
020 treated cortex and 28.1% less in TGN-020 treated striatum,  p<0.001). The rate of inflow, 
as calculated by Time50 (the time at which half the intensity is achieved) (Figure 31 E) 
revealed that the rate of inflow was impaired in the hippocampus ( 21.4 mins less in TGN-
020 treated animals, p<0.05) and striatum (40.9 mins less in less in TGN-020 treated animals, 
p<0.001), with both regions achieving statistical significance. The ‘penetration efficiency’, 
which factors in both maximal intensity achieved per region and the time required to reach 
half that intensity, showed that the cortex had the highest contrast between regions compared 
(Figure 31 F), with this becoming significantly impaired with TGN-020 treatment (1.1 less 
in TGN-020 treated animals, p<0.01). 
To determine if pharmacological blockade of AQP4 exhibited a similar reduction in 
clearance from the brain, intracerebral injections of tau followed by CSF measurements of 
tau were performed. Tau was chosen as a substrate to test clearance, given that a central 
theme of this thesis was to investigate its implication in glymphatic system. Thus, tau extract 
from the rTg4510 mouse model was used. Wildtype mice were treated with either TGN-020 
or vehicle, 15mins prior to intrastriatal infusion of tau containing brain homogenate. CSF 
was then extracted from the cisterna magna, 15, 30, or 60mins later to determine the extent 
of clearance into CSF compartments. Reductions in the level of total and phosphorylated 
(pS199) tau detected in CSF were observed at all timepoints (for example, 15 mins post-
striatal infusion, TGN-020 treated animal CSF Tau (pTau) content, 90.1(23.4)ng/ml vs. 
953.0(285.0)ng/ml in vehicle treated animals) (Figure 32). Similar experiments were also 
performed in Aqp4-/- mice, where vehicle or TGN-020 was given 15mins prior to 
intrastriatal infusion of tau containing brain homogenate and CSF extraction 30mins later. 
Both Aqp4-/- vehicle and TGN-020 treated groups showed reductions in CSF tau, similar to 
TGN-020 treated wildtype animals (vehicle treated Aqp4-/- mice CSF total tau, 72.2ng/ml, 
TGN-020 treated wildtype and Aqp4-/- mice CSF total tau, 53.1ng/ml and 99.08ng/ml, 





Figure 32. (A) Total tau and (B) pTau concentration of CSF samples extracted from mice injected with 
tau homogenate demonstrating reduced clearance of tau from the TGN-020 treated animal brain. 
Intrastriatal injection of tau containing brain homogenate was also performed in a cohort of Aqp4-/- 
animals after TGN-020 or vehicle treatment, and CSF extracted 30mins post-injection for quantification 
of tau in CSF extracts. (C) CSF tau concentrations demonstrate the specific nature of TGN-020 towards 
AQP4, given the lack of an effect observed of TGN-020 in Aqp4-/- animals. (D) shows the inhibition 
observed in MRI and injection experiments converted to a percentage from striatal regions. 
Abbreviations: NI, non-injected. N=5 per group. Statistical significance denoted by asterisks: 






In order to assess glymphatic function in the mouse brain using MRI, a previously published 
protocol for measurements in the rat brain was adapted [194]. By scaling down both the 
volume and flow rate at which intracisternal MR contrast agent is administered as established 
in the previous chapter, glymphatic flow in the mouse brain was characterised. The small 
size of Gd-DTPA (938 Da) also meant that contrast was expected to travel through the 
glymphatic route with minimal resistance. This aligns with the observation reported in the 
previous chapter, where the smallest tracer, Alexa Fluor 594 Hydrazide (760 Da), travelled 
the furthest into the brain parenchyma (Figure 23).  
In these experiments, regional glymphatic inflow was reproducibly imaged and quantified 
enabling real time visualisation of CSF ingress into the brain. Notably, the regional patterns 
of contrast ingress all plateaued with time, giving no indication of clearance over the three 
hours scanned. Nonetheless, this observation and the spatial-temporal dynamics captured 
here paralleled patterns of glymphatic flow described in the brain using similar contrast 
infusion techniques in rats [194]. Another study investigating glymphatic flow in a model of 
stroke  has also used a protocol similar to the one I used here. [185].  In that study, the pattern 
of contrast-enhancement qualitatively described closely followed the regional pattern 
observed here. However, detailed quantitative assessment was not carried out on discrete 
brain regions. Interestingly, they identified routes of CSF drainage along sinuses, lymph 
nodes and cranial nerves – an observation not made here. This may be explained by the 
higher scan resolution attained in that study enabling more detailed visualisation of contrast 
enhanced CSF transit. However, characterising the dynamic time course of CSF movement 
with higher resolution would require a longer scan time. This meant that the adverse 
implications to the mouse’s physiology over longer periods under anaesthesia had to be 
considered. Thus, a trade-off between resolution and scan time had to be reached. A further 
disadvantage of this MRI protocol is that the perivascular spaces cannot be resolved, and 
thus brings into question if the contrast enhancement is truly interstitial. However, based on 
the small size of the molecule, and the previous experiments using fluorescent dyes that 
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demonstrated parenchymal ingress, it is probably safe to assume the veracity of the 
observations made using DCE-MRI. This is further backed by a subsequent study which 
advanced the aforementioned rat brain glymphatic characterisation upon which this study is 
modelled, where the authors converted the dynamic T1-weighted MR signal enhancement 
to concentration maps to quantify parenchymal gadolinium in the rat brain [208]. 
Next, the role of AQP4 in glymphatic function was probed. The extent to which inflow can 
be dynamically imaged was tested by pharmacologically blocking AQP4 in wildtype mice. 
Glymphatic flow of CSF into the brain’s interstitium and its clearance out of the 
parenchyma, is thought to be facilitated by the expression and polarisation of AQP4 to the 
end feet of astrocytes surrounding blood vessels in the brain [158]. Original data supporting 
this hypothesis came from the use of AQP4 null mice, in which glymphatic function was 
impaired by ~70% compared to wildtype animals, resulting in a ~55% reduction in Aβ 
clearance from the brain [151]. Subsequently several independent groups have similarly 
demonstrated that astrocytic AQP4 is essential for fast glymphatic transport, using various 
approaches of AQP4 gene deletion [188–191].  Here I took an alternative approach, by 
pharmacologically inhibiting AQP4 function, and in doing so showed that a marked 
impairment in glymphatic function can be visualised. Pharmacological AQP4 inhibition 
visibly impairs glymphatic inflow captured by DCE-MRI. Scans of the TGN-020 treated 
animals did not demonstrate the characteristic pattern of interstitial inflow of Gd-DTPA, and 
curiously, the contrast agent did not advance beyond the fluid filled aqueduct and fourth 
ventricle. A pool of contrast was also observed around the region close to the middle cerebral 
artery. It is possible that the hindrance to AQP4 function caused the infused contrast agent 
to take the paths of least resistance, the large interconnecting fluid filled spaces and major 
periarterial spaces, in the absence of glymphatic ingress. The opposing direction of CSF 
production and flow through the ventricular system may have limited the extent to which 
the ventricular route could be taken by Gd-DTPA, thus causing it to light up as a bright pool 
in the third ventricle and aqueduct. Overall, an ~85% reduction in DCE-MRI quantified 
glymphatic inflow was observed by blocking AQP4.  
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To further validate these observations, glymphatic outflow was quantified using direct 
parenchymal injections of tau. These data showed that pathogenic tau is cleared from the 
wildtype brain and delivered into the CSF. A notable confounder of these experiments was 
the use of whole brain homogenate from aged rTg4510 brains. Such a crude suspension 
would include a myriad of non-specific tau conformations, altered neuroinflammatory 
components that come with the later stages of neurodegeneration [209], glial and neuronal 
cellular debris. How such a jumble of cellular fragments impacts glymphatic function is 
unknown, and may thus cloud observations here that are tau-specific. To overcome this, a 
refined modification of this experiment could be carried out by injecting tau fibrils purified 
from AD brains, which are known to behave in a more physiologically relevant manner 
compared to synthetic forms generated in vitro [210]. Given the crucial role of astrocytes in 
glymphatic function [151], possible neuroinflammatory changes resulting from the inoculum 
of tau homogenate into a healthy wild type brain must also be considered. Nonetheless, given 
that tau was detected in both the homogenate as well as in the circulating CSF of injected 
wildtypes, these experiments demonstrated that tau can indeed be cleared into the CSF  from 
the parenchyma.  Vitally, inhibition of AQP4 impaired tau outflow into the CSF to a similar 
degree to the impairment of tracer inflow observed using DCE-MRI in TGN-020 treated 
animals. This thus provides requisite evidence that tau is also a participant in glymphatic 
clearance. 
The effect of AQP4 inhibition on glymphatic function may be seen as particularly striking 
given previous evidence of cerebral blood flow (CBF) elevation (~20%) in the mouse brain 
upon TGN-020 treatment [211] and thus could be expected to have an opposing effect to 
what is observed here on glymphatic function. However, increases in CBF can have a 
reducing effect on pulsatility [212] and given the intrinsic link between arterial pulsatility, 
and glymphatic function [156,199], a the suppressive effect observed here by the drug may 
be amplified. Indeed, the implication of AQP4 function is further supported by the 
observation in Aqp4-/- mice  which showed that AQP4 ablation via gene deletion has 
comparable effect in supressing parenchymal clearance with or without TGN-020 treatment.  
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Consistent with data from others [184], these data suggested that tau, in the extracellular 
space, is a substrate for clearance via the glymphatic pathway. These findings demonstrate 
the importance of AQP4 for appropriate glymphatic clearance from the brain parenchyma, 
alongside studies using genetic deletion approaches [151,188–191] and suggest a role for 
AQP4 mediated clearance of tau from the brain, which therefore implies its importance in 
neurodegenerative tauopathies such as AD [204].  
Given the observations reported in AQP4 null mice, this study would have benefited from 
DCE-MRI of Aqp4-/- animals to assess if the degree of inflow impairment can be visualised 
in real time. Due to the equipment downtime during the lifespan of these mice at our Centre, 
these experiments were not carried out. It must be noted however, that Aqp4-/- mice  are 
reported to have reduced ventricular volume and intraventricular pressure, as astroglial and 
ependymal AQP4 play a role in extra-choroidal CSF production and homeostasis [213]. This 
indicates that complete and non-specific ablation of AQP4 in the mouse brain, by both 
genetic and pharmacological approaches, can significantly disrupt CSF dynamics and thus 
plausibly hinder glymphatic physiology as a consequence. Hence, disentangling the precise 
role of parenchymal AQP4 in glymphatic function crucially requires the development of a 
model system in which astroglial AQP4 can be blocked without impeding ependymal AQP4 
function. This calls for the generation of an AQP4 mouse model that is inducible, with the 
ability to silence gene function in a cell-specific manner [214]. Notwithstanding, the work 
presented here shows that a transient pharmacological blockade of AQP4 can impede both 
glymphatic inflow and outflow of CSF substrates. 
In summary, this work showed that glymphatic inflow can be imaged in the mouse brain. 
Regional differences in inflow were seen between rostral and caudal cortical regions. 
Blocking APQ4, a key mediator of glymphatic fluid transit, demonstrably impaired the 
pattern of inflow observed by imaging, and clearance was also impaired to a similar degree, 
thus adding confidence to these observations. Tau was also shown to be a substrate for 
clearance via this AQP4-mediated pathway. In the next chapter, these findings are explored 
further by assessing glymphatic function in a tauopathy mouse model using MRI.   
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5. Glymphatic Function in a Tauopathy Model of Alzheimer’s 
Disease 
In this chapter, whole brain glymphatic changes are characterised longitudinally in a mouse 




Studying the clearance of pathogenic proteins from the brain such as tau can provide unique 
insights into the causative mechanisms in elusive diseases such as Alzheimer’s disease. The 
glymphatic system provides a novel approach to understanding the movement and clearance 
of such proteins from the brain. In this work, glymphatic flow is amassed in the rTg4510 
model of tau pathology using magnetic resonance imaging. The early, mid and later stages 
of pathology are studied in order to understand if early changes on glymphatic function have 
a relationship to tau accumulation and neurodegeneration. Early changes in glymphatic 
inflow in the rostral cortex of the brain showed a relationship to tau burden, and late changes 
in glymphatic flow appeared to be affected by neurodegenerative changes in this model. 
Aquaporin-4 assessment revealed a loss of polarisation in the rTg4510 brain. This study 
provides evidence for time-dependant interactions between tau-pathology and measures of 
glymphatic function, which may be useful to inform future studies that target the role of the 
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Impaired brain clearance mechanisms that result in the accumulation of aberrant proteins 
that define Alzheimer’s disease (AD), provide new diagnostic and therapeutic opportunities 
to delay or prevent clinical symptoms. One such pathway for parenchymal protein clearance 
is the glymphatic system [153]. Its involvement in AD, however, is yet to be fully defined. 
AD is characterised by the extracellular accumulation of amyloid-β (Aβ) in the form of 
plaques, and intracellular accumulation of hyperphosphorylated tau in the form of 
neurofibrillary tangles (NFTs). Blood brain barrier clearance, intra and extracellular 
degradation, interstitial fluid (ISF) bulk flow clearance and cerebrospinal fluid (CSF) 
absorption pathways have all been implicated in removal of parenchymal Aβ 
[55,151,180,215], while tau is thought to be predominantly cleared by degradation, ISF bulk 
flow, and CSF absorption clearance mechanisms [184,216]. Recent evidence however has 
suggested that the glymphatic system may contribute to a larger portion of parenchymal 
clearance of these protein species than previously thought [151,179,183]. 
Previous studies of glymphatic function in mouse models of AD have focussed largely on 
Aβ pathology [217]. In human AD though, it is the tau burden, not Aβ load, that predicts 
both brain atrophy as well as cognitive status in patients with AD [218]. Furthermore, 
emerging evidence suggests that the extracellular space, which is cleared by the glymphatic 
system, acts as a conduit for neuron-to-neuron propagation and regional progression of AD 
tau pathology [176,219,220]. This raises the intriguing possibility that reduced glymphatic 
clearance of tau may potentiate disease progression via exacerbated neuron-to-neuron 
propagation of tangle susceptible tau protein, and as such, would be a powerful target for 
therapy. 
Here I study the glymphatic system using dynamic contrast-enhanced (DCE) magnetic 
resonance imaging (MRI), in a mouse model which develops tau NFT pathology [95] similar 
to that seen in neurodegenerative diseases such as AD [16]. By using DCE- MRI, I assess the 
function of glymphatic clearance in rTg4510 mice across the whole brain using minimally 
invasive techniques. In addition, I examine the expression pattern of AQP4 in affected 
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regions. I hypothesised that changes in CSF dynamics may differ with the varying stages of 
tau pathology and neurodegeneration, and as such, studied three distinct timepoints in this 
model’s pathological timeline. This study provides the first demonstration of impaired 
glymphatic function in an animal model of tau pathology and implicates the role of AQP4 




Generation of homozygous rTg4510 transgenic mice has been described previously [221]. 
The rTg4510 and litter matched wildtype mice were licensed from the Mayo Clinic 
(Jacksonville, Florida, USA), bred for Eli Lilly by Taconic (Germantown, Maryland, USA), 
and imported into the United Kingdom for study at University College London’s (UCL)  
Centre for Advanced Biomedical Imaging. Female mice at 2.5 months, 5 months and 7.5 
months of age were used. All animal work was performed in accordance with the United 
Kingdom’s Animals (Scientific Procedures) Act of 1986 and was previously approved by 
UCL’s internal Animal Welfare and Ethical Review Body. Mice had unrestricted access to 
food and water, and were housed under automatically controlled temperature, humidity, 
ventilation and 12h light/dark cycle settings.  
5.3.2 Surgical preparation, magnetic resonance imaging and image analysis 
The experimental methods employed in Chapter 4 were replicated for the MRI preparation, 
imaging and analysis in these experiments, and are detailed in sections  4.3.1 – 4.3.4.   
5.3.3 Tau, GFAP and AQP4  Immunohistochemistry 
Immunohistochemistry was performed in order to quantify cortical deposition of tau in 
rTg4510 mice. Mice were perfused with phosphate buffered saline (PBS) followed 10 % 
buffered formalin (VWR catalogue# 9713.1000) before being processed using the Tissue 
TEK VIP processor (GMI Inc.) and embedded in paraffin wax. 6μm thick sections of the 
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brain in the sagittal plane were collected using a rotary microtome and mounted on glass 
slides. Following de-paraffinisation and rehydration of the tissue sections, antigen retrieval 
was performed using the Lab Vision PT module system (Thermo Scientific), where sections 
were heated to 100°C for 20 min in citrate buffer (TA-250-PM1X; Thermo Scientific). Slides 
were transferred to a Lab Vision Autostainer (Thermo Scientific). 
For tau immunohistochemistry, the following incubations were performed: 10 min in H2O2 
(0.3%); 30 min in normal goat serum (1:20; Vector Laboratories); 60 min in primary antibody 
for tau phosphorylated at serine 409 (PG-5; 1:8000 from Peter Davies, Albert Einstein 
College of Medicine, NY, USA); 30 min in biotinylated goat anti-mouse IgG (1:200, 
BA9200; Vector Laboratories); 30 min avidin-biotin complex solution (PK-7100; Vector 
Laboratories); 5 min in 3,3′-diaminobenzidine (SK-4105; Vector Laboratories).   
The following primary antibodies were used for glial fibrillary acidic protein (GFAP) and 
AQP4 immunohistochemistry : rabbit monoclonal GFAP (1:3000; PU020-UP, Biogenix) 
and mouse monoclonal AQP4 (1:200; ab9512, Abcam). Slides were incubated for 60 minutes 
in primary antibody; 30 minutes in biotinylated goat anti-rabbit (1:200; BA-1000, Vector 
Labs) or goat anti-mouse (1:200; BA-9200, Vector Labs) secondary antibodies; 30 minutes 
in avidin-biotin complex solution (PK-7100, Vector Labs); 5 minutes in 3,3′-
diaminobenzidine (SK-4105, Vector Labs).   
Apart from the last two steps, PBS with 0.05% Tween-20 (PBS-T) was used for diluting 
reagents and washes between steps.  Sections were then counterstained with haematoxylin 
before dehydration and cover-slipping. Stained sections were digitised using the Scanscope 
AT slide scanner (Aperio) at 20× magnification.  
To quantify PG-5-positive tau pathology, Imagescope software (version 11.1.2.780; Aperio) 
was used to view the digitised tissue sections and delineate boundaries of the rostral and 
caudal cortex, and somatomotor and visual cortex areas. PG-5 immunoreactivity was 
quantified using the positive pixel algorithm (Imagescope, version 11.1.2.780; Aperio), and 
performed in a blinded fashion.  
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To quantify GFAP and AQP4 expression, ImageJ software (version 1.44p) was used to view 
the digitised tissue and uniformly threshold for immunoreactivity. ROIs were drawn on each 
image for extraction of percentage immunopositive coverage (% immunoreactivity of whole 
brain region) for each region, in a blinded fashion. 
5.3.4 AQP4 Immunofluorescence 
Tissue sections for subcellular localisation of AQP4 in relation to cerebral blood vessels were 
processed as above and immunofluorescently stained for both AQP4 (1:60, ab9512, Abcam) 
and the blood vessel endothelial cell marker CD31 (1:25, ab28364, Abcam). Following 
deparaffinisation and antigen retrieval, tissue sections were incubated in a cocktail of primary 
antibodies overnight at 4°C (CD31, 1:25 (ab28364, Abcam); AQP4, 1:60 (ab9512, Abcam)), 
washed in PBS-T and then incubated in a cocktail of fluorophore-conjugated goat anti-rabbit 
(Alexa Fluor 488, 1:500; A11008) and goat anti-mouse (Alexa Fluor 568, 1:500; A11004) 
secondary antibodies (Invitrogen) for 2hrs at room-temperature. Finally, sections were 
washed in PSB-T and then dH2O, before being cover-slipped in VECTASHIELD mounting 
medium with DAPI (H-1200, Vector Labs). All incubations were performed manually and 
in a humidity tray, with minimal exposure to light. Immunofluorescence images were taken 
using a Leica DMLB fluorescent microscope and Q Capture Pro7 software (QImagng). 
Images were acquired by single excitation of each wavelength (separately) and channels 
subsequently merged.   
5.3.5 Quantification of AQP4 Expression Across Blood Vessel Cross Sections 
Evaluation of the localisation of AQP4 to perivascular end feet and glial limitans was 
performed by measuring the pixel intensities of CD31 and AQP4 immunoreactivity across 
cross sections of blood vessels in each of the brain regions studied. For this, vessel containing 
ROIs were identified on DAPI images: identified using flattened nuclei, clusters or lines of 
nuclei out of focus compared to the surrounding tissue and ‘negative’ space between nuclei 
without background fluorescence. Fluorescent intensity for both CD31 and AQP4 markers 
were measured across a single 4μm axis perpendicular to the vessel orientation, and 
expressed as intensity, normalised to the intensity of a randomly selected background ROI 
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in the same image for each antigen, to generate linear plots of fluorescence extending from 
the brain tissue, into the vessel and again into the surrounding brain tissue.   
5.3.6 Quantification of AQP4 Polarisation 
Perivascular polarisation of AQP4 was measured as previously described [183]. Briefly, the 
median immunofluorescence intensity of perivascular regions was measured. A threshold 
analysis was then used to measure the percentage of the region exhibiting AQP4 
immunofluorescence greater than or equal to perivascular AQP4 immunofluorescence 
(AQP4 % area). Polarisation was expressed as the percentage of the region that exhibited 
lower AQP4 immunoreactivity than the perivascular end feet. AQP4 vessel coverage was 
measured by firstly delineating the area of the vessel from the CD31 channel image. This 
ROI was then placed on the AQP4 channel image thresholded for immunoreactivity for 
extraction of the percentage vessel coverage (% immunoreactivity of AQP4 of whole 
delineated vessel). 
5.3.7 Statistical analysis  
Statistical comparisons between groups were performed via either a repeated measures two-
way analysis of variance (ANOVA) followed by post-hoc Bonferoni post-tests for multiple 
comparisons (for MRI data), or a regular two-way ANOVA followed by post-hoc Bonferoni 
post-tests for multiple comparisons (for all other grouped comparisons not containing 
repeated measures). All statistical testing was performed using GraphPad Prism (v7 for 
Windows, San Diego, CA, USA). All data is represented as mean ± SEM for the n number 




5.4 Results  
5.4.1 Glymphatic inflow, tau and AQP4 in rTg4510 transgenic mice with age 
The regions most affected by pathology in the rTg4510 model – the cortex and hippocampus, 
were analysed. Based on the observations in Chapter 4 (section 4.4.1), where a difference in 
contrast enhancement was seen between the rostral and caudal cortices, the cortex was also 
further separated into these sub regions. Contrast enhancement to the caudal cortex was 
elevated in the wild types at all ages compared to the rostral cortex, as previously observed 
(Figure 33). Compared to the wildtype group, in the transgenic group, glymphatic inflow 
was reduced in the caudal cortex at 2.5 months (Figure 33 D; p<0.05 from 48 – 60 mins, 
p<0.01 from 72 – 96 mins, p<0.001 from 108 – 180 mins ) and then markedly elevated in the 
rostral cortex at 7.5 months of age (Figure 33 C; p<0.01 from 108 – 180 mins). This elevation 
of glymphatic function was also observed in the hippocampus of the transgenic group, but 
did not attain statistical significance during the time course (Figure 33 I). To then determine 
if these differences were a caused by differences in rates of contrast ingress into these regions, 
the slopes of the curves were calculated as a surrogate estimate of glymphatic inflow (Figure 
34). In these analyses, the hippocampus showed the most marked difference in ingress rate, 
however, this did not achieve statistical significance.  
Next, to further probe potential differences in the dynamic MRI timeseries data between the 
rTg4510 and WT groups, the ‘penetration efficiency’ was calculated as described in Chapter 
4, section 4.3.4. This metric revealed an increase in the in the rostral cortex (Figure 35 A; 
mean difference = 0.51 more in the rTg4510s compared to wildtype, p=0.13) and 
hippocampus (Figure 35 I; mean difference = 0.18 more in the rTg4510s compared to 
wildtype, p=0.01) of the rTg4510s in the 7.5 month group when compared to their wildtype 
counterparts, with the hippocampus (Figure 35 I) achieving statistical significance at this age. 
GFAP, a marker of astroglial activation, increased  with increasing burden of tau across ages 
and regions,  with the most significance observed in the cortex  at 5 months, a stage reflecting 
mature tangle formation (Figure 35 C, G; rostral cortex mean difference = 5.89% more in 
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rTg4510s compared to wildtype, p<0.0001; caudal cortex mean difference = 4.54% more in 
rTg4510s compared to wildtype, p=0.0005), and 7.5 months, during neurodegeneration 
(Figure 35 C, G; rostral cortex mean difference = 8.19% more in rTg4510s compared to 
wildtype, p<0.0001; caudal cortex mean difference = 11.22% more in rTg4510s compared to 
wildtype, p<0.0001). In the hippocampus, the most significant elevation was observed at 7.5 
months (Figure 35 K; mean difference = 8.13% more in rTg4510s compared to wildtype, 
p=0.0002). AQP4 levels mirrored the elevations in GFAP levels, but did not attain 






















































































































































































































































































































































































































































































































































































































































































5.4.2 Regional differences between the rostral and caudal cortices of the rTg4510 
mouse model 
In order to tease out the differences in inflow between the rostral and caudal cortex and study 
the association to pathological burden, these two cortical regions of the transgenics were next 
analysed against each other (Figure 36). This was carried out to build on the findings from 
Chapter 4 (section 4.4.1), where higher contrast enhancement was observed in the caudal 
cortex compared to the rostral cortex (Figure 28 D).  
Here, a significant impairment in contrast enhancement was apparent in the rostral cortex in 
the 2.5 month group (Figure 36 A; p≤0.05 from 96 – 168 mins, p=0.005 at 180 mins), a 
similar trend of which was also seen in the 5 month group (Figure 36 B). In the 7.5 month 
group however, this trend was reversed, with the caudal cortex showing impairment in 
contrast enhancement compared to the rostral cortex, but without statistical significance 
(Figure 36C). Visual assessment of the histological sections (Figure 36 E) revealed a modest 
increase in tau burden in the rostral cortex at 2.5 months and 5 months, compared to the 
caudal cortex. PG5 quantification too showed that the tau burden in the rostral cortex was 
elevated at 5 months compared to the caudal cortex (Figure 36 F; mean difference = 8.25% 
more in the rostral cortex). The corresponding penetration efficiency from the MRI 
experiments revealed that this metric was inversely related to tau accumulation at 5 and 7.5 
months of age (Figure 36 D; mean difference = 0.33 less at 5 months and 0.6 more at 7.5 
months in the rostral cortex). 
On studying GFAP (Figure 36 G), this marker increased with age in both rostral and caudal 
regions, showing increased astroglial activation. A significant increase in GFAP was 
observed at 7.5 months of age during the most severe stage of pathology, in the caudal cortex 
compared to the rostral cortex (mean difference = 3.58% more in the caudal cortex compared 
to the rostral cortex, p<0.05). AQP4 also increased with age in both regions, with the caudal 





Figure 36. MRI T1 signal intensity (% change from baseline) vs. time data acquired from the rostral 
and caudal cortices of rTg4510 (A) 2.5 month (n = 5), (B) 5 month (n = 4) and 7.5 month (n = 4) 
animals. (D) Penetration efficiency in each of the brain regions in which raw data and sigmoidal curves 
are displayed in A - C. Percentage immunoreactivity of (F) tau, (G) GFAP and (H) AQP4 in the 
corresponding regions from D. (E) Representative histological images with PG-5 staining demonstrating 
the gradient of tau accumulation in the rostral cortex from 2.5, 5 and 7.5 months. Statistical significance 
denoted by asterisks: *=p<0.05, **=p<0.01. 
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5.5 Discussion  
In this work, whole brain assessment of glymphatic inflow was carried out using the MRI 
protocol set up in the previous chapter. The rTg4510 model was assessed at 3 stages of 
pathology – 2.5 months, during the onset of tangle formation; 5 months, where the presence 
of mature tangles is expected; and 7.5 months, when neurodegeneration commences [94]. 
This approach attempted to tease out  if glymphatic impairment was related to pathological 
tau burden, and if changes occurred early, prior to the onset of severe pathology. The 
rTg4510 model expresses pathological mutant tau throughout the cortex and hippocampus 
given the strong action of the CaMKIIa forebrain promoter [95]. Thus analyses were focused 
in these regions.  
Notably, the overall percentage inflow in the wild type brains was lower compared to the 
previous C57BL/6J wild type experiments. A reasonable explanation for this variance may 
be the difference in background genetic strain, as the rTg4510 is on a mixed 129S6xFVB 
background, and littermates from the transgenic cohort were used here as controls. Strain 
differences can account for a myriad of brain differences. In one study that compared the 
129S6 strain to the C57BL/6, they found the most significant morphological variances in 
areas corresponding to the motor and the anterior somatosensory cortices [222]. 
Interestingly, these regions are included in the rostral and caudal cortices analysed in the 
work presented here, and so regional glymphatic patterns can be expected to vary between 
morphologically distinct strains. In another study, analyses of vascular branching and 
cerebral blood flow in C57BL6 and BALB/c strains found morphological differences 
between arterial branching patterns, which then influenced the values of blood flow between 
strains [223]. Given the evidence for such inter-strain differences in the brain morphology 
and perfusion, changes to glymphatic function between strains may be expected. In light of 
these findings, a future comparison between commonly used inbred strains, which 




Given the difference in contrast intensity observed between the rostral and caudal cortices in 
the wild type characterisation in Chapter 4 (section 4.4.1), these subregions were segmented 
separately. This was particularly of interest in this study, given the early histological 
difference in tau deposition observed between these regions. If the levels of cortical tau in 
this model solely corresponded to the transgene expression, one would expect homogenous 
burden throughout the cortex given the strong forebrain CaMKIIa promoter driven pattern 
of the transgene [95]. The reduction in contrast penetration in the rostral cortex (Figure 35 
D), as measured by MRI in the 5 month group, coupled with the increase in tau deposition 
in this region (Figure 35 F) suggests that the regional differences in glymphatic function may 
be a contributing factor towards the difference in pathological burden between these regions. 
Improved glymphatic clearance in the caudal cortex of the mouse brain, prior to 
neurodegenerative changes, may be reducing the amount of deposited tau in that region. The 
subsequent loss of this effect by 7.5 months could be attributed to the continued robust 
expression of the transgene with age. At later stages in the pathological timeline, the severe 
tau accumulation throughout the forebrain may surpass the benefits of any regional 
glymphatic clearance efficiencies.  
Neurodegenerative changes may also account for the differences observed between 
transgenics and wild types at 7.5 months. Previous MRI studies of the rTg4510 brain has 
revealed significant atrophy of the cortex and hippocampus [224] – the regions that suffer the 
most tau burden, with the progressive nature of this loss markedly detectable by 7.5 months 
using morphometric analyses [225]. In these data, the earliest tau pathology is apparent in 
the hippocampus and the rostral cortex (Figure 35E). This places the rostral cortex as the 
region that closely follows the hippocampus, with the caudal cortex coming in last in the 
pathological cascade. Taking this view, the elevation in contrast in the hippocampal and 
rostral cortical regions of the rTg4510s compared to wild types at 7.5 months indicates  that 
the magnitude of inflow is related to the regional degree of tau pathology at this age. This 
can be explained by the corresponding degree of neurodegeneration within these regions. 
Extracellular volume [182] and tortuosity [161] are both factors that contribute to glymphatic 
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efficiency. If the extracellular space increases in volume and becomes less tortuous with 
increasing cell loss in these regions, the movement of solutes through these regions, including 
MR contrast agents, may accelerate. 
Changes to cytoarchitecture during neurodegeneration may also manifest as glymphatic 
changes at a cellular scale. GFAP is an astrocytic marker which is known to be upregulated 
during aging and neurodegeneration [226]. The amount of GFAP in the rostral and caudal 
cortices closely mirrored the degree of tau pathology within these regions at all time points, 
demonstrating increasing astrogliosis with progression of pathology. AQP4 also increased 
with age. In mice, perivascular loss of AQP4 is a feature of the aging brain [183], is associated 
with glymphatic impairment, and this perivascular loss is accompanied by the redistribution 
of AQP4 to parenchymal processes of reactive astrocytes [153]. In a study exploring AQP4 
in human AD subjects, the loss of perivascular AQP4 was accompanied by an increase in 
AQP4 expression [205]. It is likely that the regional observations here reflect these discrete 
cellular changes, brought about by mutant tau overexpression and the subsequent onslaught 
of the neurodegenerative process. However, it must be noted that experimental factors 
precluded the broader analysis and interpretation of immunofluorescence data (Section 
5.3.6) which was performed to study AQP4 polarisation. Due to limited sample availability, 
combined with perfusion artefacts giving rise to mouse-on-mouse reactivity, a 
comprehensive analysis was hindered. This was further mired by the variation in vessel size 
across collected sections, as well as non-specific fluorescent signals arising from the nuclei 
and other organelles which pointed to an error in the immunostaining process.  
Exploring distinct regional differences in the AD brain is of  interest given the staged nature 
of pathology through the course of the disease. Studies mapping cytoarchitecture indicate 
that the human homologue of the mouse rostral cortex topographically maps to the human 
anterior cingulate cortex, whereas the mouse caudal cortex closely resembles the human 
retrosplenial cortex [227]. Studies segmenting these distinct regions in the brains of familial 
AD subjects note that volumetric differences exist between these regions despite their close 
connectivity [228].  As such, it is judicious to study fine and progressive fluctuations in 
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glymphatic function in the regions most vulnerable to AD pathology, in order to understand 
how rates of tau clearance may contribute to these detrimental neurodegenerative changes. 
Furthermore recent observations have suggested that tau, using the extracellular space as a 
conduit, is able to propagate from neuron-to-neuron via a prion-like mechanism  [229]. The 
functional relevance of appropriate glymphatic clearance of extracellular tau may therefore 
be of prime importance in neurodegenerative tauopathies, in which propagating pathology 
is thought to occur.  
An additional consideration to take is the recirculating nature of the glymphatic pathway 
and its contribution to ongoing pathology. CSF tau is highly stable compared to Aβ (12-
14hrs half-life in CSF compared to 2hrs for Aβ) [230,231]. Once tau is cleared from the 
parenchyma into the CSF sink, tau-laden CSF may be re-internalised into the parenchyma 
itself, or at the very least, may enter the periarterial space [157]. Periarterial deposition is 
known to occur with other parenchymal proteins cleared via this pathway, such as Aβ, in 
the form of cerebral amyloid angiopathy (CAA). Interestingly, tau labelling has been shown 
to colocalise with CAA in AD brains [232].  As  such, in understanding the glymphatic 
contributions towards the mechanisms of AD onset, both tau and Aβ pathologies must be 
investigated in tandem to elucidate a clear mechanistic picture. To that end, the study that 






6. Glymphatic Function in Amyloidosis Models of Alzheimer’s 
Disease 
Following on from the previous chapter, here, whole brain glymphatic changes are investigated 
in two mouse models of amyloid pathology, using magnetic resonance imaging. 
 
6.1 Summary 
Cerebrospinal fluid levels of Aβ are a vital clinical marker of Alzheimer’s disease onset. Thus, 
understanding the transit of Aβ species through the fluid compartments of the brain and it’s 
causative mechanisms in plaque pathology is beneficial in understanding disease 
progression. Previous glymphatic studies of Alzheimer’s disease and related pathologies have 
had a particular focus on Aβ, but have not characterised amyloid-driven glymphatic changes 
taking a whole brain approach. This study aimed to address that gap and build on the 
previous work presented, which characterised glymphatic changes in disease models of 
tauopathy and aquaporin-4 dysfunction. Here, the whole brain magnetic resonance imaging 
methodology was replicated on two models of amyloid pathology – one which overexpresses 
mutant human amyloid and a second which expresses mutant amyloid at endogenous levels. 
This two-tiered approach was designed to elucidate any subtle changes in dynamic fluid 
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Understanding the various clearance mechanisms of Aβ and tau from the brain is surely a 
vital step towards developing new treatment strategies for Alzheimer’s disease (AD). 
Aquaporin-4 mediated glymphatic clearance of amyloid-β (Aβ) and tau and its role in AD 
onset is still not fully explored. However, given the presence of both molecules in 
cerebrospinal fluid (CSF) during AD progression [117], they both present as viable 
candidates for removal via the glymphatic pathway.    
CSF levels of two amyloid species, Aβ40 and Aβ42, are clinically used biomarkers. 
Decreases in CSF Aβ42  correlates with disease progression and increasing plaque load, and 
although CSFAβ40 levels are relatively unaffected, a decrease in ratio of CSF Aβ42:Aβ40 is 
associated with AD status [118]. If these decreases in CSF levels are caused by Aβ species 
being sequestered into plaques, it is important to understand if glymphatics play a part in 
propagating this pathology – either by recirculating glymphatic delivery of CSF species into 
the brain encouraging plaque formation, or by a lack of glymphatic removal contributing to 
an increase of these Aβ  species within the parenchyma.   
In the original work that characterised glymphatic function, the movement of Aβ via this 
pathway took the spotlight. In that work, Iliff et al. showed that clearance of radioactively 
labelled Aβ40 injected into the brain was cleared over time, and fluorescently labelled Aβ40 
accumulated along large draining veins. Radioactive Aβ40 infused intracisternally also 
entered the brain in a pattern that was characteristic of other glymphatic solutes. Notably, 
they also showed a reduction in of all these measures in AQP4 null mice [151]. Subsequently, 
using a similar approach, Peng et al., showed glymphatic impairment in the APP/PS1 mouse 
model of AD. They found that brain uptake and clearance of radioactively labelled Aβ 
reduced with advancing age in APP/PS1 mice, with glymphatic impairment being apparent 
at an age prior to plaque formation. Additionally, by infusing fluorescently labelled Aβ40 
and Aβ42, they showed that these species  can enter the brain along penetrating arteries, with 
the infused Aβ40 having an affinity to gather around existing endogenous plaques [217]. 
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Previous studies in this amyloidosis model have also shown that deletion of AQP4 
exacerbates memory deficits and Aβ accumulation in these mice [204].  
Taking these findings into account, the next experiments aimed to dynamically image 
glymphatic flow patterns in amyloidosis models of AD, using dynamic contrast-enhanced 
(DCE) magnetic resonance imaging (MRI). If perturbances in glymphatic inflow contribute 
to the aforementioned observations implicating Aβ as a substrate, I hypothesised that this 
will be observable by DCE-MRI and provide a wider, more detailed picture of these changes, 
above and beyond the single snapshot view enabled by florescent and radioactive tracers. 
Here, I aim to build on the work I presented in Chapter 4, where I showed that glymphatic 
inflow can be visualised in real time using MRI and this can be visibly altered by  
pharmacologically blocking AQP4, as well as the work in Chapter 5, where differences in 
glymphatic function were demonstrated in tauopathy. In this work, to surpass any 
macroscopic effects due to neurodegeneration and atrophy, the model J20 (PDGF-
APPSw,Ind) was used, as it is one that which accumulates plaque pathology in the brain, 
but shows minimal neurodegeneration [96]. Given that a significant criticism that mouse 
models of AD are met with is the artificial exacerbation of phenotypes due to overexpression, 
a second newer amyloid model, the APP NL-F mouse model, was also included in this study. 
This mouse model expresses endogenous levels of APP, and develops plaque pathology 
slower and later in its lifespan [98], thus enabling a more timely study of the preclinical stages 
of disease.   
 
6.3 Methods  
6.3.1 Mice 
Generation of homozygous J20 (PDGF-APPSw,Ind) [96] and APP NL-F [98] transgenic 
mice have been described previously. The J20 (n = 6) and litter matched wildtype (n = 8) 
mice were licensed from the J. David Gladstone Institute (San Francisco, California, USA). 
The NL-F (n = 9) and litter matched wildtype (n = 13) mice were licensed from the Riken 
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Institute (Tokyo, Japan). Both strains were imported into the United Kingdom, bred at the 
University College London (UCL) Institute of Neurology, and transferred for study at UCL’s 
Centre for Advanced Biomedical Imaging. For the J20 study, male and female mice at 6 
months of age were used. For the NL-F study, male and female mice at 8 months of age were 
used. All animal work was performed in accordance with the United Kingdom’s Animals 
(Scientific Procedures) Act of 1986 and was previously approved by UCL’s internal Animal 
Welfare and Ethical Review Body. Mice had unrestricted access to food and water, and were 
housed under automatically controlled temperature, humidity, ventilation and 12h 
light/dark cycle settings.  
6.3.2 Surgical preparation, magnetic resonance imaging and image analysis 
The experimental methods employed in Chapter 4 were replicated for the MRI preparation, 
imaging and analysis in these experiments, and are detailed in sections  4.3.1 – 4.3.4.   
6.3.3 Amyloid Immunohistochemistry  
Immunohistochemistry was performed in order to quantify cortical deposition of amyloid in 
J20 and NL-F mice. Mice were perfused with phosphate buffered saline (PBS) followed by 
10 % buffered formalin (VWR catalogue# 9713.1000) before being processed using the 
Tissue TEK VIP processor (GMI Inc.) and embedded in paraffin wax. 6μm thick sections of 
the brain in the sagittal plane were collected using a rotary microtome and mounted on glass 
slides. Following de-paraffinisation and rehydration of the tissue sections, antigen retrieval 
was performed using the Lab Vision PT module system (Thermo Scientific), where sections 
were heated to 100°C for 20 min in citrate buffer (TA-250-PM1X; Thermo Scientific). Slides 
were transferred to a Lab Vision Autostainer (Thermo Scientific). 
The following incubations were performed: 10 min in H2O2 (0.3%); 30 min in normal goat 
serum (1:20; Vector Laboratories); 60 min in primary antibody for amyloid  (b3D6; 1:1000 
from Eli Lilly, USA); 30 min in biotinylated goat anti-mouse IgG (1:200, BA9200; Vector 
Laboratories); 30 min avidin-biotin complex solution (PK-7100; Vector Laboratories); 5 min 
in 3,3′-diaminobenzidine (SK-4105; Vector Laboratories).   
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Apart from the last two steps, PBS with 0.05% Tween-20 (PBS-T) was used for diluting 
reagents and washes between steps.  Sections were then counterstained with haematoxylin 
before dehydration and cover-slipping. Stained sections were digitised using the Scanscope 
AT slide scanner (Aperio) at 20× magnification.  
6.3.4 Statistical Analysis 
Statistical comparisons between groups were performed via either a repeated measures two-
way analysis of variance (ANOVA) followed by post-hoc Bonferoni post-tests for multiple 
comparisons (for MRI data), or a regular two-way ANOVA followed by post-hoc Bonferoni 
post-tests for multiple comparisons (for all other grouped comparisons not containing 
repeated measures). All statistical testing was performed using GraphPad Prism (v7 for 
Windows, San Diego, CA, USA). All data is represented as mean ± SEM for the n number 
of animals in each group, which are detailed in figure legends. 
 
6.4 Results 
6.4.1 Glymphatic inflow in J20 transgenic mice 
Glymphatic inflow in the J20 transgenic mice was not altered compared to wildtype 
littermates at 6 months of age (Figure 37). Inflow in the cortex and hippocampus, areas 
vulnerable to plaque accumulation in this model, was low, however, this was no different to 
the wildtypes. Regions closest to the infusion site such as the cerebellum and hindbrain 
showed the most marked increases in contrast enhancement in all mice.  
Histopathological study of the brains revealed few to no visible mature plaques in the cortical 
and hippocampal regions (Figure 38), confirming that this model did not have profound 
pathology at the age that was assessed and represents a preclinical phase in its timeline. 
Quantification of the plaque load confirmed that whilst % burden of pathology was relatively 
low, the highest amyloid immunoreactivity was seen in the hippocampus (Figure 39).  
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A notable observation in the J20 cohort was that they were very sensitive to anaesthesia. In 
order to maintain optimal depth of anaesthesia, the isoflurane levels were continually 
adjusted throughout the imaging time for some mice. This was particularly apparent in mice 
that were subsequently revealed to be wildtype (after unblinding, post-analysis), but not 
restricted to this group. Two mice from this cohort did not complete the MRI protocol due 
to a leak in the infusion line found after commencement of the experiment. Routine 
regenotyping results retuned at the end of the project revealed that a further two mice were 
genotypically ambiguous. These mice were also eliminated from the study, thus resulting in 
the total loss of four mice in the cohort from the MRI analysis. 
  
Figure 37. MRI T1 Signal Intensity (% change from baseline) vs. time plots from J20 (PDGF-
APPSw,Ind) (n = 4) and wild type (WT) animals (n = 6) at 6 months of age, demonstrating penetration 




Figure 38. (A - D) Representative immunohistochemistry images of 6 month old J20 (top) and wildtype 
(WT) (bottom) sections stained with b3D6, taken at 0.3x (left) and 4 (right) magnifications. Limited 




Figure 39. Percentage immunoreactivity of amyloid quantified in a subset (n = 6) of brains in the mice 
from the J20 cohort. The cortex and hippocampal regions are presented as areas of high pathology and 
the thalamus is presented as a control region. Statistical significance denoted by asterisks: ***=p<0.001. 
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6.4.2 Glymphatic inflow in NL-F transgenic mice 
No changes in glymphatic inflow were observed between NL-F transgenic and wildtype 
littermates (Figure 40). However, the interpretation of these data were marred by several 
factors which I believe adversely affected this dataset. Due to delays in shipment, the mice 
had minimal in-house acclimatisation time. In addition, several mice arrived marked with 
health concerns, three of which got progressively worse during housing at our Centre, or 
during experimental set up. These mice were eliminated from the experiments based on 
advice from the Named Animal Care and Welfare Officer. Routine regenotyping performed 
at the end of the project also revealed nine further genotypic changes (with there being 
ambiguity between mutants and wildtypes), an observation also apparent in the phenotypic 
characterisation of plaques during histology (Figure 41). Thus, a total of twelve mice from 
this cohort were eliminated from the MRI analysis. 
 
Figure 40. MRI T1 Signal Intensity (% change from baseline) vs. time plots from homozygous 
transgenic NL-F (n = 3) and wildtype (WT) animals (n = 7) at 8 months of age, demonstrating 
penetration of Gd-DTPA tagged CSF over time in selected brain regions. 
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A subset of histologically confirmed transgenic mice were quantified for amyloid burden in 
the cortex and hippocampus, regions expected to have high pathology, and thalamus, used 
as a control region (Figure 42). This analysis confirmed the significant elevation of plaque 
pathology in phenotypically confirmed NL-F homozygotes, some of which were shipped as 
wildtypes. Given these discrepancies, no further analysis was carried out on this cohort.  
 
Figure 41. (A - D) Representative immunohistochemistry images of 8 month old NL-F (top) and 
wildtype (WT) (bottom) sections stained with b3D6, taken at 0.3x (left) and 4 (right) magnifications. 
Virtually no plaque pathology is seen in NL-F mice at this early age. 
 
 
Figure 42. Percentage immunoreactivity of amyloid quantified in a subset (n = 8) of brains in the mice 
from the NL-F cohort. The cortex and hippocampal regions are presented as areas of high pathology and 





In this work, glymphatic changes in models of amyloid pathology were probed to advance 
the observations reported in the two previous chapters. Two different transgenic lines, at the 
relevant stage in each model’s timeline prior to the accumulation of plaques, were used to 
elucidate if glymphatic changes precede protein accumulation as previously described, and 
if these changes could be detected regionally and globally across the brain. In both models, 
no changes in inflow were observed using DCE-MRI, with histology confirming low levels 
or absence of plaques in the brain. This is at odds with the work published by Peng et al. 
[217], which this work aims to build on, which showed early glymphatic impairment in 
APP/PS1 mice. However, several procedural and experimental variances may have 
contributed to these discrepancies. 
Looking first to the J20 cohort, at first glance it is tempting to speculate that no changes in 
glymphatic function are seen prior to plaque formation, and such changes may occur 
downstream of the neurodegenerative process, particularly taking into account the finding 
from the rTg4510 study in Chapter 5. But given that APP/PS1 amyloid mice show 
glymphatic changes even prior to plaque accumulation, which then progresses during 
pathology [217], it suggests that differences between varying strains of transgenic models 
may exist.  
Previous studies in the J20 mouse have reported a reduction in cerebral perfusion in this 
model [233]. Changes in perfusion can interplay with a number of physiological parameters 
including perfusion pressure, vascular radius and changes in blood viscosity [234]. Given 
that arterial pulsations are thought to be a key driving force in CSF ingress into the brain 
[156], then it is plausible that changes in cerebral haemodynamics can also affect glymphatic 
influx by proxy. Additionally, pre-treatment with Aβ40 has been shown to reduce 
glymphatic inflow in the mouse brain [217], and interestingly, this is the species that is more 
abundant in the interstitial fluid of the J20 brain as early as 3 months [235]. These findings 
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would collectively imply that J20 mice would be expected to have reduced glymphatic inflow 
compared to wildtypes.  
However, the cohort of J20 mice did not show differences between their wildtype 
counterparts, with even the wildtypes curiously not fully following the characteristic pattern 
of inflow previously described. Regions closest to the infusion site such as the cerebellum 
and hindbrain showed the most contrast enhancement, with deep brain structures such as 
the hippocampus, and regions furthest away from the route of glymphatic flow, such as the 
cortex, showing the least contrast. These characteristics point to an experimental shortfall.  
A notable observation made during the J20 experiments was the  ineptitude of this strain to 
tolerate isoflurane anaesthesia in the robust way observed in the wildtype C57/BL6J mice 
used in the TGN-020 experiments, or the rTg4510 transgenic cohort. Several but not all of 
the mice in the J20 cohort took longer to achieve a depth of anaesthesia required for surgical 
preparation, and once in the scanner, had to be carefully regulated to maintain an optimal 
physiological range in parameters that monitor the mouse’s welfare, including heart rate and 
core temperature, during the experiment. In a recent study that investigated glymphatic 
function under a variety of anaesthetic regimens, choice of anaesthetic was found to be a 
sensitive factor in determining glymphatic efficiency. Using fluorescent tracer experiments, 
Hablitz et al. showed that ketamine/xylazine anaesthesia enabled the highest tracer influx, 
and isoflurane had the least, however, influx under isoflurane was markedly increased when 
supplemented with dexmedetomidine [236]. This observation is in keeping with similar 
findings from a different study which found that a combination of low dose isoflurane with 
dexmedetomidine evoked a higher glymphatic response (as measured by DCE-MRI in rats) 
than a high dose of isoflurane alone. But the authors also noted that the depth of anaesthesia 
was deeper in the higher dose of isoflurane, as quantified using electroencephalography  
[237]. This study also noted a 2% increase in the CSF compartment volume in the animals 
treated with the combination of the two anaesthetics, which contributed to the increased 
glymphatic efficiency reported.  
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Isoflurane is also known to have a marked effect on cerebral blood flow and volume [238].  
Given the continuous fluctuations in anaesthetic dose that were required to maintain the J20 
mice at a physiologically safe and experimentally acceptable depth in this cohort, it is 
possible that this negatively affected cerebral haemodynamic stability and contributed to data 
drift, thus marring glymphatic observations during this study. The variable response to 
isoflurane in the J20 mice was intriguingly more apparent in, but not restricted to the 
wildtype mice in this study. Since the J20 mice are bred on the C57/BL6J background, a 
strain which tolerated isoflurane in the previous experiments, this then raises the intriguing 
possibility that differences in anaesthesia tolerances can differ between lineages of mice bred 
in different centres or conditions, even on the same genetic background, and thus 
consequently indirectly contribute to differences in glymphatic and other physiological 
measures. To rectify this, a repeat study of this nature would ideally benefit from utilising 
ketamine/xylazine anaesthesia. However, the prolonged dose required for dynamic imaging 
must be carefully considered, given the deleterious cardiac and respiratory effects brought 
about by high ketamine/xylazine exposure [239], which may also consequently affect 
glymphatic measures. This poses a trade-off between experimental design and data integrity 
when undertaking investigations in whole brain glymphatic function across different strains 
and lineages. 
Surveying the NL-F data, the small number of mice that were retained in the preliminary 
analysis suggest that no changes in glymphatic inflow are apparent prior to the onset of 
plaque formation. However, given the unfortunate obstacles faced by the cohort in this study, 
it is imprudent to make hasty interpretations about this model from this dataset. The NL-F 
line was included in this experimental plan to study a model with more naturally progressing 
pathology, as it is not an overexpression model. Although artificial overexpression of 
amyloid in other models may be perceived as a problem, in practical terms, the extremely 
slow progression of NL-F mice may also hinder the experimental progress and diminish the 
high-throughput advantage of using mouse models. Although plaque pathology is expected 
by 6 months of age, in this study, very few plaques were observed, with very little phenotypic 
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distinction between transgenics and wild types. An alternative approach to study this model 
would be the use of the NL-G-F mouse model. Whilst the NL-F mice harbour the Swedish 
and Iberian familial APP mutations, the NL-G-F mice also carry a third additional mutation 
from an Arctic kindred, and develops plaque pathology as early as 3 months, but still without 
overexpression [98]. The use of this transgenic line would seem more practical whilst still 
presenting a realistic model of disease progression, and may thus be more useful in 
understanding the glymphatic changes that precede amyloid accumulation. Alternatively, a 
carefully timed older cohort of NL-F mice with slightly more advanced pathology may be 
worth studying. This may provide a view of glymphatic changes during the onset of 
endogenous Aβ accumulation. Given the logistics required to procure, breed, age and 
genotype these mice, it was infeasible to schedule these follow up experiments within the 
duration of this research programme.  
With the ups and downs of this study, aquaporin-4 profiles were not characterised in this 
study. However, given the evidence presented earlier in this thesis and that available in the 
body of literature, studying the molecular signature of aquaporin-4 in mouse models of AD 
and in human brains may act as a conduit for glymphatic changes in the brain. In doing so, 
it may be possible to glean a better understanding of the relationship between altered  
clearance mechanisms and the onset of AD brought about by the hallmark accumulation of 






7. Relationships Between Alzheimer’s Disease Pathology and 
Aquaporin 4 in Humans 
This chapter extends the theme of this thesis into human brain, by studying aquaporin-4 profiles 
in Alzheimer’s disease and assessing its relevance to the development of human pathology. 
 
7.1 Summary 
There is currently limited evidence that pertains to the function of the glymphatic system in 
the human brain. Given the invasive nature and challenging experimental set up required for 
dynamic imaging of the glymphatic system in animal models, quantifying glymphatic 
changes during Alzheimer’s disease progression in human subjects is currently infeasible. 
With the abundance of evidence showing the role of aquaporin-4 in maintenance of brain 
homeostasis and glymphatic function, probing this water channel provides a surrogate 
measure for gauging glymphatic function and possible perturbances to this system in the 
human brain. Here, by studying aquaporin-4 alongside the gold standard neuropathological 
confirmatory hallmarks of the disease, amyloid-β and tau, some barriers to studying changes 
to glymphatic components in humans are partially overcome. It’s implication in the human 
disease is probed by comparing histological measures in Alzheimer’s, cognitively impaired 
and cognitively normal subjects. Additionally, the possible role of polymorphic changes in 
the aquaporin-4 gene in humans is examined, and changes to dystrobrevin, a protein linked 
to aquaporin-4, is investigated in mouse models. 
 
The work in this chapter was carried out in the laboratory of Jeffery Iliff during a collaborative research 
placement at Oregon Health and Science University, USA. I would like to thank Randy Woltjer for 
preparing the human brain sections and guiding the hippocampal ROI drawings, Natalie Roese for 
performing the wet laboratory work on these human tissues and Marie Wang for harvesting the mouse 
tissue used in these experiments prior to the commencement of my placement.
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7.2 Introduction  
With the desperate lack of  disease modifying treatments for Alzheimer’s Disease (AD), and 
no clear indication as to what brings about sporadic AD, much is yet to be resolved on disease 
onset and modification. The failure of clearance of amyloid beta (Aβ) causing build-up, and 
the prion-like spread of tau and accumulation into neurofibrillary tangles (NFTs), are 
research themes that provide targets of significant interest. The glymphatic system has been 
highlighted as a clearance pathway for Aβ [151] and tau [184] via exchange between 
cerebrospinal fluid (CSF) and interstitial fluid (ISF). Experiments in mouse models have 
provided evidence that these pathogenic molecules are participants in this clearance 
pathway, and that aging can deplete the dynamics of this system [183]. This therefore 
implicates glymphatic clearance as a potential target for the understanding and treatment of  
AD. Readily visualising this system in vivo requires the translation of contrast-dependant 
imaging techniques which pose several significant hurdles – performing long serial magnetic 
resonance imaging (MRI) scans in humans is impractical and the administration of contrast 
has clinical limitations. Furthermore, if arterial pulsations drive inflow [156], then humans 
would be expected to have slower dynamics than rodents, given the significantly lower heart 
rate, significantly larger brain volume and differential CSF production rates compared to 
rodents [240]. Indeed, the precise relationships between these parameters and glymphatic 
function remain to be seen. 
Limited studies exist in demonstrating glymphatics in humans [241–243]. In one study 
glymphatics were measured in humans with idiopathic normal pressure hydrocephalus, a 
neurodegenerative disease which relies on CSF diversion as a treatment method. When a 
bolus of contrast agent gadobutarol was intrathecally administered, they observed the inflow 
of contrast along leptomeningeal arteries in both patient and healthy control groups, but 
delayed parenchymal enhancement in the patient cohort [241]. Interestingly, enhancement 
peaked overnight, which is in line with observations reported in rodents, where sleep was an 
enhancer of glymphatic function [182]. In another study tracing the draining route of CSF to 
peripheral lymphatics via glymphatic transit, cervical lymphatic enhancement of 
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galdobutorol coincided with enhancement in the parenchyma, and not ahead of this time, 
indicating that CSF was not directly draining into the lymphatic system [242]. These human 
experiments pave the way for the study of human glymphatic function.  
Before these experiments can be extended to the more challenging scenario of AD, it is 
prudent to study the cellular and molecular components in isolation. Aquaporin-4 (AQP4) 
is a water channel known to modulate the dynamics of exchange between CSF and ISF. If 
glymphatics are altered during pathology in the mouse brain, and aquaporin-4 is a key 
mediator of these alterations [151], then probing AQP4 in human tissue offers a good starting 
point. Astrocytic AQP4 in rodents is highly polarised to the brain vasculature, but the 
distribution profile in humans is markedly different. The degree of polarisation to the end 
foot in humans is 1/3rd of that in mice and parenchymal astrocytic AQP4 expression is higher 
[244]. It is conceivable that this difference between species would change fluid exchange 
dynamics.  
Loss of perivascular AQP4 associated with plaque formation has been shown in a mouse 
model of AD [244]. Additionally, recent work in human post mortem brains have shown 
that AQP4 in the cortex in AD brains is less polarised, and that expression patterns change 
in the aging human brain [205]. Genetic studies in human subjects with AD have revealed 
that single nucleotide polymorphisms (SNP) in AQP4 may be predictive of AD status as they 
show significant associations with AD biomarkers [245]. In particular, one SNP known as 
rs3763043, is emerging in ongoing studies as a significant candidate for AD prediction (data 
unpublished, personal communication J. Iliff, 2019).  This may allude to a change in the 
astrocytic end foot profile of AQP4, and as such, associated end foot proteins are also of 
interest. One such candidate, dystrobrevin (DTNA), part of dystroglycan anchoring complex  
(DAC) which anchors AQP4 to the membrane (Figure 43), has also emerged as a gene of 
interest. Recent genetic and expression studies have revealed that DTNA shares a similar 
developmental expression profile to AQP4 [246], and hippocampal expression of DTNA in 
AD subjects is elevated, with this elevation being associated with P-tau pathology in the 
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temporal cortex [247]. Furthermore, SNPs of DTNA are also beginning to show associations 
with several AD biomarkers (data unpublished, personal communication J. Iliff, 2019).  
In this work, these observations are extended upon by novel histological examination of 
human brain slices. Firstly, Aβ and tau pathologies are measured using a more 
comprehensive method than clinicopathological staging, by taking a region-by-region direct 
quantification approach in areas of interest specific to AD. Next, AQP4 is quantified for 
expression and polarisation in the same regions and subjects. These measures are then cross 
examined to establish regional relationships between AQP4 and AD pathology. The data is 
also interrogated to establish if SNPs in AQP4 can be predictive of AD pathology in the 
human brain. In addition, changes in DTNA during aging and during AD pathology are 
examined in mouse models, to build upon my findings from human brain samples.  
 
 
Figure 43. Schematic representation of the dystroglycan anchoring complex and associated end foot 
elements, including aquaporin-4 and dystrobrevin. Reproduced from Simon et.al, 2018 [246].     
 
7.3 Methods 
7.3.1 Human subjects and tissues 
Human samples and subject clinical information (which included age, sex, Braak stage, 
CERAD score, clinical status, clinicopathological status and SNP genotype) were obtained 
from the Oregon Health and Science University (OHSU) Layton Aging and Alzheimer’s 
Disease Centre and associated post-mortem tissue repository, the Oregon Brain Bank. All 
tissue came from volunteers that already signed written informed consent. All subjects 
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underwent brain autopsy after consent was obtained from the next of kin and in accordance 
with OHSU guidelines. The research protocols for these studies were reviewed and granted 
ethical approval by the OHSU Institutional Review Board. A total of 76 subjects, both male 
and female, with an age range of 75 – 105 were included in this study. For the frontal cortex 
analysis, 54 of the immunostained sections were successfully quality controlled and analysed 
and 30 underwent Western blotting due to sample availability. For the hippocampal analysis, 
36 of the immunostained sections were successfully quality controlled and analysed and 20 
underwent Western blotting due to sample availability. 
7.3.2 Immunostaining of human brain sections 
Following post-mortem processing, brains were fixed for at least 2 weeks in 10% neutral 
buffered formalin and dissected into regions of interest, and then embedded into paraffin 
blocks.  Sections were sliced on a microtome at 7μm thickness. Tissue sections, selected from 
the hippocampus and the frontal cortex, were deparaffinised and treated with 10% formic 
acid. Antigen retrieval was performed in sodium citrate buffer (pH 6.0) in a steamer for 20 
minutes. Samples were incubated in the primary antibody in 4% normal serum in PBS with 
0.3% Triton X overnight at 4°C. Primary antibodies used were as follows:  rabbit anti-AQP4 
(1:800; Millipore; catalogue #AB3594), mouse anti-human phospho-PHF-Tau monoclonal 
(AT8; 1:1000; ThermoFisher; catalogue #MN1020), and mouse purified anti-β-Amyloid, 17-
24 (1:800;Biolegend; catalogue# 800701). Following overnight primary incubation, sections 
were incubated with secondary antibody for 1hr at room temperature. Secondary antibodies 
used were donkey anti-rabbit Alexa Fluor 488 (1:400; Life Technologies, catalogue 
#A21207) and donkey anti-mouse Alexa Fluor 594 (1:400; Life Technologies; catalogue 
#A21202). Two batches were stained for each subject and brain region, one batch for tau 
and AQP4 and a second batch from a consecutive section for Aβ and AQP4. Slices were 
mounted using Fluoromount-G mounting medium containing Hoechst 33342 nuclear stain 
(1:10000; Molecular Probes; catalogue #H3570). Immunofluorescence imaging was 
performed on the Zeiss Axio Scan.Z1 fluorescent scanner.  
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7.3.3 Western blotting of human brain sections 
Human Western blot data was available for a subset of subjects also selected for this study, 
and blotting was performed and quantified prior to the commencement of this project as 
previously described [205,247]. Briefly, frozen frontal and hippocampal sections were 
homogenised on ice in tissue homogenization buffer (62.5 mM Tris (pH 6.8), 10% glycerol, 
and 2% SDS) and ultrasonicated. Total protein content in the supernatant was quantified 
using the Pierce™ BCA protein assay kit (ThermoFisher catalogue #23225). 0.1% 
bromophenol blue and 50 mM DTT were added to the sample and denatured at 95°C for 5 
minutes. 50–100 µg of samples were loaded for electrophoresis. Gels were transferred using 
a BioRad Trans-Blot® Turbo™ Transfer System. Primary antibody used was rabbit anti- 
AQP4 (1:500, Millipore catalogue# AB3594) and secondary antibody used was anti-rabbit 
horseradish peroxidase (1:1000; GE Healthcare catalogue #RPN4301). Transferred blots 
were imaged on a BioRad ChemiDoc™ Touch Imaging System. Images were background 
subtracted and band intensities extracted using FIJI ImageJ software (version 1.52i). Bands 
were normalised to a β-actin loading control  (1:1000, Novus Biologicals catalogue # NB600-
501) and normalised values for each blot corrected against a nominated running control for 
each cohort. An average of two replicates for each sample was used. Quantification of the 
expression of the two isoforms by Western blot has also previously been described by this 
laboratory. This was performed by taking the dual band near the 35kDa mark, AQP4-M1 
was defined as the upper band and AQP4-M23 was defined by the lower band [205]. 
7.3.4 Manual counting of plaques and tangles 
Micrographs were analysed using FIJI ImageJ software (version 1.52i) and the investigator 
was blinded to subject dementia status. For the cortex, 12 regions of interest (ROI) that were 
a 1000 x 1000 pixels were placed across the section (Figure 44 A), with 6 spread across the 
frontal cortex grey (FCG) matter and 6 across the frontal cortex white (FCW) matter. 
Composite micrographs were then separated into their single channel images for analysis. 
Each ROI was then extracted and a grid placed across it for ease of counting. For the sections 
stained for Aβ, the number of dense core, diffuse and cerebral amyloid angiopathy plaques 
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were tallied using the manual cell counter function and included as a total count per ROI. 
The ROI was then converted into mm2 area and the total counts were converted to calculate 
counts per mm2. These were averaged across the 6 ROIs to give each subject a single plaque 
count value. For the hippocampus, ROIs were drawn in the CA1, CA2 and CA3 regions by 
an experienced pathologist (Figure 44 B). Due to the availability of section, orientation of 
cutting and section quality, only a subset of hippocampal sections were analysed. Dense core, 
diffuse and cerebral amyloid angiopathy plaques were tallied using the manual cell counter 
function and included as a total count per ROI. Each ROI was then converted into mm2 area 
and the plaque counts converted to present them as counts per mm2 for CA1, CA2 and CA3 
regions separately. 
The method was then replicated across the sections stained for tau. ROI placement had to 
be manually adjusted to account for locational discrepancies between consecutive sections 
and preparations. FCG and FCW tau counts were presented as counts per mm2  across an 
average of 6 grey matter ROIs and 6 white matter ROIs per subject. Hippocampal CA1, CA2 






Figure 44. Widefield representative composite (red, green, blue) micrographs of human sections stained 
for AQP4 (red), nuclear stain DAPI (blue) and tau or Aβ (green). Consecutive sections were stained for 
either tau or Aβ. (A) Frontal cortex. Yellow squares indicate the 1000 x 1000 pixel ROI placements used 
for analyses: 6 in grey and 6 in white matter). (B) Hippocampus. Yellow ROIs indicate the placement 
of CA1, CA2 and CA3 regions. (C) Zoomed in view of green channel within one square ROI on Aβ 
stained section. Red triangle highlights a dense core plaque, red square highlights a diffuse plaque and 
red circle indicates CAA. (D) Zoomed in view of green channel within one square ROI on tau stained 
section. Red arrows indicate NFTs. A blue grid is placed for counting efficiency.  
 
7.3.5 Threshold analysis of aquaporin-4 
The tau-stained batch was selected for the AQP4 analysis, except where a micrograph was 
not of sufficient quality for analysis as determined by the blinded investigator, in which case 
the Aβ-stained section was used. Composite micrographs were separated into their respective 
channels, and ROIs used in the tau and Aβ analysis opened on the red channel. ROIs were 
occasionally moved in instances where the red channel section was out of focus. Each ROI 
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was duplicated and the mean unthresholded intensity and area was measured. A threshold 
was then applied to highlight the edges of vessels, which was designated as the vessel 
threshold, and the minimum value at this threshold recorded. A second threshold was then 
extended to capture the cellular threshold including the intensity at the fine processes of 
astrocytes where they could be readily identified. This was designated the cellular threshold 
and the mean value and area of this threshold was recorded. Area coverage and AQP4 
polarisation ratio was calculated as described below in Figure 45. The average of 6 ROIs 
were taken for FCG and FCW per subject. Single values were obtained per subject for the 
hippocampal CA1, CA2 and CA3 regions.   
 
 
Figure 45. Workflow used for analysing AQP4 stain on micrographs and the formulae used to compute 
the AQP4 measures investigated in these analyses.   
 
7.3.6 Mice and tissue collection 
All animals were treated in accordance with National Institute of Health (NIH) Guidelines 
for the Care and Use of Animals. All procedures were performed under approved 
Institutional Animal Care and Use Committee (IACUC) protocols. For the aging study, 
male and female wildtype (WT) C57BL6 mice that were 3 months (n = 9) and 15 months (n 
= 7) old were used. For the study of AD pathology, male and female Tg2576 (Tg) mice  at 
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12 months (n = 5) on a C57BL6  background and WT C57BL6 (n = 5) were used. Mice had 
unrestricted access to food and water, and were housed under automatically controlled 
temperature, humidity, ventilation and 12h light/dark cycle settings.  
Brains were perfused with saline and 1U/ml heparin, and then hemisected. One hemi section 
was snap frozen by dropping it in isopentane supercooled on dry ice, to maintain fresh tissue 
for Western blotting. The other hemi section was drop fixed in 4% paraformaldehyde 
overnight. Following fixation, it was fully sectioned coronally on a cryostat at 50μm 
thickness and cryoprotected in sucrose for long term storage.  
7.3.7 Western Blotting of mouse brain samples 
For Western blotting, frozen brains were homogenised on ice in Pierce™ RIPA lysis buffer 
(ThermoFisher  catalog #89900) containing  proteinase and phosphatase inhibitors and 
ultrasonicated for 5 minutes. Homogenates were spun at 1800 rpm for 5 minutes to remove 
cellular debris and the supernatant  collected. Total protein content in the supernatant was 
quantified using the Pierce™ BCA protein assay kit (ThermoFisher catalog #23225). 
Equivalent volumes for 60μg of protein per sample were then prepared for loading in a mix 
of 5μl  NuPAGE™ LDS sample buffer (ThermoFisher catalog #NP0007), 2 μl NuPAGE™ 
sample reducing agent (ThermoFisher catalog #NP0009) and purified water made up to a 
total loading volume of 20μl. Preparations were denatured at 95°C for 5 minutes, allowed to 
reach room temp and then loaded on to Bio-Rad Mini-PROTEAN® TGX Stain-Free™ 
precast gels (Bio-Rad catalog #456-8085) in a Bio-Rad Mini Trans-Blot® Cell tank filled with 
Tris-glycine SDS buffer, immersed in ice. 5μl of 10 to 180 kDa PageRuler™ prestained 
protein ladder (ThermoFisher catalog #26616) was run alongside the samples on each gel.  
Gels were run between 90V and 120V for a total time of 1.5 hours. Proteins were then 
transferred to a mini PDVF membrane using the BioRad Trans-Blot® Turbo™ transfer 
system at 25V, 1A for 30 minutes. Following transfer, membranes were split between the 85 
and 50 kDa mark. The top section was incubated with mouse anti-DTNA (1:500, BD 
catalogue #BDB610766) and the bottom section was incubated with mouse anti- β-actin 
(1:1000, Novus Biologicals catalogue # NB600-501) in 3% milk overnight. Primary 
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antibodies were washed with Tris-buffered saline with 0.1% Tween-20 (TBS-T) and anti-
mouse horseradish peroxidase secondary antibody (1:10,000, Jackson ImmunoResearch 
catalogue #115-035-003) was applied for 2 hours at room temperature. Secondary antibody 
was washed with TBS-T and the membranes then incubated with chemiluminescent 
substrates for 5 minutes. For β-actin visualisation, Pierce™ ECL Western blotting substrate 
(ThermoFisher catalogue #32209) was used and for DTNA, SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate (ThermoFisher catalogue #34577) was used. Blots were 
imaged on the BioRad ChemiDoc™ Touch Imaging System. Using FIJI ImageJ software 
(version 1.52i), images were background subtracted and band intensities extracted. Bands 
were normalised to the loading control (β-actin) and normalised values for each blot 
corrected against a nominated running control for each cohort. An average of two replicates 
for each sample were used. 
7.3.8 Immunostaining of mouse brain samples 
3 sections were selected per mouse, which included cortical and hippocampal regions. Slices 
were mounted onto Superfrost slides, and antigen retrieval was performed using sodium 
citrate buffer (pH 6) with steaming for 30 minutes. Primary antibodies rabbit anti-AQP4 
(1:1000; Millipore catalog #AB3594) and mouse anti-DTNA (1:50; BD catalog# 
BDB610766) were prepared in donkey serum and applied overnight at 4°C. The next day, 
primary antibodies were thoroughly washed with phosphate buffered saline with 0.1% 
Triton-X and secondary donkey anti-rabbit Alexa Fluor 488 (1:400; Life Technologies 
catalog# A21207), donkey anti-mouse Alexa Fluor 594 (1:400; Life Technologies catalog# 
A21202) and Hoechst 33342 nuclear stain (1:10000; Molecular Probes catalog# H3570) 
antibodies applied and incubated at room temperature for 5 hours. All incubations were 
performed manually and in a humidity tray, with minimal exposure to light. Slides were then 
mounted using Fluromount medium, dried overnight and then imaged on the Zeiss Laser 
Scanning Confocal microscope at 20x magnification. Images were acquired by single 
excitation of each wavelength (separately) and channels subsequently merged.  3 ROIs were 





Figure 46. Widefield example micrographs of hemisections of mouse brains used for DTNA analyses. 
A total of three sections were stained for each mouse. 3 cortical and 3 hippocampal ROIs were placed on 
each section (shown as grey squares on one section in this example image). Following data extraction, 
the average of 9 regional ROIs were used per mouse for each measure. 
 
7.3.1 Statistical analyses 
Statistical comparisons between groups were performed via either a Mann-Whitney test, a 
one-way analysis of variance (ANOVA) followed by Dunn’s test for multiple comparisons, 
or a two-way ANOVA followed by Sidak’s test for multiple comparisons. A linear regression 
was performed for correlation analyses. Unpaired t-tests were used for single comparisons. 
All statistical testing was performed using GraphPad Prism (v7 for Windows, San Diego, 
CA, USA). All data is represented as mean ± SEM for the n number in each group, which 
are detailed in figure legends.
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7.4 Results  
7.4.1 Measurements of plaque and NFT burden 
In order to probe the sensitivity of the manual counting approach to the disease status 
allocated to each subject, data was assessed categorised by both clinical (in life) diagnosis – 
classified as “not demented” (ND), “mild cognitive impairment” (MCI) or AD, and 
clinicopathological (post mortem) diagnoses – classified as “probable AD” (AP) or AD 
(Figure 47). Using the manual counting approach, when classified by clinicopathological 
diagnosis, significantly elevated plaque counts were observed in the AD group in the FCG 
(p<0.0001 AP vs AD), and hippocampal CA1 (p<0.0001 ND vs AD) and CA3 (p=0.0014 
AP vs AD) regions. FCW was not different between groups, and hippocampal CA2, though 
elevated in the AD group, did not achieve statistical significance. When separated by clinical 
status, significant elevations in plaque counts were seen in FCG in the AD and MCI groups 
when compared to the ND group (p=0.0001 ND vs AD; p=0.0058 MCI vs AD), as well as 
in the CA3 (p=0.0086 ND vs AD; p=0.0019 MCI vs AD) region. Plaques in the CA1 region 
of the AD group was significantly elevated from ND (p<0.0001 ND vs AD), and CA2 though 
elevated was not significant. FCW was not different between groups (Figure 47). 
In the NFT counts, when classified by clinicopathological diagnosis, significantly elevated 
counts for AD were recorded in FCG (p=0.0034 AP vs AD), CA1 (p<0.0001 AP vs AD), 
CA2 (p=0.0001 AP vs AD) and CA3 (p=0.0025 AP vs AD) regions. FCW had no difference 
between groups. When categorised by clinical diagnosis, significantly elevated plaques in the 
AD group were seen in CA1 (p=0.0003 ND vs AD; p=0.019 MCI vs AD), CA2 (p=0.0007 
ND vs AD; p=0.0051 MCI vs AD)and CA3 (p=0.0152 ND vs AD; p=0.0122 MCI vs AD) 
regions, with the counts being significantly elevated compared to both MCI and ND. By this 
categorisation, FCG had a trend towards increased NFTs in the MCI group, which increased 
further in the AD group, however, these differences did not attain statistical significance. 





Figure 47. Manually counted plaque and NFT densities in frontal cortex grey matter, white matter and 
hippocampal CA1, CA2 and CA3 regions. The left panel shows data categorised by clinicopathological 
diagnosis: AP = Probable Alzheimer’s (n = 21 frontal cortex and 20 hippocampus); AD = Alzheimer’s 
Disease (n = 26 frontal cortex and 13 hippocampus). The right panel shows data categorised by clinical 
diagnosis: ND = Not Demented (n = 15 frontal cortex and 14 hippocampus) ; MCI  = Mild Cognitive 
Impairment (n = 9 frontal cortex and 9 hippocampus); AD = Alzheimer’s Disease (n = 27 frontal cortex 
and 9 hippocampus). Statistical significance denoted by asterisks: *=p<0.05, **=p<0.01, 
***=p<0.001, ****= p<0.0001. 
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To assess the robustness of these measures, manual counts were correlated against the 
clinically relevant CERAD and Braak scores. Positive correlations were observed for plaque 
counts in FCG (r2=0.4447, p<0.0001), CA1 (r2=0.5729, p<0.0001), CA2 (r2=0.1737, 
p=0.0142) and CA3 (r2=0.2627, p=0.0027) and for NFT counts in FCG (r2=0.1389, 
p=0.0108), CA1 (r2=0.4294, p<0.0001), CA2 (r2=0.4026, p<0.0001) and CA3 (r2=0.2193, 
p=0.006),  thus validating these counts (Figure 48).  
 
 
Figure 48. Manually counted pathology correlated to clinical scores. Solid line through data points 
indicates a significant correlation. Upper left: frontal cortex (n = 76) plaques vs CERAD score (frontal 
grey r2 =0.44, p<0.0001) ; upper right: frontal cortex (n = 76) NFTs vs Braak stage (frontal grey r2 
=0.13, p=0.01). Lower left: hippocampal (n = 75) plaques vs CERAD score (CA1 r2 =0.57, p<0.0001; 
CA2 r2 =0.17, p=0.01; CA3 r2 =0.26, p=0.003) lower right: hippocampal (n = 75) NFTs vs Braak 
stage score (CA1 r2 =0.43, p<0.0001; CA2 r2 =0.40, p<0.0001 p<0.0001; CA3 r2 =0.22, p=0.006).  
 
7.4.2 Quantification of aquaporin-4 
To test the AQP4 polarisation measure, a subset of ROIs were first manually scored as 
“polarised” or “not polarised” under a blinded analysis alongside the threshold approach 
(Figure 49). Following completion and unblinding, the metric (minimum vessel intensity to 
mean cellular intensity ratio) proved sensitive to detecting polarisation. Having verified this, 




Figure 49. Test analyses of AQP4 polarisation ratio on a subset of ROIs, carried out on a mixed range 
of subjects with the user blinded to subject information. Based on visual intensity of the AQP4 stain at 
the vessels using the threshold analysis (Section 6.3.5), ROIs were classified as “polarised” or “not 
polarised” and ratios calculated using this threshold analysis. Of n = 60 square ROIs from frontal cortex 
grey sections analysed here, 25 were not polarised and 35 were polarised. Statistical significance denoted 
by asterisks: **** = p<0.0001 
 
 
Figure 50. Composite micrographs of frontal cortex sections showing AQP4 (red) and DAPI nuclear 
(blue) stains. The left micrograph was taken from a representative non-demented (ND) subject and the 
right from an Alzheimer’s disease (AD) subject. Insets: zoomed in ROIs showing a high degree of AQP4 
polarisation around vessels on the non-demented subject and depleted polarisation with patchy AQP4 
staining with uniform astrocytic profiles on the Alzheimer’s disease subject. 
 
FCG polarisation in the AD group was significantly reduced compared to ND when 
categorised by clinical diagnosis (p=0.0301) and the same was observed in the 
clinicopathological categorisation (p=0.0209), where AD polarisation was reduced 
compared to AP (Figure 52). Figure 50 shows an example the appearance of a very polarised 
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cortical section in an ND, with homogenous AQP4 expression also apparent through the 
cortical layers, compared to an AD individual with reduced polarisation, where a depletion 
of cortical AQP4 signal was also noted. Western blot data for a subset of subjects in this 
cohort has previously revealed no differences between AD and non-AD subjects [247]. Here, 
when reclassified by clinical status no differences are seen between groups (Figure 51).  
No changes were observed in FCW in both categorisations. No differences in area coverage 
were seen between groups categorised by clinicopathological diagnosis. When classified by 
clinical diagnosis, in the hippocampus CA1, the MCI group had significantly reduced 
polarisation compared to AD (p=0.0467) but not ND. No other changes were observed in 
any other hippocampal regions in this analysis. When area coverage was measured, CA1 in 
the MCI group was significantly lower compared to ND (p=0.0196) but not AD (Figure 52).  
 
 
Figure 51. AQP4 expression by Western blot. Data is categorised by clinical diagnosis: ND = Not 
Demented (n = 9 frontal cortex and 6 hippocampus) ; MCI  = Mild Cognitive Impairment (n = 6 frontal 





Figure 52. AQP4 polarisation and area coverage measures calculated using threshold analyses in frontal 
cortex grey matter, white matter and hippocampal CA1, CA2 and CA3 regions. The left panel shows 
data categorised by clinicopathological diagnosis: AP = Probable Alzheimer’s (n = 21 frontal cortex and 
20 hippocampus); AD = Alzheimer’s Disease (n = 26 frontal cortex and 13 hippocampus). The right 
panel shows data categorised by clinical diagnosis: ND = Not Demented (n = 15 frontal cortex and 14 
hippocampus) ; MCI  = Mild Cognitive Impairment (n = 9 frontal cortex and 9 hippocampus); AD = 





Correlating AQP4 measures against measures of plaque and NFT counts revealed that there 
was a negative correlation between NFTs and area coverage in the FCG (Figure 53; r2=0.14, 
p=0.0113).  Next, these data were also correlated to the different isoforms of AQP4 
quantified by Western blot in a previous study.  The purpose of this exploratory analysis was 
to determine if protein expression levels had relationships to the novel measures of AQP4 
polarisation and coverage developed here in this study. When AQP4 measures were 
correlated to Western blot expression of the different isoforms, a positive correlation was 
seen between polarisation ratio and total AQP4 (r2=0.3123, p=0.0037), M1 (r2=0.3999, 
p=0.00007) and M23 (r2=0.2307, p=0.0151) isoforms. Area coverage positively correlated 





Figure 53. AQP4 polarisation and area coverage measures in the frontal cortex grey matter correlated 
to manual plaque counts (n = 53), manual NFT counts (n = 46) and AQP4 expression by Western blot 
(n = 30). Solid line through data points indicates a significant correlation. Upper right: NFT counts vs 
AQP4 coverage (r2 =0.14, p=0.01). Lower left:  AQP4 expression vs AQP4 polarisation (AQP4 total r2 
=0.31, p=0.004; AQP4-M1 r2 =0.40, p=0.0007; AQP4-M23 r2 =0.23, p=0.02). Lower right: AQP4 




7.4.3 Testing relationship to the rs3763043 SNP 
To test if the rs3763043 SNP was influential on AQP4 and dementia status, subjects were 
assessed by SNP status and by dementia status (ND vs MCI & AD). rs3763043 SNP carriers 
had an increase in AQP4 polarisation which was not significant (Figure 54 A). When subjects 
were split by dementia status, MCI & AD subjects collectively categorised as the demented 
group (“cognitively impaired” - CI) had significantly increased polarisation in the FCG 
compared to undemented (“not demented” - ND) subjects used as controls (Figure 54 B; 
p=0.0114). AQP4 coverage showed no differences here (Figure 54 C). When burden of 
pathology was assessed by this categorisation, plaque load and NFT burden was lower in the 
rs3763043 SNP group within the demented cohort, but this did not achieve statistical 
significance (Figure 54 D & E).  
 
 
Figure 54. AQP4 measures and pathology by SNP status. (ND = not demented; CI = cognitively 
impaired which includes Mild Cognitive Impairment and Alzheimer’s Disease subjects. 043 = 
rs3763043 SNP carriers; WT = wild type for rs3763043). (A) AQP4 polarisation by SNP status. (B – 
C) AQP4 measures by SNP and dementia status. (D – E) Plaque and tangle pathology by SNP and 




7.4.4 Probing DTNA changes during aging and Aβ pathology in the mouse brain 
 
 
Figure 55. Representative micrographs of young (A-C) and aged (D-F) mouse brain sections stained for 
AQP4 (red), nuclear stain DAPI (blue) and DTNA (green). Composite (red, green, blue) images (A, D) 
show merged channels and single channel images (B, C, E, F) show the same view of the individual 




Figure 56. Representative micrographs of wildtype (A-C) and Tg2576 (D-F) mouse brain sections 
stained for AQP4 (red), nuclear stain DAPI (blue) and DTNA (green). Composite (red, green, blue) 
images (A, D) show merged channels and single channel images (B, C, E, F) show the same view of the 
individual stains.   
 
DTNA expression and polarisation was assessed in a cohort of Tg2576 APP mice. Figures 
55 to 56 show representative immunofluorescence images for each cohort. No differences in 
174 
 
polarisation were observed between young and old mice (Figure 57 D, F). However, a 
reduction in overall whole brain expression was seen in the aged mice in the Western Blot 
analyses (Figure 57 B; p=0.0079). A reduction in polarisation of DTNA was observed in the 
cortex of Tg2576 mice (Figure 57 E; p=0.0465), but not in the hippocampus (Figure 57 G). 
Overall expression of DTNA was not different between the WT and Tg2576 groups (Figure 
57 C). 
 
Figure 57. (A) A single representative image of a Western blot indicating bands for DTNA and β-actin 
loading control, presented as an example blot and taken from the wildtype vs Tg2576 analysis batch. 
(B) Whole brain DTNA expression by Western blot quantified in young vs aged mice and (C) wildtype 
vs Tg2576 mice. (D) DTNA polarisation in the cortex and (F) hippocampus of young and aged mice. 
(E) DTNA polarisation in the cortex and (G) hippocampus of wildtype and Tg2576 mice. Statistical 




In this section of my thesis, the work attempted to undertake a paradigm shift in the 
methodological approach to the study of glymphatic clearance in AD. By moving from 
preclinical mouse work to the clinical human condition I attempted to begin to bridge the 
gap between mouse and human studies of the glymphatic system. Possible changes to 
glymphatic function in human AD was probed by examining AQP4 profiles in human 
subjects diagnosed with AD, MCI and undemented individuals, and correlating these 
measures to Aβ and tau burden with precision. AQP4 polarisation was found to be reduced 
in the frontal cortex of AD subjects, and NFT burden inversely correlated with AQP4 
coverage. Carriers of the rs3763043 SNP who had been diagnosed with MCI or AD had 
increased AQP4 polarisation in the frontal cortex.   
The detailed histological characterisation of Aβ and tau employed here enabled a thorough 
evaluation of the relationship between these recognised correlates of AD and molecular 
features that are mechanistically important to glymphatic function. This approach also aimed 
to get a more refined value of pathology than the gold-standard of Braak and CERAD 
scoring, which takes a more global qualitative approach based on select brain regions [15,16]. 
In doing this, a more direct correlation to AQP4 was enabled, as the same smaller regions 
could be interrogated for AQP4 measures  against Aβ and tau burden. Manual counting of 
a range of smaller ROIs has notable benefits. First, it does not assume uniform pathology 
across the whole anatomical region in question. By taking a more direct region by region 
count and averaging across multiple regions, it provides each subject with a value of Aβ and 
tau burden that is more representative as to the discreet, regional nature of the pathology 
across the brain. When these measures were categorised by clinicopathological status, it 
reliably separated confirmed AD subjects from probable AD on several measures, including 
FCG, CA1 and CA3 for  plaque burden and FCG, and all CA regions for NFT burden. These 
counts were appraised by their positive correlation to  CERAD and Braak scores. Of interest 
were the clinically diagnosed MCI and ND subjects who showed a high level of pathology 
that was histopathologically comparable to AD subjects. It is plausible that these subjects 
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represent the range of the AD pathological continuum, and this supports the notion that 
some individuals are protected from the neurotoxic effects of AD pathology. Previous studies 
have reported that high-pathology nondemented individuals do not suffer synaptic loss to the 
degree that symptomatic AD sufferers do [248], preserve brain morphology in the 
hippocampal regions usually vulnerable to neuronal loss [249], and have larger brains with 
higher volumes even in the face of pathology [250]. It is therefore conceivable that these 
individuals benefited from having a higher brain reserve, that is, they possessed greater brain 
volume or larger numbers of neurons that made them less likely to present with clinical 
outcomes. Or perhaps, they had a higher cognitive reserve, where their neural networks were 
more capable of coping with or compensating for the pathological changes that were 
occurring and prevented them from manifesting as clinical AD [39]. This could be further 
investigated by correlating pathological burden against measures of CNS volume, 
hippocampal volume or cognitive scores. However, in the prior data acquisition phase of this 
study, brain volume data were not collected for MCI subjects within this cohort and 
insufficient data on cognition was available for the already small number of MCI subjects, 
and thus could not be corroborated. 
AQP4 expression was assessed in a subset of subjects and showed no differences in 
expression by Western blot, but a reduction in perivascular polarisation was observed in the 
frontal cortex of AD subjects. This is in keeping with previous findings. In mice, glymphatic 
impairment has been reported in the presence of Aβ pathology [217]. Loss of end foot 
processes along with reduced AQP4 polarisation has also been observed in the presence of 
CAA in both mice and humans [251]. Zeppenfeld et al. showed that loss of cortical 
perivascular AQP4 was associated with AD status and they suggested that this loss may 
contribute to impairments in glymphatic clearance, thus bringing about signature AD 
pathology [205]. In this study, the findings of Zeppenfeld et al. are extended upon, by 
quantifying regional Aβ and tau levels and correlating these to measures of AQP4 in the 
corresponding regions. Although an AD-related reduction in polarisation is reported, no 
correlations were observed between polarisation and Aβ and tau burden. However, a 
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negative correlation was observed between NFT burden and AQP4 area coverage across all 
subjects. Thus, this may suggest that a reduction in NFT  burden may be brought about by a 
high amount of aquaporin-4 coverage across the brain.  Studies in mice have shown that the 
loss of perivascular polarisation is accompanied by a redistribution of AQP4 to non-end foot 
domains [252]. Perhaps then, a greater distribution of AQP4 is more beneficial over greater 
polarisation in reducing tau pathology. Interestingly here, a positive correlation between 
AQP4 area coverage and the AQP4 M1 isoform is also observed. AQP4 M1 is known for its 
propensity to move freely across the plasma membrane and towards extending processes, 
thus facilitating cellular migration, over the M23 isoform which is responsible for the 
formation of rigid orthogonal arrays at the end foot [166]. This indicates that the M1 isoform 
is more beneficial in facilitating expansive coverage of AQP4 whereas the M23 isoform is 
more important in maintenance of polarisation integrity. Thus, the positive correlation 
between AQP4 M1 and AQP4 coverage here is appropriate. 
In a study that mathematically modelled AQP4 mediated water movement, a reported 
observation was that the removal of non-perivascular connecting astrocytic units resulted in 
a reduction in fluid flow between periarterial and perivenous compartments [162]. This 
indicates that the formation of a network of an AQP4 via a continuous astrocytic syncytium 
is crucial for fluid movement, above and beyond the perivascular presence of AQP4, to 
maintain solute movement through the brain parenchyma. It has been reported that 
perivascular astrocytic AQP4 is a third less in human astrocytes compared to mice, due to a 
higher degree of AQP4 expression in parenchymal astrocytes [244]. Continuous 
parenchymal expression may be more beneficial in glymphatic movement of solutes such as 
tau from the parenchyma and may explain the negative correlation observed here between 
NFT burden and AQP4 coverage.  
Curiously, in the hippocampal CA1 region, a reduction in polarisation and area coverage of 
AQP4 was observed in the MCI group. However, no associations were observed between 
AD pathology and AQP4 measures. The CA1 region is known to suffer both tau and Aβ 
pathology from the mid to late stages of the disease [14], and  in the subjects tested here, 
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significant pathology was observed in this region. In the mouse brain, hippocampal 
astrocytes express higher AQP4 in the CA1 region in particular [253]. Reactive astrogliosis 
is a feature of the AD brain, and studies using transgenic mice have also shown that astroglial 
atrophy with diminished processes and decreased numbers are associated with increasing 
AD pathology [254]. Taken together, it is plausible that AQP4 changes are no longer 
detectable in the hippocampal regions given the significant pathological changes.  
Nonetheless, this study for the first time reports an association between cortical tau pathology 
and AQP4 in the human brain.  
Looking to the AQP4 rs3763043 SNP associations, while I report that AD subjects have 
reduced polarisation, I found that the demented carriers of this SNP had increased 
polarisation, with a trend towards reduced plaque and tangle pathology in these subjects. In 
the study that originally identified this as one of several SNPs associated with AD outcomes, 
the rs3763043 SNP was associated with faster cognitive decline [245]. Interestingly, this SNP 
has been investigated in the context of other brain anomalies including sudden infant death 
syndrome [255], traumatic brain injury (TBI) [256], neuromyelitis optica [257,258], oedema 
[259], migraine [260] and intracerebral haemorrhage [261].  In these studies, the rs3763043 
SNP was associated with poorer outcomes in TBI [256] and higher incidence of 
neuromyelitis optica [257], both neurodegenerative conditions. Given these findings and the 
growing body of experimental evidence implicating AQP4 changes in glymphatic clearance 
of Aβ and tau pathology, further pursual of this SNP in the AD setting is warranted. 
In this study, I find that in the dementia setting in the presence of this SNP, AQP4 is more 
polarised than usual. Thus this may suggest that this SNP offers a protective effect towards 
maintaining AQP4 end foot integrity. An ongoing larger cohort study indicates that the 
rs3763043 SNP is associated with reduced tau, P-tau and rate of change of cortical thickness 
(data unpublished, personal communication J. Iliff, 2019). If these isolated findings are taken 
in concert, it then drives new mechanistic hypotheses: it is conceivable that this SNP 
improves AQP4 profile, and therefore may help clear more tau, thus reducing CSF tau levels 
and slowing atrophy to a certain degree. Perhaps this helps these individuals maintain a 
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higher brain and cognitive reserve even in the face of AD. Given that individuals who have 
a high cognitive reserve suffer a faster cognitive decline once diagnosed with AD [39], the 
previous observation of faster cognitive decline with this SNP may allude to this 
phenomenon. The data here do not enable such conclusive connections to be made, but helps 
drive future experimental design around these hypotheses. In order to test this, an ideal 
cohort requires a large group of AD and healthy age matched subjects, containing both 
carriers of the SNP and wild type alleles, studied longitudinally, with cognitive measures and 
brain volume measures longitudinally collected from the point of diagnosis, and followed up 
post-mortem with detailed histological study for AQP4 measures and pathology. Collecting 
these detailed in-life and post-mortem measures in the same subjects will tease out if the 
rs3763043 SNP of AQP4 modulates brain changes in the mechanistic way hypothesised here.  
The precise molecular pathways through which this SNP acts to change pathology by 
changing AQP4 profile also needs to be verified. rs3763043 is a noncoding SNP found in the 
3’ untranslated region (3’ UTR) of the AQP4 gene [245]. The 3’ UTR can post-translationally 
influence the expression a gene via a myriad of regulatory mechanisms: from altered 
translation which can change overall protein expression levels, to variants via alternative 
splicing [262]. Biological aspects of this noncoding region could be explored to understand 
how these SNPs change AQP4 structure, function or location. The previous study that found 
reduced polarisation of AQP4 in AD subjects reported that the ratio of AQP4-M1 to AQP4-
M23 was decreased, and was thought to contribute to this altered polarisation [205]. It is 
plausible that SNPs may contribute to such a mechanistic change, however, this was not 
probed in that study. The Western blot data in this study was unable to probe isoform 
expression levels by SNP status due to a lack of sample numbers on this assay, but probing 
this in a future comprehensive study is of benefit given the previous findings. In order to 
overcome the limitations of studying the human brain in vivo, these mechanisms could be 
modelled and studied in vitro. Generation of human induced pluripotent stem cells (iPSC) 
from SNP carriers enables a feasible in vitro laboratory approach to study the influence of 
SNPs on protein behaviour, as well as their response to experimentally controlled modifiable 
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factors [263]. This may provide a novel window into the study of the components of human 
glymphatics in AD.   
In trying to understand how glymphatic changes play out in human AD, exploring other 
astrocytic end foot elements, particularly those associated with AQP4, may offer additional 
pieces in the puzzle. AQP4 is anchored to the astrocytic end foot by the DAC [264], of which 
DTNA is also member [265]. In addition to DTNA expression being predictive of AD status 
[247], a large ongoing cohort study is revealing several DTNA SNPs  to be associated with 
AD markers (data unpublished, personal communication, J.Iliff 2019).  
Here, I observed a decrease in age related expression of DTNA but not polarisation and a 
decrease in DTNA polarisation in the presence of Aβ pathology in mice. Previous studies 
have shown that AQP4 polarisation is reduced in the aging brain [183,205].  These data 
suggest that DTNA does not undergo the same polarisation change despite having a 
reduction in overall expression with age. However, AQP4 polarisation has been reported to 
be reduced with the presence of Aβ pathology [252]. Given that DTNA and AQP4 share 
expression profiles [246], it is conceivable that this decrease is also expected with Aβ 
pathology. Yet in humans, an increase in DTNA is associated with cortical tau pathology 
[247]. Thus, alterations in DTNA profiles may be distinct between the two pathologies or 
even species. Nonetheless, this is the first time DTNA has been probed directly in models of 
aging and amyloid pathology, and these findings warrant further investigation. Verifying 
these changes in expression and polarisation against other models that that demonstrate 
AQP4 mislocalisation would be beneficial – one such example would be knockout mice of 
alpha1-syntrophin (SNTA), another DAC candidate. SNTA has been shown to colocalise 
with AQP4 at the astrocytic end feet in mice, and mice lacking SNTA show an absence of 
polarised AQP4 [266].  
The pursuit of gene variants that are associated with AD has the potential to uncover as yet 
undiscovered mechanisms in the AD continuum. If glymphatic failure in clearance of 
pathogenic proteins is one pathway towards disease onset, studying gene variants of the 
molecular components of the glymphatic system is prudent. In understanding the 
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relationships between the molecular components of the glymphatic system and the 
proteinaceous aggregates implicated in AD, we may be able to modulate this mechanism via 
AQP4 and related proteins, thus exposing a unique therapeutic target. As such, 
understanding these mechanisms in the laboratory setting of mouse models as well as in the 
clinical context of the human disease will help paint a clearer mechanistic picture. The data 






8. Concluding Remarks 
Despite significant research advances in various avenues of Alzheimer’s disease (AD) 
research, finding a disease modifying cure has been challenging. The precise mechanisms 
that bring about the pathogenic accumulation of amyloid-β (Aβ) plaques and tau 
neurofibrillary tangles (NFTs) are still a conundrum. These however have been major focal 
points in the AD research sphere and studying these proteins have given rise to several 
strands of new and interesting research areas.  
Clearance of proteins from the brain via the glymphatic system is one such novel research 
avenue. Both Aβ and tau have been implicated as candidates for clearance via this system, 
demonstrated via a myriad of experiments including two photon imaging, florescence 
microscopy, radioactive counting and histological analyses [151,179,183,217]. However, 
these studies only provided a snapshot view of isolated components of the glymphatic 
pathway, and thus gave room for whole brain characterisation and real-time observation of 
glymphatic flow. In the work presented in this thesis, I attempted to address this gap by using 
magnetic resonance imaging (MRI) on mouse models of AD.  
By first reproducing parts of the experimental work in Iliff et al.’s seminal publication [151], 
I demonstrated the size based dependence of the spatial pattern and ingress of solutes from 
the cerebrospinal fluid (CSF) into the brain tissue. These experiments provided the 
foundations for the large part of the subsequent methods used in this thesis, and revealed the 
intricacies of working with a surgically manipulated mouse model system of CSF-ISF 
exchange measurement. The work enabled me to attain a suitable flowrate to use in long 
MRI experiments which aimed to use dynamic contrast enhancement (DCE) to track and 
quantify solute ingress in real time. However, a key learning point that was highlighted 
through these and the succeeding MRI experiments in the tau and amyloid mouse models 
was that when undertaking experiments of this nature, several other factors need to be 
considered. Burdens to physiology as a result of surgery and anaesthesia, genetic background 
strain, origin of mouse cohort and health status all contributed to variability in quantifying 
glymphatic ingress by DCE-MRI.  
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Despite these challenges, I show here that glymphatic inflow can be characterised in the 
mouse brain, with temporal and special clarity, and this pattern was diminished with 
pharmacological blockade of the water channel aquaporin-4 (AQP4). The demonstration of 
AQP4 blockade was crucial in this characterisation given the imperative role of this protein 
previously demonstrated in glymphatic study and its association with neurodegenration.  
Whilst the MRI protocol does not resolve the perivascular space, the question of whether it 
was indeed glymphatic ingress that was observed in the DCE-MRI experiments was 
supported here with these observations.  
The regional pattern in the cortex of wild type C57BL/6J mice combined with the early 
observation of a corresponding regional variance in tau deposition in the rTg450 mice 
provides evidence that clearance rates can potentiate levels of pathology at an early stage. 
This was buoyed by the observations in the experiments that injected tau into the brain and 
observed a reduction in clearance when AQP4 was blocked. Further indications towards the 
role of glymphatic function in tau burden was also alluded to in the human post mortem 
investigations, with an increase in AQP4 coverage showing decrease in tau burden.  
The data investigating human brains also paved way for several novel hypotheses to be 
investigated. In particular, understanding the role of single nucleotide polymorphisms 
(SNPs) in AQP4 function, as well as the link to dementia status could provide novel, as yet 
undiscovered genetic markers for AD. Furethermore, exploring other cellular components 
related to AQP4, such as dystrobrevin (DTNA) or associated dystroglycan anchoring 
complex proteins may also provide new markers and biological insights into the relationship 
between fluid exchange, clearance and disease onset. 
Several challenges currently exist with this field. First, the precise driving mechanisms 
underlying glymphatic function need to be fully resolved and reproducibly quantified. 
Additionally, the body of evidence towards perivascular fluid movement and clearance in 
the direction opposing blood flow [267] as well as the recently discovered meningeal 
lymphatics in the mouse brain [152] must also be considered. A key question that remains to 
be answered in the body of neuroscience research being undertaken in clearance 
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mechanisms, is the precise contributions and coexistence of these various pathways. It 
remains to be seen if one specific pathway failure contributes to the specific cascade of events 
that bring about AD. Quantifying these in tandem presents a major challenge for this field 
given the scarcity of combined data in these emerging strands of research, but also presents 
as a necessity. More broadly, the existence of glymphatic clearance in the human brain needs 
to be confirmed. While some imaging studies have functionally alluded to this [241–243], 
emerging studies that are attempting to characterise perivascular spaces may provide the 
requisite physiological evidence of the physical features that form this clearance network in 
the human brain [268].  
A key advantage of working within the glymphatic component of the various fluid networks 
of the brain is that, first, it provides an alternative route to the blood brain barrier (BBB). 
Second, if AQP4 can be pharmacologically manipulated to stop CSF ingress, it may also 
theoretically present a therapeutic target. Drugs to help speed up the clearance of toxic 
proteinatious molecules via AQP4 mediation may provide a promising approach; one such 
agent, TGN-073 [269] is currently being investigated for its neuroprotective potential in a 
murine model of tauopathy, within our laboratory.   
A significant limitation in the work presented in this thesis, is the inability of the techniques 
used here to resolve the perivascular space in the rodent brain. But new work emerging from 
our laboratory, that stemmed from the work I presented here, is showing promise towards 
this goal [270]. Given the invasive nature and technical setup required to quantify glymphatic 
function, the next major challenge this body of work presents is the ability to quantify 
glymphatic changes non-invasively and without the use of contrast. The development of a 
non-invasive imaging method is particularly crucial if we are to develop a protocol that can 
be clinically translated to clearly quantify glymphatic changes during the onset of 
neurodegenerative pathologies. The work I presented here provides significant insights into 
the relationship between AQP4 and AD pathology in the context of glymphatic clearance, 
and as such, paves the way for the development of non-invasive characterisation of 
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